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The Role of Cocrystals in Solid-State Synthesis of Imides and the Development of 
Novel Crystalline Forms of Active Pharmaceutical Ingredients 
Miranda L. Cheney 
ABSTRACT 
 
 With a greater understanding of the fundamentals of crystal engineering lays the 
potential for the development of a vast array of novel materials for a plethora of 
applications.  Addressed herein is the latent potential of the current knowledge base with 
an emphasis upon cocrystallization and the desire for scientific exploration that will lead 
to the development of a future generation of novel cocrystals.  The focus of this 
dissertation is to expand the cocrystallization knowledge base in two directions with the 
utilization of cocrystals in the novel synthetic technique of cocrystal controlled solid-state 
synthesis and in the development of active pharmaceutical ingredients.  
 Cocrystal controlled solid-state synthesis uses a cocrystal to align the reactive 
moieties in such a way that the reaction occurs more quickly and in higher yield than the 
typical solution methodology.  The focus herein is upon cocrystal controlled solid-state 
synthesis of imides where an anhydride and primary amine were the reactive moieties.  
Forty-nine reactions were attempted and thirty-two resulted in successful imide 
formation.  In addition, the cocrystal was isolated as part of the reaction pathway in three 
cases and is described in detail. 
 xx
 The impact of cocrystals upon active pharmaceutical ingredients is also addressed 
with a focus upon generating novel crystal forms of lamotrigine and meloxicam.  
Cocrystallization attempts of lamotrigine resulted in ten novel crystal forms including 
three cocrystals, one cocrystal solvate, three salts, one solvated salt, a methanol solvate, 
and an ethanol hydrate.  Additionally, cocrystallization attempts of meloxicam afforded 
seven novel cocrystals.  Solubility and pharmacokinetic studies were conducted for a 
selected set of lamotrigine and meloxicam crystal forms to determine the crystal form 
with the most desirable properties.  Properties between crystal form and cocrystal former 
were also examined.   
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Chapter 1- Introduction 
 
1.1. Introduction 
1.2. Supramolecular chemistry 
Supramolecular chemistry,1, 2 or the chemistry of the intermolecular bond,3 has 
been defined by Jean Marie Lehn as “chemistry beyond the molecule”.4  Supramolecular 
chemistry is therefore inherently reliant upon the understanding of molecules at the 
molecular level, i.e. the chemistry of covalent interactions that hold atoms together, to 
facilitate the study of the intermolecular interactions between neighboring molecules.  
Initial studies of complexes once called “Übermolecüles” 5 or “supermolecules”  were 
examined to gain insight into the intermolecular interactions that afforded such 
conglomerations.  The basic concepts that developed were premised upon the reliability 
of molecular recognition events between two different but complementary molecules 
initially described as the receptor and the substrate.  Investigations into substrate-receptor 
binding was first examined in the context of biological processes which led to the 
development of the “lock and key” model described by Emil Fischer.6  The realization of 
Nature’s success with molecular recognition led to the deliberate design of complexes 
founded upon molecular recognition events such as crown ethers,7 cavitands,8 and 
cryptands9 designed for ion selection.10-12  Further exploration into molecular recognition 
 2
devices produced functional supramolecular receptors for applications such as catalysis13, 
14 and carrier-mediated membrane transport.15, 16   
 
1.3. Self Assembly and Intermolecular Interactions 
Supramolecular chemistry is reliant upon molecular recognition and self assembly 
of target molecules via weak non covalent intermolecular interactions such as hydrogen 
bonds, metal coordination bonds, CH-π, π-π, van der Waals forces, and electrostatic 
interactions.2  A summary of the bond energies of a select set of intermolecular 
interactions with a relevant example is provided in Table 1.1.17   
 
Table 1.1. Summary of intermolecular interactions commonly exhibited in supramolecular 
chemistry with the covalent bond included for comparison 
 
Interaction Strength 
(kJ/mol) 
Example 
Covalent 
 
150-450 O-O to C-C bond 
Non Covalent 
 
2-300 Dispersion to ion-ion 
Hydrogen Bond 
 
4-120 CH??? π to HF 
Dipole-Dipole 
 
5-50 Acetone 
π-π Stacking 
 
<50 Benzene 
van der Waals 
 
<5 Inert gas 
  
The hydrogen bond is of particular importance in supramolecular chemistry 
because of its relative strength and directionality.18  A definition of a hydrogen bond has 
been suggested by many authors with the earliest examples being the most restrictive 
(electronegative atom interacting with another electronegative atom with a hydrogen in 
 3
between).19-23  However, more recent definitions include weaker interactions such as 
CH???O as hydrogen bonds.24  For the purpose of this dissertation a hydrogen bond will 
include interactions between two electronegative atoms, typically separated by a distance 
less than the sum of the van der Waals radii, where one atom can be defined as the 
hydrogen bond donor and the other atom acts as the acceptor, where hydrogen is located 
between the two atoms and is directional in nature.  Table 1.2 summarizes strong, 
moderate, and weak hydrogen bonds and their characteristic bond strengths, lengths, 
angles, interaction type, and the position of the hydrogen (closer to the donor (D) or 
acceptor (A)) relative to the strength of the bond.18   
 
Table 1.2. Summary of hydrogen bonds and their characteristics (D = donor, A = acceptor) 
 
Hydrogen bonding is also of great importance in biological systems.  DNA, for 
example, is a molecular complex comprised of two strands of long chains of base pairs 
held together by hydrogen bonds.  The replication of DNA relies upon the reversibility of 
hydrogen bonding as the process breaks then makes new hydrogen bonds facilitating data 
transcription and eventually cell replication.25  Without the occurrence of hydrogen bonds 
base pairs would not interact, DNA could not replicate, and life could not exist.  
 Strong Moderate Weak 
Hydrogen bond energy (kcal/mol) 
 
15-40 4-15 Less than 4 
D???A distance (Å) 
 
2.2-2.5 2.5-3.2 Less than 3.2 
D-H vs. H???A 
 
X-H ≡ H???A X-H > H???A X-H >> H???A 
Bond angles (º) 
 
170-180 >130 >90 
Hydrogen bond interaction type covalent electrostatic electrostatic or 
dispersion 
 4
 Hydrogen bonding is a key element throughout this dissertation and it will be the 
main intermolecular interaction focused upon for crystal structure analysis.  Π system 
overlap resulting in charge-transfer complexes will also be highlighted.    
 
1.4. The Design of Supramolecular Solids – Crystal Engineering  
Supramolecular chemistry was initially focused upon the study of supermolecules 
in solution.  However, the field has since split into two directions: the study of 
supermolecules in solution and the study of supermolecules in the solid-state.  The 
explorations into solid-state supramolecular chemistry led to the development of crystal 
engineering.  The term crystal engineering was introduced by Pepinsky26, 27  in 1955 and 
was first practiced by Schmidt who utilized trans-cinnamic acids to design organic solid-
state photochemical reactions.26, 28  The term “molecular engineering” was also 
introduced and used by Hippel to describe the building of materials and devices to 
order.29  Crystal engineering was later defined in 1989 by Desiraju as “the understanding 
of intermolecular interactions in the context of crystal packing and the utilization of such 
understanding in the design of new solids with desired physical and chemical 
properties”.30  Thus, Desiraju’s definition portrays the potential of crystal engineering to 
result in the development of novel materials.  Further exploration of organic 
supramolecular assemblies via crystal engineering by Etter,31-33 Desiraju, 30, 34-37 Wuest,38-
41 Aoyama,42, 43 Whitesides,44-48 Stoddart,49-51 and many others has since realized this 
potential, affording a plethora of materials that are sustained by various molecular 
recognition events, including supramolecular synthons.34, 37 
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1.4.1. Supramolecular Synthons 
Supramolecular synthons have been defined as non-covalent bonding between at 
least two complementary functional groups.34  The study of supramolecular synthons 
began with the carboxylic acid dimer formation with acetic acid in solution52 and has 
since progressed into two distinct types:  the supramolecular homosynthon and the 
supramolecular heterosynthon.53  The supramolecular homosynthon is generated by a 
non-covalent interaction between two of the same moieties.  A supramolecular 
heterosynthon also incorporates a non-covalent interaction however the interaction is 
between two different but complementary moieties.  
Supramolecular synthons are typically sustained via hydrogen bonds formed 
between two electronegative atoms where one atom is also covalently bound to a 
hydrogen atom.  Additionally, other weaker interactions such as π-π stacking54 can also 
be considered a supramolecular synthon.  Commonly employed supramolecular 
heterosynthons sustained via hydrogen bonding include carboxylic acid-amide,55-68 
carboxylic acid-aromatic nitrogen,69-81 carboxylate-aromatic nitrogen,71, 82-84 alcohol-
aromatic nitrogen,85-92 and alcohol-amine.93-96  Typical distance ranges for these common 
supramolecular heterosynthons are ca. 2.5-2.8 Å, 2.4-2.8 Å, 2.5-3.0 Å, and 2.5-3.1 Å, 
respectively.  Supramolecular homosynthons can also exist with any self complementary 
moiety such as a carboxylic acid or a primary amide.  An example of an amide-amide 
supramolecular homosynthon and a carboxylic acid-amide supramolecular heterosynthon 
are shown in Figure 1.1. (a) and (b), respectively.   
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(a)                  (b)  
Figure 1.1. (a) Supramolecular homosynthon exemplified by an amide-amide dimer (b) 
Supramolecular heterosynthon exemplified by an acid-amide dimer 
 
A commonly employed supramolecular heterosynthon is the carboxylic acid-
aromatic nitrogen supramolecular heterosynthon, most likely due to its strength and 
reliability.55, 64, 69-81, 97-107  Additionally, the aromatic nitrogen-alcohol supramolecular 
heterosynthon has also been researched to examine its dependability.85-92  A pictorial 
representation of the two supramolecular heterosynthons is provided in Figure 1.2.   
(a)              (b)  
Figure 1.2. (a) Alcohol-aromatic nitrogen supramolecular heterosynthon 
 (b) Carboxylic acid-aromatic nitrogen supramolecular heterosynthon 
 
The ability to manipulate supramolecular synthon formation to generate a desired 
supramolecular synthon has been explored by many.  The work of Margret Etter is 
particularly noteworthy as, based upon her experimental data, she developed a set of rules 
to determine the potential for supramolecular synthon formation given various donor-
acceptor systems.31, 33  Her studies concluded with the development of three general 
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rules: (1) all good proton donors and acceptors are used (2) six membered ring 
intramolecular hydrogen bonds will form in preference to intermolecular hydrogen bonds 
and (3) the best proton donors and acceptors remaining after intramolecular hydrogen 
bonding will form intermolecular hydrogen bonds with each other.33  She also developed 
a plethora of more specific rules that applied only to certain functionalities.  For further 
knowledge one is directed to her Accounts of Chemical Research article entitled 
“Encoding and Decoding Hydrogen-Bond Patterns of Organic Compounds”.  Etter was 
also influential in the development of graph set analysis of supramolecular synthons.32  
Although the use of graph set notation to describe a supramolecular synthon can be 
beneficial, the complexity that arises from larger supramolecular synthons has limited the 
use of the terminology.     
 
1.5. Cocrystals – A History 
The history of cocrystals began in 1844 with Friedrich Wöhler’s synthesis of 
quinhydrone from hydroquinone and quinone.108  The material, however, was not called a 
cocrystal.  In fact, many early cocrystals were hidden under the guise of other names such 
as addition compounds,109 molecular complexes,110 organic molecular compounds,111 and 
solid-state complexes.112  The term “co-crystal” was not used until 1967 to describe the 
hydrogen bonded complex formed between 9-methyladenine and 1-methylthymine.113  
The term was then later popularized by Margret Etter in the 1990’s.   
The debate over the term cocrystal began in 2003 with a controversial letter from 
Desiraju where he asks: “what is co- to what?”.114  Desiraju continues to explain that he 
would prefer to call a multiple component system that is held together by non-covalent 
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interactions a “molecular complex”.  Dunitz replies to Desiraju’s letter in agreement that 
the term is inaccurate and inelegant; however, he argues that the term molecular complex 
is too vague and could be interpreted to include solvates, inclusion compounds or 
amorphous solids.  Dunitz also insists that the hyphen remain as it is used to signify a 
“togetherness” of two components.115  Aakeröy later defined cocrystals with a strict 
definition where three criteria must be satisfied: the components must be neutral, the 
solid must be made from components that are solids under ambient conditions, and it 
must consist of homogenous crystalline material where the components are present in 
stoichiometric ratios.116  However, Andrew Bond did not agree with the restrictions 
placed by Aakeröy (specifically that all components must be solids) as he calls the 
distinction “contrived and inappropriate”.  He suggests that the term “multiple-
component molecular crystals” be employed to describe a crystalline material containing 
components that are either liquid or solid under ambient conditions.117  Currently a 
ubiquitous definition for the term cocrystal does not exist.  For the purpose of this 
dissertation, however, a cocrystal is defined as a stoichiometric multiple component 
crystal that is formed between two crystalline materials that are solids under ambient 
conditions.  At least one of the components is molecular and forms a supramolecular 
synthon with the remaining component.118, 119    
Cocrystals are typically comprised of two or more molecules that contain multiple 
functional groups and are sustained by various supramolecular synthons.  In general 
supramolecular heterosynthons are used in the formation of cocrystals; however, there are 
a few select examples where cocrystals are sustained via supramolecular mixed 
homosynthons, i.e. the carboxylic acid dimer formed by two chemically distinct 
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carboxylic acids.120  Due to the frequent use of supramolecular synthons to sustain 
cocrystals, cocrystals have played an integral part in furthering the understanding of 
supramolecular synthons and their hierarchy.  The seminal works of Aakeroy,116 
Shattock,121 and Bis85 are particularly noteworthy as they employ cocrystallization to 
delineate supramolecular synthon formation in the presence of carboxylic acids, amides, 
aromatic nitrogens, alcohols, and cyanos.   
Aakeröy and co-workers tested Etter’s rules to determine if the strongest 
acid/base from their dataset would form a supramolecular synthon with the next strongest 
acid/base.19, 116, 122-124  Specifically, Aakeröy targeted ternary cocrystal formation60, 116, 125, 
126 by using three molecules that contained carboxylic acid, amide, and aromatic nitrogen 
moieties to determine which of the many possible supramolecular synthons would persist, 
however, this resulted in ternary cocrystals that were sustained by carboxylic acid-
aromatic nitrogen and carboxylic acid-amide supramolecular synthons.58  An additional 
study for the generation of ternary cocrystals involved two carboxylic acid containing 
molecules (one stronger acid, one weaker acid) and one molecule with two aromatic 
nitrogen moieties of different basicities.  The results confirmed one of Etter’s rules as the 
ternary cocrystals were sustained by the stronger acid forming a supramolecular synthon 
with the stronger base while the weaker acid formed a supramolecular synthon with the 
weaker base.116, 125  The ternary cocrystal is shown in Figure 1.3. with the stronger acid 
(3,5-dinitrobenzoic acid (left)) paired with the imidazole nitrogen (1-((3-
pyridyl)methyl)benzimidazole) and the weaker acid (3-(dimethylamino)benzoic acid 
(right)) paired with the aromatic nitrogen.   
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Figure 1.3. Ternary cocrystal developed by establishing a synthon hierarchy 
 
Shattock121, 127 and Bis85, 128 have taken a different approach to delineating the 
hierarchy of supramolecular synthons with the utilization of cocrystallization.  Their 
studies involved three functional groups and three combinations of molecules.  Each 
experiment was comprised of two molecules, one with two moieties present on the same 
molecule and another molecule that only contained one moiety.  All permutations of 
molecular combinations were attempted.  The experiments were designed in such a way 
that if a supramolecular synthon hierarchy existed then two out of the three experimental 
arms would succeed in cocrystal formation while the third would not form cocrystals.  
The experimental work was divided into two separate competitive studies.  Bis’ work 
tested the supramolecular synthon formation between alcohols, aromatic nitrogens, and 
cyanos128 while Shattock’s studies employed carboxylic acids, aromatic nitrogens, and 
alcohols.127  From the first set of moieties it was determined that the alcohol preferred to 
form a supramolecular synthon with the aromatic nitrogen, not the cyano moiety.  The 
second set of moieties was more complex as the number of donor molecules increased to 
two with still only one acceptor.  An additional unforeseen problem occurred due to the 
selection of molecules with more than one carboxylic acid or aromatic nitrogen moiety.  
 11
Thus in some cocrystals both the carboxylic acid-aromatic nitrogen and aromatic 
nitrogen-alcohol supramolecular heterosynthons were visualized.  However, the study 
concluded that the carboxylic acid-aromatic nitrogen supramolecular heterosynthon was 
stronger than the alcohol-aromatic nitrogen due to the absence of cocrystal formation 
when a molecule containing both a carboxylic acid and aromatic nitrogen moiety was 
paired with an alcohol. Schematic representations of the potential supramolecular 
heterosynthons from both studies are shown in Figure 1.4.  The reliable supramolecular 
heterosynthons (a, c, d) are shown with a green check mark while supramolecular 
heterosynthons with low percentage of occurrences (b, e) are indicated by a red X.   
 
Figure 1.4. Possible supramolecular synthons from supramolecular heterosynthon 
 competitive studies.  Green check marks indicate common supramolecular synthons.   
Red X’s indicate supramolecular synthons with a low percentage of occurrences 
 
The previously described crystal engineering studies employ cocrystal formation 
to determine the reliability of supramolecular synthon formation in a competitive 
situation.  The success of these studies has provided valuable insight into the 
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supramolecular synthon hierarchy that can be applied to future cocrystallization attempts 
with molecules containing more than one moiety.  
That cocrystals are an expanding field that continues to gain interest from both 
academia and the pharmaceutical industry is made evident from a search of SciFinder 
Scholar for references in the chemical abstracts that contain the term “cocrystal”.129  The 
search provided a list of 1,523 references.  Analyzing those references by year elucidates 
their growing popularity.  A pictorial representation is highlighted in Figure 1.5.  The 
rapid increase can be attributed to their variety of applications such as non-linear optics 
for polar molecules,130-132 Polaroid film development,133 decrease tendency for 
hydration,134-138 improve thermal stability,139-141 chiral separation,142 improve 
compressibility and tabletting,143 increase % yield for solid-state synthesis,144 and alter 
solubility139, 145-154 which can lead to improved bioavailability for active pharmaceutical 
ingredients. 
 
Figure 1.5. Analysis of SciFinder Scholar references by year for the term “cocrystal” 
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1.5.1. Cocrystal Synthesis 
 Cocrystals can be synthesized by various techniques including dry grinding or 
neat grinding,155, 156 solvent-drop grinding (also called liquid-assisted grinding),119, 155, 157-
167 mixing, milling,168 reaction crystallization,169 slurring,158, 170-172 sonic slurring,161 and 
solution crystallization techniques designed to grow single crystals119 including slow 
evaporation from solution, vapor diffusion, and layering for liquid diffusion.  The oldest 
cocrystallization technique is perhaps dry grinding as it was performed as early as the 
1800’s.108  It was only since 2002 that solvent-drop grinding has been implemented for 
the synthesis of cocrystals.164  Grinding and milling are beneficial over traditional 
solution techniques as they are a “greener” approach requiring much less solvent and 
cocrystal formation tends to occur at a faster rate with higher yields.155  Solvent-drop 
grinding with multiple solvents has also proven to be a reliable method to generate 
polymorphs of a particular cocrystal.173  Recently the ability to interconvert between 
cocrystals of different stoichiometries via solvent-drop grinding has also been highlighted 
by Jones et.al.163  Additionally, the slurry methodology, widely used as a screening 
technique in the pharmaceutical industry, can be advantageous when gram-level amounts 
of cocrystal are required. 
Attempts to illuminate cocrystal formation conditions were initiated by studies of 
the two components interacting in solution.  Rodríguez-Hornedo pioneered the area with 
her studies of the carbamazepine nicotinamide cocrystal in solution by measuring the 
amount of cocrystal formed with variable concentrations of either carbamazepine or 
nicotinamide present in solution.174  Her studies showed that the greater the concentration 
of nicotinamide in solution, the greater the reduction in solubility of the cocrystal.175  
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This is most likely due to the solid phase that is present in equilibrium with the liquid 
phase shifting from cocrystal to nicotinamide.176  Additional studies to investigate the 
equilibrium between solid and liquid phases of two molecules in solution have been 
conducted by the determination of ternary phase diagrams.177  The ternary phase diagram 
plotted by Chiarella et al. for trans-cinnamic acid and nicotinamide was generated to 
assist in the understanding of why solvent-drop grinding can be such a successful 
cocrystallization technique in lieu of traditional solution crystallization methods.178  
Chiarella179 concluded that in a solvent system where the two components are of similar 
solubility then a 1:1 stoichiometric ratio solvent-drop grind will produce the cocrystal due 
to the correct balance of cocrystal formers and solvent.  However, if cocrystal formation 
is attempted in a solvent in which the two components are of varying solubility then the 
region where the cocrystal formation occurs will be skewed to one side of the ternary 
diagram.  Thus if a slow evaporation experiment was attempted, which inherently 
progresses down the center of the phase diagram as it looses solvent, the likelihood of 
cocrystal formation is decreased.  
 
1.6. The Cambridge Structural Database and the Supramolecular Synthon 
Approach  
With the vast improvements in X-ray crystallographic equipment within the past 
decade the amount of crystallographic data has grown exponentially as structural data can 
be collected and crystallographic details resolved more quickly than ever before.  The 
increase in crystal data is reflected in the Cambridge Structural Database (CSD) which 
currently contains ca. 481,000 crystal structures.180  The CSD is a structural visualization 
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and analysis software developed by the Cambridge Crystallographic Data Centre.  The 
contents of the CSD can be readily searched by multiple methods including chemical 
structures, names, authors, etc.  The ability to search the CSD for a desired 
functionality181 can be useful in the design of cocrystals, moreover, the ability to search 
for specified supramolecular homosynthons and heterosynthons make the CSD an 
invaluable tool for crystal engineering of supramolecular solids including cocrystals.182-
186   
The first step in a cocrystallization experiment is to conduct a search of the CSD 
for the moiety present on the target molecule.  The resulting entries are then cross 
referenced with the presence of a plethora of additional complementary moieties.  The 
next step is to determine if the supramolecular homosynthon or heterosynthon is the 
dominant interaction between the moieties in question.  If the supramolecular 
heterosynthon has a greater percentage of occurrences then a cocrystal can most likely be 
made, however, if the supramolecular homosynthon is dominant then the likelihood of 
cocrystal formation is reduced.  This type of statistical analysis of the CSD has been 
coined the “supramolecular synthon approach”.85, 119, 121  The statistics that can be 
procured from the CSD is beneficial for cocrystal synthesis and has proven to be fairly 
reliable for simple systems were there are only one or two functional groups such as 
carboxylic acid-aromatic nitrogen, alcohol-aromatic nitrogen, or carboxylic acid-amide.  
The major weakness of the CSD is that even with its ca. 481,000 entries there is still not 
enough data to address some competitive supramolecular synthon situations.  This lack of 
data spawned the works of Shattock127 and Bis128 which has since provided partial 
guidance in the design of cocrystals in the presence of multiple functional groups.     
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1.7. Solid-State Synthesis is Green Chemistry  
The emergence of green chemistry187 in the early 1990’s has lead to an increased 
interest in the development of many solid-state synthetic methodologies.  
Photodimerization,188 for example, is a widely accepted solid-state reaction technique 
first practiced in the early 1900’s, and incorporates the principles of topochemistry189-191 
into solid-state organic synthesis.  Schmidt’s192 exploration of topochemical reactions via 
photodimerizations193, 194 led him to further develop the field of topochemistry towards 
the development of the topochemical postulate, first proposed by Kohlschutter in 1919.195   
The postulate states that a “reaction in the solid state occurs with a minimum amount of 
atomic or molecular movement”.189  The postulate therefore implies that the reactivity of 
a complex is controlled by the distances and orientations established by the molecular 
packing within the crystal structure.  Schmidt’s studies involving the [2+2] 
photodimerizations of α- and β-cinnamic acids to their corresponding truxillic acids led 
him to the conclusion that typically, if the reacting moieties are at a distance less than 
4.2Å apart in the solid-state, the photodimerization will occur.196  From these findings 
Schmidt was able to develop a variety of principles which served to guide others in the 
field including the requirement for π electron system overlap for photodimerization to 
occur.  With these imposing restrictions, solid-state reactions tend to be more selective 
than those in solution, however, if the reaction does occur it is typically with higher 
yields and greater stereospecificity.197-199 
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Figure 1.6. [2+2] Photodimerization of cinnamic acid to truxillic acid  
 
More recently, the field of solid-state synthesis has been explored by many 
scientists including Fumio Toda,197, 200, 201 Reiko Kuroda,202-204 and Gerd Kaupp.205-209  
Interestingly, through the use of a multiple of reaction types, Kaupp has shown that solid-
state reactions can and do often result in 100% yield.208  Kaupp employs multiple solid-
state synthetic techniques such as grinding, heating, and photoirradiation and monitors 
the reactions with atomic force microscopy and scanning electron microscopy.210  With 
these powerful tools, he has found that molecular movement can occur across distances 
of greater than 4.2Å therefore questioning the guidelines imposed by Schmidt.  In 
particular, anthracene can undergo photodimerization when the distance between 
anthracene molecules is 6.038Ǻ, as was proven by atomic force microscopy.  After 
analysis of a group of solid-state reactions that occur where the reactants are at a distance 
hv
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greater than 4.2Å apart he concludes that “we found no fundamental differences between 
topochemically allowed and forbidden reactions”.211     
 
1.7.1. Cocrystals and Solid-State Synthesis 
The influence of the principles of crystal engineering upon cocrystallization in 
solid-state synthesis has afforded an effective synthetic reaction design strategy.  As was 
previously discussed, a cocrystal can be designed by utilizing the supramolecular synthon 
approach and the crystallographic information in the Cambridge Structural Database.  
The target molecule and cocrystal former are chosen such that complementary moieties 
are present, allowing for robust and reliable supramolecular heterosynthon formation.  
The cocrystal is then subjected to conditions under which the reaction can occur.  [2+2] 
photodimerization212-217 and nucleophilic substitution reactions218 have thus far been 
successful in the utilization of cocrystals for solid-state chemistry.  It is believed that the 
presence of the cocrystal prior to the reaction allows for the proper orientation of the 
molecules in the solid-state (less than 4.2Å for the reacting synthons) such that the 
reaction will occur faster and with a higher yield than if the cocrystal was not formed. 
Primary interactions commonly employed to sustain cocrystals are strong hydrogen 
bonds; however, cocrystals are also supported by other weaker interactions such as 
CH???π and π-π stacking. 
Leonard MacGillivray has pioneered the area of template directed solid-state 
synthesis via cocrystallization.212-215  A protypal cocrystal for MacGillivray is comprised 
of an aromatic dialcohol such as resorcinol and an olefin containing two aromatic 
nitrogens.  The cocrystal is sustained via alcohol-aromatic nitrogen interactions, which 
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forces a geometrical alignment of the alkene segments such that the cocrystal facilitates 
the [2+2] photodimerization reaction.  A prototypal example is shown in Figure 1.7. 
where the cocrystal is formed between resorcinol and trans-1,2-bis(4-pyridyl)ethylene.  
The cocrystal allows for the appropriate alignment of the molecules such that when the 
solid is photoirradiated the [2+2] photodimerizations occurs resulting in rctt-tetrakis(4-
pyridyl)cyclobutane.87  The cocrystal is considered by MacGillivray to be a reaction 
template because without the formation of the cocrystal, the olefins would not be in the 
proper orientation in the solid for the reaction to occur.  MacGillivrays recent work has 
implemented his cocrystal template photodimerization reactions for the development of 
novel ligands for the synthesis of metal-organic frameworks.219     
 
 
Figure 1.7. MacGillivray’s [2+2] photodimeraztion utilizing a cocrystal template 
 
An additional example of a cocrystal incorporated in organic synthesis was 
conducted by Etter who performed a nucleophilic substitution reaction employing a 
cocrystal as a reagent.218  The cocrystal, generated from solvent-drop grinding of 4-
hv
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chloro-3,5-dinitrobenzoic acid and 4-aminobenzoic acid, was sustained by a carboxylic 
acid dimer and, in the solid state, the chlorine and the primary amine were in close 
proximity (less than 4.2Å) allowing for the SN2 nucleophilic substitution reaction to 
occur upon heating of the cocrystal at 180°C. 
Cocrystallization is also particularly amenable to condensation reactions in the 
solid-state.  The condensation of a primary amine and a carboxylic acid anhydride to 
generate an imide provides an exemplary case as the supramolecular synthon formation 
can be envisioned between the amine and anhydride moieties and the loss of water 
molecules can be accomplished by simple heating of solids.  The focus of the second 
chapter of this dissertation addresses the use of cocrystals as reactive intermediates with 
an emphasis upon the cocrystals ability to align the reactive moieties and bring them into 
close proximity to encourage the minimal amount of molecular movement required to 
conduct the synthetic reaction in the solid-state.   
 
1.8. The Impact of Crystal Form 
 A crystal has been suggested by Dunitz to be a “supermolecule par excellence” 220 
as it involves a complicated array of molecular recognition and periodic arrangement to 
result in long range order.  The molecular recognition events and desire for energy 
minimizations drive the arrangement of the molecules in the crystal lattice.221  
Additionally the particular arrangement determines the physical properties of the crystal, 
including polarizability,222 magnetic susceptibility, piezoelectricity,223 melting point, and 
solubility.  The development of a crystal form is also of great importance in the 
pharmaceutical industry as crystalline forms tend to be more stable than amorphous 
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forms.224  Some drugs, however, are still marketed as amorphous forms due to the 
improved solubility in comparison to the crystalline competitor.225 
 The propensity for an alternate crystal form of an active pharmaceutical 
ingredient (API) to posses different physical and pharmacokinetic properties from the 
original API is of great value to the pharmaceutical industry especially as many (ca. 60%) 
of the new APIs being developed are of low solubility.226  The increased occurrence of 
low solubility drugs can be attributed in part to the modeling methods used in the design 
of some new drugs.  For example, the API zanamivir227 was synthesized after molecular 
modeling provided insight into the binding sites of the influenza virus.  The drug was 
then designed to bind to the virus with the intent of virus inhibition.228  This drug design 
plan does not consider the physicochemical properties of the resulting API. 
     
1.8.1. Crystal Form Types  
There are a plethora of crystal form types that can be isolated for an API.  The 
synthesis and investigation of physical properties of various crystal forms is the subject 
of many review articles.229-243  The diversity of moieties and torsional flexibility of many 
APIs predisposes the formation of multiple crystal forms including, pharmaceutical salts, 
cocrystals, solvates, hydrates, cocrystals of salts, and polymorphs of all of the above.  
Some API’s, however, may not possess an ionizable group thus limiting its ability to 
form salts.   In such a situation the API can then be targeted for cocrystal formation.  
Additional crystal forms such as solvates and hydrates that may not be intentionally 
created are not uncommon in the pharmaceutical industry.  Polymorphs may also be 
formed for all crystal forms and are prevalent in ca. 50% of all drug substances.244   
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All of the crystal forms highlighted above can alter the physicochemical 
properties of the API.  The earliest crystal forms intentionally studied for their unique 
properties were pharmaceutical salts.  Due to the well established history of 
pharmaceutical salts and their ability to alter physicochemical and pharmacokinetic 
properties, only one example will be provided herein.  Pharmaceutical cocrystals,118 first 
developed in 2003, will be addressed in much greater detail as there are only a few 
published reports providing solubility or pharmacokinetic data of pharmaceutical 
cocrystals.      
Pharmaceutical salts are materials formed by an ionic API and a suitable, 
pharmaceutically acceptable counterion.245  They have been a part of crystal form 
selection for decades as they offer diversity of composition and can therefore exhibit a 
wide range of physicochemical properties.246 The most commonly used anion and cation 
in the generation of pharmaceutical salts is chloride and sodium, respectively.  
Pharmaceutical salts have been used to enhance the solubility of poorly soluble APIs 
which represent approximately 40% of the drugs on the market247 and as many as 60% of 
APIs in development.248  Improving the solubility or dissolution rate of a 
Biopharmaceutics Classification System (BCS)249, 250 Class II API is possible via 
pharmaceutical salt formation.246  For example, in the late 1950’s Juncher and 
Raaschou251 developed three novel salt forms of penicillin V that exhibited superior 
dissolution profiles in comparison to the original API.  When conducting a 
pharmacokinetic study, it was observed that the salt form enabling the highest in vivo 
exposure of penicillin V was the same form that possessed the most rapid dissolution 
rate.   
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The BCS scheme was developed as a method of classifying drugs based upon 
their solubility and permeability.  A BCS type I drug is high solubility and high 
permeability, type II shows low solubility but high permeability, type III is high 
solubility and low permeability, and type IV exhibits low solubility and low permeability.  
The definition of high solubility for the BCS system is determined by the ability of the 
largest dose size of the drug to dissolve in less than 250 mL of water over the pH range of 
1-7.5.  If the API does not fit these criteria then it is classified as low solubility.  BCS 
defines high permeability as the ability for greater than 90% of the dose of the API to be 
absorbed.  If the absorption is less than 90% then it is classified as low permeability.  The 
initial intention of the BCS was to correlate the solubility and permeability of a drug such 
that an estimation of absorption could be made.  Currently the federal drug administration 
implements the BCS as guidance for qualification for a biowaiver, i.e. a waiver for the in 
vivo bioavailability and bioequivalence studies.  To obtain a biowaiver from the federal 
drug administration there are many restrictions including that the drug must be BCS class 
I (high solubility, high permeability) and must be an immediate release drug that is 
administered as a solid dosage form.252 
The importance of hydrates and solvates in pharmaceutical development has also 
been recognized.253, 254  Various examples have demonstrated that the formation of 
hydrates and solvates can significantly alter the physicochemical properties of APIs, such 
as chemical stability, solubility, and dissolution rate.255-258   
A more recently applied technique for crystal form development is 
pharmaceutical cocrystallization.118  Pharmaceutical cocrystals can be defined as multiple 
component crystals in which at least one component is molecular and a solid at room 
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temperature (the cocrystal former) and forms a supramolecular synthon with a molecular 
or ionic API.118  The cocrystal former must also be a pharmaceutically acceptable 
compound.119, 121  Pharmaceutical cocrystals have demonstrated that they can profoundly 
modify the physicochemical properties of the parent API molecule136, 139-141, 145-147, 149-154, 
259-268 and at least 90 APIs have been studied in the context of cocrystallization.  Often 
APIs that are targeted for pharmaceutical cocrystallization experience undesirable 
solubility and/or stability and possess multiple hydrogen bonding sites.269  The following 
sections summarize a set of existing pharmaceutical cocrystals were their solubility and 
animal pharmacokinetic behavior is known.   
 
1.8.2. Pharmaceutical Cocrystals with Solubility Data 
Solubility can be defined as the concentration at which the solution phase is in 
equilibrium with the solid phase at a given temperature and pressure.270  The solubility of 
a pharmaceutical cocrystal is of great importance as it can be the limiting factor in the 
absorption of a drug.271  Solubilities of pharmaceutical cocrystals have been measured in 
water, pH 1 HCl solutions, fasted and fed simulated gastric fluid, and fasted and fed 
simulated intestinal fluid.  Variability amongst the conditions is attributed to the desire to 
mimic specific regions along the gastrointestinal tract to gain a better understanding of 
the drugs behavior after it is administered orally.  Furthermore a solubility study can 
indicate whether the cocrystal disassociates back to its original components in solution by 
testing the solid post solubility study. 
The first dissolution profile for a pharmaceutical cocrystal was published by 
Almarsson et.al.154  The target API was itraconazole, an antifungal drug with poor 
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aqueous solubility.  The resulting pharmaceutical cocrystals include a fumaric acid, 
succinic acid, L-malic acid, L-tartaric acid, D-tartaric acid, and DL-tartaric acid cocrystal.  
The crystal structure of the itraconazole succinic acid cocrystal is shown in Figure 1.8.  
The solubility of the succinic acid, L-malic acid, and L-tartaric acid cocrystals was 
measured in 0.1 N HCl and compared to an amorphous formulation of itraconazole 
coated on Sporanox® beads and a crystalline form of itraconazole.  The study showed 
that the L-malic acid cocrystal was as soluble as the on the market Sporonox® bead form 
of itraconazole thus proving that a cocrystal can be just as soluble as an amorphous form. 
 
Figure 1.8.  Hydrogen bonding of itraconazole succinic acid cocrystal  
with succinic acid molecule in green 
 
During an attempt to generate pharmaceutical cocrystals of fluoxetine HCl a 
unique supramolecular synthon was discovered in 2004 by Childs et.al.153  The 
supramolecular synthon involved a secondary amine and a carboxylic acid hydrogen 
bonded together with a chloride anion positioned in between.  Childs’ JACS article 
published in 2004 highlighted three pharmaceutical cocrystals with the commonly 
prescribed antidepressant that were all sustained via the novel supramolecular synthon.  
Fluoxetine HCl fumaric acid, fluoxetine HCl succinic acid, fluoxetine HCl benzoic acid 
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cocrystals were synthesized from crystallization of the HCl salt of fluoxetine with the 
respective cocrystal formers.  The supramolecular synthon is exemplified in the 
fluoxetine HCl succinic acid cocrystal shown in Figure 1.9.  The dissolution profiles were 
conducted both on free flowing powdered cocrystal and on compressed tablets of 
cocrystal.  Both methods were conducted to elucidate the solubility of the cocrystals 
before forty minutes.  The dissolution profiles from the free flowing powder study 
showed that the benzoic acid cocrystal was the least soluble cocrystal.  The fumaric acid 
cocrystal achieved a 30% improvement in solubility in comparison to fluoxetine HCl and 
the succinic acid cocrystal doubled the concentration of fluoxetine HCl.  Interestingly, the 
succinic acid cocrystal concentration begins to decline after twenty minutes into a profile 
that is now commonly referred to as a spring and parachute profile.272  This behavior is 
attributed to the cocrystal initially enhancing the solubility of the API but then 
disassociating into the original components in solution.   
 
Figure 1.9. Fluoxetine HCl succinic acid cocrystal supramolecular synthons  
were the Cl is shown in dark green 
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 The next solubility study published chronologically incorporated both salts and 
cocrystals of saccharin with various APIs.152  When saccharin was complexed with 
quinine, hapoperidol, mirtazapine, pseudoephedrine, lamivudine, risperidone, sertraline, 
venlafaxine, zolepidem, and amlodipine the result was a pharmaceutical salt.  Attempts to 
complex saccharin to piroxicam led to the only cocrystal reported in the study.  The 
solubilites of the various saccharin salts previously mentioned will not be covered in 
detail, however, it is noteworthy to mention that eight out of the ten saccharin salts 
showed appreciably higher solubility than the pure API.  The piroxicam saccharin 
cocrystal, shown in Figure 1.10., obtained a solubility level similar to that of pure 
piroxicam.  Thus the conclusions of this study imply that salts can be more soluble than 
cocrystals.   
 
Figure 1.10. Intermolecular and intramolecular interactions found 
in the piroxicam saccharin cocrystal 
 
 
 
 Norfloxacin, a  potent antibacterial agent, was targeted for salt and cocrystal 
formation due to its low aqueous solubility.151  When complexed with acidic molecules 
such as succinic acid, malonic acid, and maleic acid norfloxacin has formed salts.  When 
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complexed with isonicotinamide norfloxacin remained neutral thus generating a 
cocrystal.  The cocrystal was determined via single crystal X-ray diffraction to be a 
chloroform solvate.  Figure 1.11. highlights the key supramolecular synthons including 
the persistent isonicotinamide dimer.  Equilibrium solubility measurements were 
conducted for anhydrous norfloxacin, the cocrystal solvate, and three hydrated salts.  The 
solubility of the cocrystal improved by ca. 3-fold and the solubility of the salts improved 
ca. 20-45 fold.    
 
Figure 1.11. Supramolecular synthons present in the norfloxacin isonicotinamide cocrystal 
solvate highlighting the persistence of the amide dimer, solvent molecules have been  
deleted for clarity 
 
 
 
 Another interesting complex from a supramolecular synthon perspective is the 
pharmaceutical cocrystal of a monophosphate salt, illustrated in Figure 1.12.139  The 
phosphoric acid cocrystal of a monophosphate salt is the first example of a salt 
cocrystallized with an inorganic acid.  Early attempts to develop a suitable crystal form of 
the target API resulted in an unstable hydrochloride salt.  Furthermore, attempts to 
develop a stable crystalline form of the free base were unsuccessful.  An extensive 
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screening process provided the phosphoric acid cocrystal of the phosphate salt that 
achieved a solubility greater than 250 mg/ml in water. 
 
Figure 1.12. Phosphoric acid cocrystal of a monophosphate salt 
 
Sildenafil, the active ingredient in Viagra®, was also a target for 
cocrystallization.149  The currently marketed crystal form of Viagra® is the citric acid salt 
of sildenafil that was synthesized to improve the poor aqueous solubility of sildenafil.  
However, the citrate salt proved to be only moderately soluble in water.  Zegarac and 
coworkers have since developed an aspirin cocrystal of sildenafil with improved 
solubility under acidic conditions.  Specifically, the intrinsic dissolution rate for the 
aspirin cocrystal was approximately twice that of the citrate salt. Due to the increased 
solubility of the aspirin cocrystal under acidic conditions, the crystal form is particularly 
amenable as an oral dosage form.  Desiraju has also targeted sildenafil for the 
development of novel crystal forms.  Eleven different solvates of the saccharinate salt of 
sildenafil were identified and characterized via single crystal X-ray diffraction.  The 
solubility of the solvated crystal forms was not determined. 
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A study reported by Remenar et.al., highlighted the importance of excipients 
when measuring the solubility of a cocrystal.150  The celecoxib nicotinamide cocrystal, 
shown in Figure 1.13., was presented as an example.  Celecoxib is a COX-2 inhibitor and 
anti-inflammatory agent with an aqueous solubility of less than 1 μgram/ml and is known 
to exist in four polymorphic forms.  An examination of the literature of pure celecoxib 
revealed that the bioavailability could be altered based upon the formulation technique 
employed.  The article attributed the differences in dissolution profiles, which varied with 
the formulation technique, to the variability in bioavailability.  The focus of Remenar’s 
study was similar, except the dissolution study was of the celecoxib nicotinamide 
cocrystal.  The solubility of the cocrystal was measured in aqueous solutions containing 
small percentages of sodium dodecyl sulfate on polyvinylpyrolle.  It was found that the 
cocrystal was more soluble in solutions containing higher levels of the excipients. 
 
Figure 1.13. Hydrogen bonding of the celecoxib nicotinamide cocrystal 
 
 31
 The solubility and stability of twenty-seven carbamazepine cocrystals has also 
been recently investigated.148  Carbamazepine has been extensively studied for cocrystal 
formation (carbamazepine aspirin cocrystal shown in Figure 1.14.) and solution behavior 
in the presence of cocrystal formers.  The most recent contribution of carbamazepine 
cocrystals incorporated both diacids and monoacids as cocrystal formers and in many 
cases led to polymorphic cocrystals.  While no numerical solubility values were given, it 
was stated that the solubility of the cocrystal was dependent upon the cocrystal former 
concentrations.  The stability of the cocrystal was measured by testing the solid phase 
post slurry.  The cocrystals were stirred in water and allowed to reach equilibrium.  The 
remaining solid was tested post slurry and for thirteen cocrystals, was found to convert to 
carbamazepine dihydrate.  Seven of the cocrystals remained intact during the study.   
 
Figure 1.14. Carbamazepine aspirin cocrystal 
 
 AMG 517, an API in development stages at Amgen for indications of chronic 
pain was recently the target for cocrystallization.  Ten cocrystals were developed 
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employing cocrystal formers containing carboxylic acid moieties.146  The solubility of 
AMG 517 is very low in 0.01N HCl but slightly higher in fasted simulated gastric fluid 
(FSGF) (5 μg/mL) thus the dissolution profiles for AMG 517 and its cocrystals were 
measured in FSGF.  All cocrystals except for the tartaric acid cocrystal were examined.  
Six of the nine cocrystals obtained their maximum solubility within 1-2 hours.  Their 
concentrations then decreased throughout the remainder of the study producing a spring 
and parachute profile reminiscent of the fluoxetine HCl succinic acid cocrystal previously 
mentioned.  The solubility of the three remaining cocrystals was less than that of AMG 
517.  Interestingly, powder X-ray diffraction studies confirmed that the solids remaining 
after the dissolution study were AMG 517 hydrate in all cases except for with the benzoic 
acid cocrystal.  While the spring and parachute type profile indicated that the benzoic 
acid cocrystal had converted to the dihydrate, powder X-ray diffraction showed that the 
remaining solid was in fact cocrystal.  The DSC, however, suggested that the benzoic 
acid was not present in the crystal lattice, but was instead in solution.  This argument was 
supported by HPLC analysis that indicated an increase in benzoic acid concentration in 
solution.   
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Figure 1.15. 2-point recognition supramolecular synthon of AMG 517 succinic acid cocrystal 
  
 The next study describes the cocrystallization of two steroid-type molecules, 
exemestane and megestrol acetate, that could not be formulated as pharmaceutical salts 
due to their lack of strongly acidic or basic functionalities.147  Exemestane is used to treat 
breast cancer while megestrol acetate is used to reduce the suffering caused by some 
cancers and treats the loss of appetite in some AIDS patients.  The unique cocrystal 
screening technique employed in this study involving dimethylsulfoxide slurries followed 
by lyophilization produced two novel cocrystals, exemestane maleic acid and megestrol 
saccharin.  The solubility was obtained via intrinsic dissolution and loose powder 
dissolution measurements.  Intrinsic dissolution studies showed that the exemestane 
maleic acid cocrystal solubility was of similar solubility to that of the pure drug while the 
megestrol saccharin cocrystal was twice that of the pure drug.  The free flowing powder 
dissolution profiles indicate a similar solubility trend, with the megestrol cocrystal 
achieving a six-fold increase in solubility.  The influence of particle size of the cocrystal 
was also measured but it did not have a strong impact upon the cocrystal solubility.   
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 The most recent cocrystallization study that measures the solubility of the 
cocrystals was reported by Bak et.al.145  AMG 517 was again employed but complexed 
with alternative cocrystal formers containing either amide or carboxylic acid moieties.  In 
addition to AMG 517, six more transient receptor potential vanilloid 1 antagonist APIs 
were targeted producing 15 cocrystals in total.  AMG 517 produced 12 cocrystals while 3 
(AMG 678809, AMG 831664, AMG 670129) of the additional 6 APIs each formed a 
cocrystal with sorbic acid.  The solubility and dissolution profiles were measured for all 
15 cocrystals in fasted simulated intestinal fluid.  Many of the cocrystals resulted in a 
spring and parachute dissolution profile with the remaining solid converting to either the 
free base or hydrated free base.  However, two of the AMG 517 cocrystals remained 
intact throughout the study.  The most soluble cocrystal of AMG 517 was the L-malic 
acid cocrystal, highlighting an increase from 5 μg/mL to 24 μg/mL.  A comparison of the 
two AMG 517 cocrystallization studies shows that both cocrystal formers containing 
carboxylic acids or amides can improve the solubility of the API.  The sorbic acid 
cocrystals of AMG 678809, AMG 831664, and AMG 670129 also displayed marked 
improvements in solubility with the most notable increase of 0.9 μg/mL to 14.8 μg/mL 
for the AMG 670129 sorbic acid cocrystal.  
 
1.8.3. Pharmaceutical Cocrystals with Animal Data 
Many of the APIs targeted for cocrystallization are selected because of their low 
solubility and/or poor bioavailability.  Enhancing the solubility of a crystal form via 
cocrystallization can translate to an increase in drug present in solution and available at 
the absorption site in vivo.  Depending on the mechanism of absorption, a more 
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concentrated solution of API can ultimately lead to a higher bioavailability (i.e. increased 
concentration of unchanged drug in the plasma).  In each of the following case studies the 
solubility of a low solubility drug was increased via cocrystallization.  The effect of 
solubility improvement upon drug absorption and bioavailability is summarized herein.    
The first publically available study where an animal was administered a cocrystal 
was performed at Transform Pharmaceuticals Inc.  Itraconazole, an antifungal drug, was 
the target API.267  The cocrystal with L-malic acid was dosed to dogs and found to reduce 
the time required to reach the maximum concentration (Tmax) by 10-80% over the pure 
drug.  The maximum concentration (Cmax) and area under the curve (AUC) were also 
increased by 10-80%.  The bioavailability (reported as 40%) for the cocrystal was 
equivalent to the currently administered amorphous form of itraconazole coated on 
Sporanox beads.   
Transform Pharmaceuticals Inc. also filed a patent in 2004 containing the results 
of an in vivo testing of the modafinil malonic acid cocrystal.265  Modafinil, used for 
indications of narcolepsy, is practically insoluble in water, however, the malonic acid 
cocrystal dissolved at a faster rate than the pure API.  The pharmacokinetic study 
utilizing a capsule formulation of the cocrystal administered in a single dose study to 
dogs highlighted an increase in Cmax and bioavailability.  The Tmax was practically 
unchanged despite the increase in solubility at early time points.       
In 2006 Childs et al.,140 reported a set of five novel solid phases of 2-[4-(4-chloro-
2-fluorophenoxy)phenyl]pyrimidine-4-carboxamide, or CFPPC.  CFPPC is a sodium 
channel blocker used for alleviating pain with an aqueous solubility of < 0.1 μg/ml.  
Interestingly, the cocrystal comprised of CFPPC and glutaric acid showed an intrinsic 
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dissolution rate ca. 18 times greater than pure CFPPC.  The dog pharmacokinetic study 
resulted in an AUC increase from 374 to 1,234 ng h/ml for the 5 mg/kg dose and an 
increase from 889 to 2,230 ng h/ml for the 50 mg/kg dose.  Thus after a single oral dose 
of the cocrystal the dogs exhibited an approximately 4-fold increase in plasma 
concentration over the pure API. 
Chronologically, the next cocrystal pharmacokinetic study details to appear in the 
literature pertained to the carbamazepine saccharin cocrystal.141  The study was a single 
dose administration of the cocrystal and the marketed Tegretol® tablet to beagle dogs.  
The results showed higher Cmax and AUC values for the cocrystal and a Tmax value that 
was one hour for the cocrystal and 1.75 hours for the Tegretol® tablet.  Furthermore the 
cocrystal reached slightly higher plasma levels than the marketed drug, but remained 
within the standard error and therefore was not statistically significant.   
The pharmaceutical cocrystal of a monophosphate salt with phosphoric acid, 
previously mentioned for its improved solubility in comparison to the free base, is 
noteworthy as it briefly mentions the results of a pharmacokinetic study.  Unfortunately 
there are no details concerning this portion of the study in the article.  The article simply 
claims that the cocrystal “exhibited excellent in vivo performance”. 139          
In 2008 Bak and co-workers highlighted the ability of a series of pharmaceutical 
cocrystals to improve the solubility of AMG 517.146,259  A particular focus was upon the 
AMG 517 sorbic acid cocrystal and it was studied with respect to its stability in vitro as 
well as its ability to modify the plasma concentration of AMG 517 in Sprague-Dawley 
rats.  It was found that after oral administration of a 500 mg dose of the cocrystal, the 
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Cmax and AUC0-inf was 8 and 9 times greater, respectively, compared to oral 
administration of the same dose of pure API.  
The two most recent studies are from the patent literature.  The first describes 
tenofovir which is a nucleotide reverse transcriptase inhibitor for the treatment of HIV.261  
The commercially available form of tenofovir is a fumarate salt however, the product 
contains various mixture of solid forms in unpredictable ratios.  In an attempt to solve the 
commercial product problem, tenofovir was cocrystallized with fumaric acid resulting in 
a 2:1 molecular complex that could be isolated cleanly.  A pharmacokinetic study (a 
single dose Male Wister rat study) comparing the cocrystal to the existing salt form 
proved that the cocrystal was bioequivalent to the on the market product. 
The most recent pharmacokinetic study of a pharmaceutical cocrystal describes 
the cocrystal formed between a C-glycoside derivative and proline.264  Previously the 
pure drug was found to crystallize as a clathrate hydrate that interconverts from an 
anhydrous compound to a non-stoichiometric hydrate.  The instability of the API led to 
the develop the additional crystal forms.  The resulting 1:1 C-glycoside derivative L-
proline cocrystal was administered as a suspension to non-fasted mice.  Levels of the 
cocrystal and original API were measured in the blood concluding that the cocrystal was 
present at a sufficient level to treat diabetes.  The patent further claims that the patient 
would experience the same or higher efficacy after administration of the cocrystal.   
As was made evident in the previously mentioned studies, the crystal form of a 
pharmaceutical can have a significant impact upon the solubility and pharmacokinetic 
properties of an API.  Table 1.3. provides a summary of the pharmacokinetic data 
presented in this chapter.   
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Table 1.3. Summary of the pharmacokinetic metrics for the presented pharmaceutical cocrystals 
API Cocrystal 
former 
Pharmacokinetic metrics 
Itraconazole L-Malic acid Bioavailability = 40%, Equivalent to amorphous 
drug 
Modafinil 
 
Malonic acid Increase Cmax and bioavailability 
CFPPC 
 
Glutaric acid Decrease Tmax, increase Cmax and AUC by 4-fold
Carbamazepine 
 
Saccharin Increase AUC and Cmax, however, not 
statistically significant plasma level 
 
Monophosphate salt 
 
Phosphoric acid No data, stated “excellent in vivo performance” 
AMG 517 Sorbic acid Increased Cmax and AUC by 8 and 9 fold 
 
Tenofovir Fumaric acid Bioequivalent to commercially available drug 
 
C-Glycoside 
Derivative 
L-proline Cocrystal showed strong antihypoglycemic 
action 
 
1.8.4. Polymorphism and the Pharmaceutical Industry  
A polymorph has been defined by McCrone as “a solid crystalline phase of a 
given compound resulting from the possibility of at least two different arrangements of 
the molecules of that compound in the solid state”.273  The number of compounds that 
exhibit polymorphism is uncertain as McCrone argues that the number of polymorphic 
compounds is proportional to the time and money spent in research on that compound.274  
In an attempt to quantify the number of known polymorphs a search of the CSD was 
conducted.  The term “polymorph” retrieved 15,633 entries out of 481,521 or 3% of the 
entire database.   
An important aspect of polymorphism is the inherent differences in physical 
properties between crystal forms.258, 275  Variations in properties such as solubility can 
have a dramatic impact upon the pharmacokinetic behavior of an API.  Thus crystal form 
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screening is of utmost importance in the pharmaceutical industry.  However, traditional 
crystal form screening does not always reveal all possible polymorphs.  The negative 
impact that crystal form screening can have upon the pharmaceutical industry is 
exemplified in the historic cases of ritonavir,276 ranitidine HCl,275 and paroxetine HCl.277  
Ritonavir, marketed as Norvir®, was formulated as an oral liquid and a semi-solid 
capsule.  Since both formulations were solutions of ritonavir there was little concern with 
crystal form.  During early manufacturing of the capsules only the one crystal form of 
ritonavir was found.  However, years later, a new form was discovered that was much 
less soluble than the original form.  This new form was referred to as form II.  Form II 
was soon found at all manufacturing facilities, dramatically reducing the supply of the 
original form.  Form II was so much less soluble that it could not be used to make the oral 
liquid or semi-solid capsule formulations via the current methods.  Ultimately ritonavir 
had to be reformulated due to the omnipotent less soluble form II.              
 Ranitidine HCl (Zantac®), a histamine H2 antagonist originally developed by 
GlaxoSmithKline, was also found to be polymorphic.  The polymorphic transformation 
of what is now called form I to form II occurred during the scale up manufacturing 
process.  Form I was covered under an original synthesis patent and form II was 
subsequently covered under an additional patent.  Due to the success of the drug, many 
generic companies were waiting for form I to go off patent to introduce their own generic 
version on the market.  Novopharm in particular attempted to reproduce form I from the 
claimed method in the patent, however, Novopharm produced form II.  Novopharm then 
tried to invalidate Glaxo’s patent for form II citing that they had reported a method for 
form I that actually produced form II; therefore form II would be anticipated from the 
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earlier patent.  Novopharm eventually lost the case as Glaxo was able to prove that their 
method did lead to generation of form I in the original researchers’ notebook.  However, 
Novopharm was granted the ability to market a pure product of form I.   
 GlaxoSmithKline also entered into a legal battle over paroxetine HCl (Paxil®).  
The original form developed was a hemihydrate of paroxetine marketed since 1993.  
While waiting for Glaxo’s patent to expire, Apotex developed an anhydrate crystalline 
form of paroxetine HCl.  Glaxo was aware of the anhydrate and its conversion to the 
hemihydrate under specific conditions that were claimed in their original patent.  Glaxo 
claimed that Apotex was operating under conditions that would partially convert the 
anhydrate to the hemihydrate that was covered under their patent.  The legal battle ensued 
with the court ultimately ruling against Glaxo as they could not prove that Apotex would 
make the hemihydrate in sufficient quantities.   
   
1.9. Summary   
 Supramolecular chemistry has grown exponentially since the description of the 
lock and key model in 1890.  The subset of crystal engineering has also grown and 
attracted interest from many different facets including academia and industry.  
Contributing factors that have fueled the rapid development have been the advancements 
in X-ray technology as well as augmented interest from large corporations and university 
collaborations.  In particular the pharmaceutical industry is currently infatuated with the 
ability to fine tune a crystal form to possess desired physical and pharmacokinetic 
properties.  The potentials and pitfalls of polymorphism are also a topic of current 
interest.   
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Cocrystals in solid-state synthesis and cocrystals in pharmaceutical development 
both show great promise in their respective areas.  Cocrystals as reaction intermediates or 
photodimerization templates have afforded novel materials typically coupled with 
increased reaction yields.  Pharmaceutical cocrystals have also proven their utility with 
their ability to change an API’s solubility and bioavailability.  The ability to manipulate 
the properties of a cocrystal to customize a product is still a future goal but as the field of 
crystal engineering continues to grow and its applications extend, new materials will 
emerge with inherent properties that will most likely be the result of a designed 
experiment rather than serendipity. 
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Chapter 2 – Cocrystal Controlled Solid-State Synthesis of Imides 
 
2.1. Preamble 
 The chemical industry has played a major role in the production and accumulation 
of hazardous waste and toxins in the environment.1  Unfortunately, it was not until the 
1960’s that the public became aware of the toxicity and harm to human health some 
chemicals, such as DDT (dichlorodiphenyltrichloroethane),2-4  in the environment could 
cause.  The increased public awareness began the conscious effort to reduce chemical 
waste and its presence in the environment. A giant leap forward was made in 1990 with 
the Pollution Prevention Act5 which stated that one should strive to prevent or reduce 
pollution whenever possible.6  This act facilitated the development of more 
environmentally friendly chemical practices that lead to the creation of the chemical 
genre of green chemistry.7-12  Green chemistry has been defined as “the utilization of a set 
of principles that reduces or eliminates the use or generation of hazardous substances in 
the design, manufacture, and application of chemical products”.13  Implementation of the 
twelve principles of green chemistry can provide greater reaction yields and less 
hazardous waste production, resulting in cheaper overall chemical synthetic 
methodologies.14  With the consideration of these benefits in mind, many chemists have 
strived to develop the field of solid-state synthesis, however, in some areas their focus 
has been relatively narrow in scope.15-17  For example, the particular application of 
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cocrystal controlled solid-state synthesis (C3S3) has thus far been limited to 
photodimerizations or photopolymerizations18-27 and nucleophilic substitution.28  In the 
case of the former, one cocrystal former typically serves to align or “template” the 
reactant, which is the other cocrystal former.  In the case of the latter both cocrystal 
formers are reactants although there are examples in which the reactive moieties are in 
the same molecule and therefore generate polymeric structures.29  In this chapter, the 
details of an exploration into furthering the development of C3S3 are delineated for the 
design and synthesis of novel materials.  
C3S3, defined as the generation of a cocrystal in the solid-state which can then be 
utilized to conduct a chemical reaction, typically condensation, in order to generate novel 
materials, can be described as a two part process.  The initial stage applies crystal 
engineering30, 31 design principles to a recently developed low waste, high yield cocrystal 
synthesis method which is followed by a traditional condensation reaction that has been 
modified to be conducted in the solid-state.  There are two strict sets of criteria for 
conducting a reaction by C3S3: 1) the materials must posses the appropriate moieties to 
sustain a reliable supramolecular synthon32, 33 and 2) the moieties required for the 
supramolecular heterosynthon must be chemically reactive such that when heated they 
lose a volatile component, typically water.  Based upon the requirements imposed for 
C3S3, there are six reactions that fit this criteria, aldehyde + primary amine to generate a 
Schiff base,34 carboxylic acid + primary amine to make a secondary amide,35 carboxylic 
acid + carboxylic acid to form an anhydride,36 carboxylic acid + alcohol to generate an 
ester,37 alcohol + alcohol to make an ether,35 and anhydride + primary amine to form an 
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imide.38  This contribution will focus upon imide formation employing an anhydride and 
primary amine via C3S3 as illustrated schematically in Figure 2.1.  
 
 
Figure 2.1. Reaction scheme for imide formation from primary amine  
and carboxylic acid anhydride via cocrystallization 
 
Imides represent a class of compound that is primarily synthesized in solution;39 
however, there are prior examples that highlight the ability to synthesize imides in the 
solid-state via microwave chemistry40-42 or upon a solid-phase support.43, 44  Both 
methods prepare imides via condensation of carboxylic acid anhydrides and primary 
amines (mechanism shown in Figure 2.2.) i.e. two functional groups that are 
complementary and could form a supramolecular synthon45; however, prior to 2007, there 
were only two entries (REFCODES: AMYGLA, BEFWEO) in the Cambridge Structural 
Database (CSD)46 that exhibit both the amine and  anhydride moieties in the same entry, 
both of which were comprised of a single component therefore neither were cocrystals.  
The lack of data in the CSD precludes a definitive statement concerning the reliability of 
the supramolecular heterosynthon formation.  C3S3 provides the opportunity to address 
the occurrence of this supramolecular heterosynthon and its potential to generate novel 
imides.  
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Figure 2.2. Proposed reaction mechanism for carboxylic acid anhydride  
and primary amine producing an imide 
 
Cocrystals can be synthesized by various methodologies47-49 including the 
established solvent-drop grinding technique, i.e. two or more solid cocrystal formers are 
ground in the presence of a microliter amount of solvent.50-54  In the study presented 
herein, the cocrystals will be synthesized via solvent-drop grinding as it is the most 
environmentally friendly cocrystallization technique.  The groups of acid anhydrides and 
primary amines depicted in Figures 2.3. and 2.4. respectively that were selected for this 
study include: AA1 = 1,4,5,8-naphthalenetetracarboxylic acid dianhydride (NTCDA), 
AA2 = pyromellitic dianhydride, AA3 = maleic anhydride, AA4 = phthalic anhydride, 
AA5 = 3,3’,4,4’-biphenyltetracarboxylic dianhydride, AA6 = 1,8-naphthalic anhydride, 
AA7 = 3,4,9,10-perylenetetracarboxylic dianhydride, PA1 = 2-methyl-4-nitroaniline, 
PA2 = 3-aminobenzoic acid, PA3 = melamine, PA4 = 1,4-phenylenediamine, PA5 = 1,5-
diaminonaphthalene, PA6 = 1-adamantylamine, and PA7 = triphenylmethylamine.  All 
combinations of the 7 anhydrides with 7 primary amines was investigated (49 total 
reactions) to determine the following: if they form cocrystals via solvent-drop grinding 
under ambient conditions; furthermore if the ground mixtures so obtained can be 
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converted to imides simply by applying heat.  A summary of the results after grinding 
then heating are presented in Table 2.1.  The majority of reactions studied were observed 
to form imides after heating but it was not always possible to isolate a cocrystal.  
However, three combinations of anhydride + amine were isolated as cocrystals that 
resulted in high yield, low waste formation of imides and will be discussed herein.  An 
additional reaction where the imide condensation reaction intermediate was isolated in 
high yield will also be discussed.  The analysis for reactions 1-4 includes reaction 
conditions and discussion of the differential scanning calorimetry (DSC) traces, UV-vis 
spectra, and color schemes for reactants, cocrystals, and imides where appropriate.  In 
addition the use of DSC to discover cocrystal formation in situ will be addressed.  
Finally, the use of characterization techniques such as powder X-ray diffraction (PXRD) 
and Fourier transform infrared (FT-IR) spectroscopy will be discussed for the detection 
of cocrystal and imide formation with a broad set of amines and anhydrides.    
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Figure 2.3. Carboxylic acid anhydrides 
 
 
Figure 2.4. Primary amines 
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Table 2.1. Table of 49 reactions color coded to differentiate outcomes after 
 solvent-drop grinding and heating 
 
 
2.2. Results and Discussion  
2.2.1. Reaction 1  2-methyl-4-nitroaniline and NTCDA  
2.2.1.1. Synthetic Techniques and Characterization   
As revealed in Figure 2.8, 1,4,5,8-naphthalenetetracarboxylic dianhydride 
(NTCDA) and 2-methyl-4-nitroaniline form a 1:2 cocrystal, 1a, which converts cleanly to 
diimide, 1b, when heated at 180 °C for 3 hours in 75% yield.  Conversion to 1b is 
expected as the distance between the amino moiety and carbonyl carbon of the anhydride 
is ca. 3.42 Å, which is less than the 4.2 Å restriction of the topochemical postulate.  1b 
crystallized from DMF and DMSO, affording solvated single crystals of 1b.  Figure 2.11. 
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represents the DMSO solvate of 1b and is presented in detail herein.  The DMF solvate of 
1b is not covered in detail as the solvate is isostructural to the DMSO solvate.   
The cocrystal of NTCDA and 2-methyl-4-nitroaniline (1a) is purple in color.  The 
purple color of 1a contrasts the starting materials (pale yellow) and reaction product 
(orange) and is indicative of charge transfer complex.55  The solid-state UV-Vis spectrum 
of 1a exhibits a broad band at ca. 600nm and is shown in Figure 2.5.  The UV-Vis 
spectrum of 2-methyl-4-nitroaniline, NTCDA, and an ethanol grind are also shown for 
comparison purposes. 
 
Figure 2.5. UV-Vis spectrum of DMF solvent drop grind versus  
Methanol grind, NTCDA, and 2-methyl-4-nitroaniline 
 
1a can be prepared from solution, solvent-drop grinding with DMF or solvent-
drop grinding followed by heating and is sustained by charge transfer interactions 
between the aromatic rings of NTCDA and 2-methyl-4-nitroaniline.  Toda et al. has also 
shown the ability to generate charge transfer complexes from solid-state grinding.56  
Interestingly, solvent-drop grinding with other solvents (chloroform, cyclohexane, 
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DMSO, ethyl acetate, methanol, toluene, and water) affords mixtures of NTCDA and 2-
methyl-4-nitroaniline.  However, heating of a mixture above the melting point of 2-
methyl-4-nitroaniline results in formation of 1a and additional heating at 150 °C for three 
hours affords 1b.  These observations suggest that formation of 1a is a key step for 
facilitating or even controlling the condensation process. 
The progression of the reaction can be monitored in the DSC (Figure 2.6.).  The 
DSC trace for 1a (shown on the right in Figure 2.6.) exhibits only one phase transition as 
the cocrystal melts and converts to the diimide 1b.  However, the DSC trace of a mixture 
(shown on the left in Figure 2.6.) shows two phase transitions.  Once the mixture reaches 
the melting point of the 2-methyl-4-nitroaniline (130 ºC) the first phase transition occurs.  
Here the amine melts and recrystallizes to form the cocrystal.  The second phase 
transition corresponds to the melt of the cocrystal at ca. 155 ºC.  After the melt of the 
cocrystal the dehydration occurs and the resulting solid is the diimide.  The color changes 
due to the phase transitions from both 1a and the physical mixture (Figure 2.7) can be 
monitored in a Mel-temp® device.  1a (purple) becomes orange after heating past 160 ºC 
and the yellow mixture turns purple as it converts to 1a.  1a then becomes orange as it 
converts to the diimide.   
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Figure 2.6. DSCs highlighting the phase transitions that occur for mixtures (left)  
and cocrystal (right).  All temperatures are in degrees Celsius. 
 
 
Figure 2.7. Color changes for reaction 1  
 
2.2.1.2. Analysis of Crystal Structures  
The 2-methyl-4-nitroaniline NTCDA cocrystal, 2:1 (1a) crystallizes in the 
space group Pī.  The basic supramolecular unit contains two 2-methyl-4-nitroaniline 
molecules and one NTCDA molecule.  The self complementary hydrogen bonding 
capability of 2-methyl-4-nitroaniline between the primary amine donor and nitro acceptor 
moieties is the primary driving force sustaining 1a.  The amino moieties that hydrogen 
bond to neighboring nitro moieties allow for an NH???O hydrogen bond distance of 
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2.946(6) Å  [N22-H22B???O21: N???O 2.946(6) Å, H???O 2.178 Å, N-H???O 145.47º] 
resulting in infinite chains of 2-methyl-4-nitroaniline molecules along the b-axis.  The 
chains are related by an inversion center located in the center of an NTCDA molecule 
positioned between two 2-methyl-4-nitroaniline chains.  The centroid-plane distance 
between the 2-methyl-4-nitroaniline and NTCDA is ca. 3.32 Ǻ, which is within the 
typical π-π interaction range and further supports the charge transfer interaction.  The 
carbonyl carbon atom of the NTCDA and the amine nitrogen atom of the 2-methyl-4-
nitroaniline are separated by only 3.42 Ǻ, i.e. well within the 4.2 Ǻ limit of the 
topochemical postulate.57, 58  The intermolecular interactions sustaining 1a are shown in 
Figure 2.8.  The hydrogen bonding and charge transfer interactions exhibited by 1a 
collectively generate a lattice that can be envisioned as two chains of 2-methyl-4-
nitroaniline molecules with NTCDA molecules inserted in between the chains stacking in 
an AABAAB fashion as is shown in Figure 2.9.  Furthermore, this 2:1 cocrystal supports 
the required stoichiometry and conformation for the topochemical reaction.    
 
Figure 2.8. Intermolecular interactions sustaining 1a.   1a obeys the topochemical 
postulate as the shortest distance between the nitrogen atoms of the amine 
moieties and the carbon atoms of the carbonyl moieties is 3.42Ǻ. 
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Figure 2.9. Crystal packing of 1a viewed down the c-axis 
 
Heating the cocrystal and recrystallizing the resulting imide from DMSO 
produces the solvated diimide of 1b shown in Figure 2.10. and 2.11.  There are three 
independent diimides and one DMSO molecule in the asymmetric unit.  Diimide A 
(Figure 2.12. red) interacts via CH???π from the center of the molecule to the central π 
region of neighboring diimide C (Figure 2.12. green) with a CH to ring centroid distance 
of 3.52 Å.  Diimide B (Figure 2.12. blue) is held in position via a CH???π interaction of 
3.21 Å sustained between the central CH region and the aromatic benzene ring of 
neighboring diimide A (Figure 2.12. red).  Diimides A and C continue in infinite chains 
parallel to the b-axis, packing in an alternating ABAB motif.  Diimide B also forms 
infinite chains along the b-axis; however, the cavity between chains is filled by two 
equivalent DMSO molecules.  Diimide B and DMSO also pack in an alternating ABAB 
motif.  The dihedral angles of diimides A, B, and C are 82.41 º, 85.12 º, and 79.18 º, 
respectively. 
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Figure 2.10. Molecular structure of diimide 1b as generated  
via recrystallization of 1b from DMSO 
 
 
 
 
 
Figure 2.11. Crystal packing of 1b DMSO solvate (3:2)  
obtained via recrystallization from DMSO 
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Figure 2.12. Color coded crystal packing of 1b?DMSO:  
diimide A = red, diimide B = blue, diimide C = green, DMSO = yellow 
 
 
2.2.2. Reaction 2  3-aminobenzoic acid and NTCDA  
2.2.2.1. Synthetic Techniques and Characterization  
NTCDA and 3-aminobenzoic acid also form a purple cocrystal (2a) via solvent-
drop grinding with DMF.  Solvent-drop grinding with other solvents leads to mixtures of 
starting materials.  Attempts at crystallization resulted in the formation of the less 
reactive 1,4-dioxane solvate of the cocrystal, 2a?1,4-dioxane, shown in Figure 2.16.    
The solid-state UV-Vis spectrum of 2a, shown in Figure 2.13., exhibits a broad band at 
550 nm which is consistent with a charge-transfer complex.  Furthermore, the distance 
between the reactive moieties (amine nitrogen and the carbonyl) was 3.14 Å. Therefore 
2a also obeys the topochemical postulate as it converts to diimide 2b after heating for 24 
hours at 200 °C in 99% yield.  Interestingly, the cocrystal also undergoes dehydration to 
the corresponding diimide after a few days under ambient conditions.  Crystallization 
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attempts of 2b were arduous due to the low solubility of the diimide in many common 
organic solvents.  However, 2b can be recrystallized from pyridine as the pyridine solvate 
of the 1:2 complex of 4 with pyridine.   
 
 
Figure 2.13. UV-Vis spectrum of DMF solvent-drop grind versus  
3-aminobenzoic acid, methanol solvent-drop grind, and NDTCA 
 
The dehydration of 2a to 2b was also monitored in the DSC; however, it was not 
as straightforward as the previously described dehydration of 1a to 1b.  The DSC (shown 
in Figure 2.14., left) indicates that the cocrystal melt occurs at ca. 127 ºC; however, the 
first phase transition of the mixture (shown in Figure 2.14., right) does not occur until ca. 
155 ºC.  The melting points do not correlate due to the melting point of the cocrystal 
occurring before the melt of the lowest melting starting material (3-aminobenzoic acid).  
Thus, the DSC of the mixture is a unique case highlighting the ability of the material to 
melt, rearrange to the cocrystal which instantaneously melts and dehydrates to complete 
the condensation reaction generating 2b.  The array of colors that are seen for this 
reaction (Figure 2.15.) are similar to that of reaction 1 where the same anhydride is 
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employed and the cocrystal is a purple charge transfer complex, however, the resulting 
imide (2b) is gold whereas 1b is orange.   
 
  Figure 2.14. DSCs highlighting the phase transitions that occur for cocrystal (left)  
and mixture (right).  All temperatures are in degrees Celsius 
 
 
Figure 2.15.  Colors of 3-aminobenzoic acid, NTCDA, dry grinding product,  
DMF grinding product, and final imide 2b 
 
2.2.2.2. Analysis of Crystal Structures  
The 3-aminobenzoic acid NTCDA cocrystal 1,4-dioxane solvate (2a?1,4-
dioxane) crystallizes in a 2:1:1 stoichiometry in the space group Pī with two molecules 
of 3-aminobenzoic acid, one molecule of NTCDA, and one molecule of 1,4-dioxane in 
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the asymmetric unit.  Similarly to 1a, the primary amine molecule assists in the formation 
of infinite chains, however, in 2a?1,4-dioxane the primary amine molecules require the 
insertion of a 1,4-dioxane molecule to sustain the chain.  The 3-aminobenzoic acid 
molecules do not favor the head to tail chain most likely because of the meta-positioning 
of the amino moiety.  The preferred orientation is a centrosymmetric dimer centered 
above and below the NTCDA molecule.  The 3-aminobenzoic acid centrosymmetric 
dimer is sustained via NH???O=C [N11-H11A???O11: N???O 3.066(4) Å, H???O 2.245 Å, 
N-H???O 155.15º] hydrogen bonds which link to additional dimers through 1,4-dioxane 
molecules [O12-H12???O31: O???O 2.643(3) Å, H???O 1.807 Å, N-H???O 172.36º] to 
generate chains that stack along the a-axis. As shown in Figure 2.16., NTCDA molecules 
stack in between the 3-aminobenzoic acid dimers with an amine-carbonyl distance of ca. 
3.14 Å.  The distance between these reactive groups is much less than the requirement for 
the topochemical postulate therefore the condensation reaction should occur.  In addition, 
the distance measured between a centroid in the center of the 3-aminobenzoic acid dimer 
and the plane of a neighboring NCDTA molecule was found to be 3.17 Å.  This distance 
is well within the typical π-π interaction and further supports the potential for charge 
transfer interactions.  The 1,4-dioxane molecules can be removed with heat to obtain 
anhydrous 2a.  However, a single crystal structure of the anhydrous cocrystal could not 
be obtained as the sample did not retain crystallinity after heating.            
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Figure 2.16. Crystal packing of cocrystal 2a?1,4-dioxane 
 
Attempts at crystallization of the 3-aminobenzoic acid NTCDA diimide (2b) 
resulted in a pyridine solvate of the 1:2 complex of 2b with pyridine.  The solvate of 2b 
crystallizes in the space group Pī .  The basic supramolecular unit is comprised of one 
diimide, two pyridine molecules hydrogen bonded to the carboxylic acid moieties of the 
diimide, and one disordered pyridine molecule centered in the cavity between two 
diimide molecules.  The crystal packing is sustained by various weak interactions 
including multiple CH???O interactions such as pyridyl CH to carbonyl of the imide (ca. 
3.25 Å) and C=O of the carboxylic acid to the central CH region of the imide (ca. 3.49 
Å).  As shown in Figure 2.17. and 2.18., additional weak interactions (π system overlap 
of 6-memebered aromatic rings) sustain the diimide molecules as they progress along the 
c-axis.  The dihedral angle between the naphthyl and benzene rings of the diimide is 
79.04º.   
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Figure 2.17. Simplified crystal packing of the 1:2 complex of 2b with pyridine 
 
 
 
Figure 2.18.  Crystal packing of the pyridine solvate of the 1:2 complex of 2b with pyridine   
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2.2.3. Reaction 3  2-methyl-4-nitroanilne and pyromellitic anhydride       
2.2.3.1. Synthetic Techniques and Characterization  
 Interestingly, solvent-drop grinding with DMF of 2-methyl-4-nitroaniline and 
pyromellitic anhydride does not give a purple cocrystal.  The cocrystal (3a) is orange 
most likely due to the reduction of the conjugated ring system from naphthyl (NTCDA) 
to benzyl (pyromellitic anhydride).  3a can be synthesized from various techniques 
including solvent-drop grinding with DMF or methanol, solution crystallization, and 
grinding with heating.  The UV-Vis absorbance maximum for 3a is ca. 400 wavenumbers 
which is expected for an orange complex, but is similar to the absorbance of the π 
systems used for the reactants and therefore is not included.  The single crystal structure 
of 3a illuminates the bond distances from the amino group to the carbon of the carbonyl 
group on a neighboring anhydride.  Based upon the topochemical postulate, the distance 
between the reactive groups in 3a (ca. 3.78 Å) is within range for the condensation 
reaction to occur.  Furthermore, 3a can be converted cleanly to 3b in approximately 80 % 
yield after heating for ca. 2 days at 150 ºC.  The different solid-state reaction rates of 1a, 
2a?1,4-dioxane solvate, the unsolvated form of 2a, and 3a is presumably an artifact of 
crystal packing.                     
 DSC traces for 3a and a mixture of the reactants are shown in Figure 2.19. with 
3a on the left and the mixture on the right.  The DSC trace of the cocrystal shows two 
phase transitions at 138 ºC and 247 ºC.  The literature melting point of 2-methyl-4-
nitroaniline (130 ºC) is similar to the first phase transition suggesting that either the 
cocrystal may begin to disassociate at a similar temperature or some excess amine may be 
present.  Additional characterization techniques (FT-IR, PXRD calculated vs. 
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experimental) confirm that the solid is at least 90% cocrystal.  Thus it is likely that the 
melting point of the cocrystal is merely a few degrees higher than the melting point of 2-
methyl-4-nitroaniline.  3a continues to rearrange on the molecular level in the DSC as it 
converts to the diimide (3b), indicated by the undulating baseline.  The second phase 
transition at ca. 248 ºC is attributed to the melt of 3b.  The mixture shown on the right in 
Figure 2.19. shows the melt of the amine at ca. 131 ºC followed by a sharp 
recrystallization as the cocrystal (3a)  is formed.  3a then melts around 200 °C and 
rearranges to generate 3b which melts at ca. 243 ºC.  The color changes as the starting 
materials are heated to produce 3a then subsequently to 3b can be followed in the Mel-
temp® device.  Representative vials are shown in Figure 2.20. 
 
 
Figure 2.19. DSCs highlighting the phase transitions that occur for cocrystal (left)  
and mixture (right).  All temperatures are in degrees Celsius. 
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Figure 2.20. Stepwise reaction of 2-methyl-4-nitroaniline and pyromellitic anhydride 
highlighting cocrystal formation (SDG = solvent-drop grind) 
 
 
2.2.3.2. Analysis of Crystal Structures  
 The 2-methyl-4-nitroaniline pyromellitic anhydride cocrystal (3a) crystallizes 
in the space group P21/n.  The basic supramolecular unit is comprised of two 2-methyl-4-
nitroaniline molecules and one pyromellitic anhydride molecule.  As was seen in 1a, the 
2-methyl-4-nitroaniline molecules in 3a form head-to-tail chains sustained by hydrogen 
bonds.  The 2-methyl-4-nitroaniline molecules hydrogen bond via amine-nitro NH???O 
interactions [N12-H12A???O12: N???O 2.943(5) Å, H???O 2.159 Å, N-H???O 148.06 º] that 
translate along the 2-fold axis.  Pyromellitic anhydride molecules are inserted between 
the 2-methyl-4-nitroaniline chains interacting via NH???O hydrogen bonds [N12-
H12B???O22: N???O 3.089(5) Å, H???O 2.307 Å, N-H???O 147.98 º] and N-O???O-C 
interactions (ca. 2.90 Å).  A centroid to plane distance measured between the center of 
the 2-methyl-4-nitroaniline molecule and pyromellitic anhydride plane was found to be 
3.26 Å, which is within the range for π-π interaction.  The distance from the reactive 
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amino group to the carbon of the anhydride carbonyl is ca. 3.78 Å which is within the 
distance requirements set by the topochemical postulate.     
 
 
Figure 2.21. Crystal structure of cocrystal 3a formed between  
2-methyl-4-nitroaniline and pyromellitic anhydride 
 
 
 The diimide 3b, synthesized from the dehydration of cocrystal 3a, crystallizes in 
the space group P21/c.  The asymmetric unit contains half of the molecule with the 
inversion center located at its center.  3b translates along the b-axis at an angle such that 
the translation about the 21 screw axis results in a herringbone motif.  The interplanar 
spacing between the central region of the diimide molecules is ca. 3.28 Å and is sustained 
mainly via CH???O interactions, specifically from CH???O=C (ca. 3.34 Å) and CH???O-N 
(ca.3.10 Å).  The dihedral angle between the central and exterior rings of the diimide is 
75.82 º.   
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Figure 2.22. Molecular structure of diimide 3b 
 
 
Figure 2.23.  Crystal packing of 3b 
 
 
2.2.4. Reaction 4  1-adamantylamine and phthalic anhydride  
2.2.4.1. Synthetic Techniques and Characterization 
When performing synthetic reactions the experimental outcome is not always 
what is expected.  Reaction 4 was an exemplary case where a synthetic pathway led to 
the unexpected isolation of the condensation reaction intermediate instead of the imide.  
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The amic-acid condensation intermediate of 1-adamantylamine and phthalic 
anhydride (4a) has been isolated from traditional solution methods for this particular 
reaction in 48% yield;59 however, in the solid-state under the conditions described herein, 
the intermediate can be isolated cleanly in ca. 90 % yield.  4a is synthesized via solvent-
drop grinding of 1-adamanytlamine and phthalic anhydride together in a stoichiometric 
ratio followed by heating of the solid at 110 ºC for 1.5 hours.  Suitable quality single 
crystals for of 4a single crystal X-ray analysis were obtained from recrystallization of the 
heated material.  The intermediate can then be heated further at 120 ºC for ca. 1 week to 
afford the imide 4b.  4b was previously reported in the literature and appears in the CSD 
under refcode: QUSKUK.     
The DSC of 4a shows two phase transitions (Figure 2.24.).  The initial phase 
transition corresponds to the literature melting point of 185 ºC.59  The breadth of the 
second phase transition is indicative of an impure material but it could also be caused by 
degradation after the melt of 4a.  An additional factor that must be considered is that the 
imide condensation reaction is reversible.  4a can hydrolyze due to excess moisture in the 
air producing phthalic acid and 1-adamantylamine which melt at 210 ºC and 205 ºC, 
respectively.  Therefore the second phase transition may be caused in part by the 
presence of either material.  Heating 4a in an oven in the solid-state can result in the 
formation of 4b following the conditions previously mentioned.  A DSC of the solid after 
heating confirms the synthesis of 4b as the DSC trace (Figure 2.25.) has one phase 
transition at ca. 142 ºC which corresponds to the literature melting point of 140 ºC.60  
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Figure 2.24. DSC of 4a  
 
 
Figure 2.25. DSC of 4b  
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2.2.4.2. Analysis of Crystal Structures 
 The intermediate 4a formed from the reaction of 1-adamantylamine and 
phthalic anhydride crystallizes with one molecule in the asymmetric unit.  4a 
crystallizes in the space group P21/c and is primarily sustained by an atypical 2-point 
recognition dimer.  The dimer is centrosymmetric and incorporates two carboxylic acid 
moieties and the carbonyl of the adjacent secondary amide.  The carboxylic acid-carbonyl 
OH???O hydrogen bond distance is 2.682(3) Å [O12-H12???O11: O???O 2.682(3) Å, H???O 
1.868 Å, N-H???O 171.61 º] and the carbonyl-carbonyl intramolecular bond distance is ca. 
3.01 Å.  Additional molecules of 4a are generated by a 21 rotation around the b-axis and a 
reflection about the c-axis followed by a translation.  A depiction of the crystal packing is 
shown in Figure 2.26. 
To determine the probability of this particular synthon formation, a CSD search 
was conducted.  The CSD revealed 803 entries that contained a carboxylic acid and a 
secondary amide.61  However when the search was restricted by two criteria: the moieties 
must both be on the same molecule and the amide must also be ortho to the acid the 
number of entries reduced to 43.  Of those 43 entries only 1 was sustained by the same 
synthon that is shown.  If the amide is not restricted to a secondary amide then an 
additional 6 entries are revealed.  Based upon the relatively low number of entries in the 
CSD, the supramolecular heterosynthon highlighted in Figure 2.26. can be considered 
rare in the presence of carboxylic acid and amide moieties.        
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Figure 2.26. Crystal packing of 4a 
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Table 2.2. Crystal structure parameters for cocrystals 1a-4a 
 
 
 
 
 
 
 1a 1b 2a 2b 3a 3b 4a 
Chemical 
formula 
(C7H8N2
O2)2  
C14H4O6 
 
(C28H16N4
O8)3?(C2H
6SO)2 
 
(C7H7NO
2)2   
C14H4O6    
C4H8O2    
(C28H14N2
O8)0 5             
C5H5N   
C5H5N 
(C7H8N2O
2)2  
C10H2O6 
C24H14N4
O8 
 
C18H21NO
3 
Form 
weight 
794.53 1765.60 824.58 726.66 980.41 486.39 299.36 
Crystal 
System 
Triclini
c 
Triclinic Triclinic Triclinic Monoclini
c 
Monoclini
c 
Monoclini
c 
Space 
group 
Pī Pī Pī Pī P21/n P21/c P21/c 
a (Å) 8.307(2) 11.309(3) 7.006(2) 7.1569(14) 7.373(3) 8.207(4) 13.045(7) 
b (Å) 8.894(2) 12.204(4) 9.990(3) 8.1962(17) 13.969(6) 16.594(8) 9.761(5) 
c (Å) 9.179(2) 16.403(5) 10.190(4) 15.448(3) 11.025(3) 7.753(4) 12.785(7) 
α (o) 110.230
(4) 
89.651(6) 83.081(7) 98.287(4) 90 90 90 
β (o) 103.873
(5) 
77.343(5) 81.603(7) 102.202(4) 93.695(8) 92.169(9) 110.402(8
) 
γ (o) 97.109(
5) 
64.623(6) 76.866(8) 96.564(4) 90 90 90 
Vol (Å3) 601.6(3) 1985.8(10
) 
684.2(4) 866.6(3) 1133.2(7) 1055.1(8) 1525.7(14
) 
Dcal (g cm-
3) 
1.580 1.476 1.530 1.392 1.531 1.531 1.303 
Z 1 1 1 1 2 2 4 
Reflections 
collected 
2412 8259 2810 3645 2623 2622 8766 
 
Independen
t reflections   
1923 6472 2188 2852 1361 985 3420 
Observed 
reflections    
996 1558 1549 1549 986 724 1471 
T (K) 100 100 100 100 100 100 293 
R1 0.0788 0.0915 0.0677 0.0869 0.0593 0.0766 0.0535 
wR2 0.2227 0.2108 0.1546 0.2019 0.1405 0.1667 0.1242 
GOF 1.042 0.741 1.047 1.018 0.884 1.095 0.896 
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2.2.5. C3S3 for the General Formation of Imides      
Whereas C3S3 can only be confirmed in the three reactions for which isolation of 
an anhydride-amine cocrystal occurred, conversion of solvent-ground anhydride-amine 
mixtures to imides was a more general occurrence.  32 out of the total 49 reactions 
resulted in imide formation.  17 reactions did not produce an imide.  A summary of the 
results is presented in Table 2.1.  Solvent-drop grinding followed by heating therefore 
appears to represent a feasible and general methodology for the preparation of imides.  In 
the following segments the reaction purity and percent yield will be addressed via DSC 
and 1HNMR.  Additionally, the ability to monitor the reactions by FT-IR and PXRD will 
be discussed as well as the possibility of cocrystal formation in situ in the DSC.   
 
2.2.5.1. Imide Purity  
 Initial monitoring for reaction completion included FT-IR and PXRD 
measurements.  Additional characterization was conducted on the 32 successful imide 
formation reactions via DSC and 1HNMR.  A typical DSC scan was 10 ºC/min from ca. 
30 ºC-350 ºC.  Analysis of the 32 samples indicated that 20/32 melted below 350 ºC; 
however, 6/32 showed no clear melt in the DSC which is most likely indicative of imide 
formation due to the lack of melt from either starting material.  Unfortunately 13/32 
samples gave either multiple or broad phase transitions, reducing the number of high 
purity reactions to 19.  However, literature melting points were compared to experimental 
DSC melts when possible resulting in 7/7 correlating melting points.  A potential cause 
for some of the low purity reactions could be the ratio at which the reactions were 
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conducted.  5 of the reactions were performed in the presence of excess amine (PA4 or 
PA5) in an attempt to terminate the potentially polymeric reaction with free amines.       
 1HNMR characterization was attempted on the 32 samples; however, due to the 
limited solubility of some of the imides, six (PA1+AA2, PA2+AA2, PA2+AA5, 
PA2+AA6, PA4+AA1, PA4+AA4) of the 1HNMR’s could not be obtained.  In general 
the purity of the imides was relatively high based on the low incidence of occurrence of 
excess signals in the 1HNMR.  In reactions PA5+AA6, PA4+AA5, and PA4+AA2 the 
purity level appears lower but the additional peaks can be associated with the excess 
amine that was input into the reaction.  The purity could perhaps be improved by 
following the heating with a washing step with an organic solvent such as methanol.  
Additionally, six samples (PA1+AA3, PA1+AA5, PA2+AA3, PA4+AA3, PA5+AA4, 
PA7+AA4) had a signal at ca.10 ppm which is indicative of the amic-acid reaction 
intermediate.  Due to the reversibility of the reaction, the presence of some of the 
intermediate is not unlikely, especially after long term sample storage.62  The six samples 
that contained some intermediate could most likely be converted to the imide cleanly 
upon further heating.  A summary of the DSC and 1HNMR data is presented in Table 2.3. 
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Table 2.3.  Summary of DSC and 1HNMR data (S.M. = starting materials, int. = intermediate, 
Lit. = literature value of melting point) 
Reactants DSC Mixture DSC Imide Melt Lit. Imide 1HNMR  Input 
PA1+AA1 S.M. to Cocrystal to Imide >350 N/A imide 2:1 
PA1+AA2 S.M. to Cocrystal to Imide 247 N/A insoluble 2:1 
PA1+AA3 S.M.  137-broad N/A int. present 1:1 
PA1+AA4 S.M. 202 20263 imide 1:1 
PA1+AA5 S.M. to Imide 263 N/A int. present 2:1 
PA2+AA1 S.M. to Cocrystal to Imide >350 N/A imide 2:1 
PA2+AA2 S.M. to Imide 237-broad N/A insoluble 2:1 
PA2+AA3 S.M. to Imide 230 23064 int. present 1:1 
PA2+AA4 S.M. to Cocrystal to Imide 289 29065 imide 1:1 
PA2+AA5 S.M. >350 N/A insoluble 2:1 
PA2+AA6 S.M. 350 N/A insoluble 1:1 
PA3+AA2 S.M. >350 N/A impurities 2:3 
PA3+AA3 S.M. >350 N/A impurities 3:1 
PA3+AA4 S.M. to Imide 276-broad N/A imide 1:3 
PA4+AA1 S.M. to Cocrystal to Imide >350 N/A insoluble 1:1 
PA4+AA2 S.M. >350 N/A excess amine 5:1 
PA4+AA3 S.M. 268 N/A int. present 1:2 
PA4+AA4 S.M. 246-broad 24766 insoluble 1:2 
PA4+AA5 S.M. 350-broad N/A excess amine 5:1 
PA4+AA6 S.M. to Cocrystal to Imide 285 N/A imide 1:1 
PA5+AA1 S.M. 320-broad N/A excess amine 5:1 
PA5+AA2 S.M. 233-broad N/A imide, low conc. 1:1 
PA5+AA3 S.M. to Cocrystal to Imide 210-broad N/A minor impurities 1:2 
PA5+AA4 S.M. to Imide 240 25067 int. present 1:2 
PA5+AA5 S.M. 298-broad N/A excess amine 5:1 
PA5+AA6 S.M. >350 N/A excess amine 5:1 
PA6+AA3 S.M. to Imide 242-broad N/A minor impurities 1:1 
PA6+AA4 S.M. 142 14060 imide 1:1 
PA7+AA2 S.M. >350 N/A minor impurities 1:1 
PA7+AA3 S.M. 206-broad N/A minor impurities 1:1 
PA7+AA4 S.M. 154 17268 int. present 1:1 
PA7+AA5 S.M. >350 N/A imide, low conc. 1:1 
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2.2.5.2. Monitoring the Condensation Reaction via DSC       
The DSC has been an invaluable tool for the discovery and development of C3S3.  
The DSC can illuminate the phase transformation of a mixture of an amine and an 
anhydride to an imide by first capturing the melt of the lower melting component as it 
converts to the cocrystal then showing the cocrystal melt as it converts to the imide.  
Examples illustrating the process were presented in Figures 2.6, 2.14, and 2.19.  With 
these details in mind, two questions are posed: can a cocrystal that could not be made by 
solvent-drop grinding be made in situ after melting the lower melting starting material in 
the DSC? Also, can the DSC run produce an imide that had otherwise failed from the 
synthetic method of applying heat in an oven? 
 To address the initial question, stoichiometric mixtures of starting materials were 
weighed out and ground together by hand without solvent.  The physical mixtures of 46 
reactions were analyzed via DSC at a scan rate of 10 ºC/min from ca. 30 ºC to 350 ºC.  
The results from this screen are shown in Table 2.3.  Many of the DSC traces showed 
phase transitions corresponding to the melts of the individual starting materials and some 
were followed by a melt of the imide.  Interestingly, seven of the physical mixtures 
showed a phase transition that occurred after the melt of the lower melting component 
and did not correspond to either starting material or to the imide.  Based upon the 
prototypal DSC traces from reactions 1-3, this phase transition is most likely the melt of a 
cocrystal, thus revealing 4 additional condensation reactions controlled by a cocrystal 
intermediate. 
 In situ cocrystal formation was possibly observed for reactions of 3-aminobenzoic 
acid with phthalic anhydride (PA2-AA4), 1,4-phenylenediamine with NTCDA (PA4-
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AA1), 1,4-phenylenediamine with 1,8-naphthalic anhydride (PA4-AA6), and 1,5-
naphthalenediamine with maleic anhydride (PA5-AA3).  Figure 2.27. illustrates the 
mixture of 3-aminobenzoic acid and phthalic anhydride.  The melting point of phthalic 
anhydride is 130 ºC, which correlates to the first phase transition of the DSC.  The 
recrystallization immediately following that transition is believed to be the cocrystal 
formation which is quickly followed by the melt of the cocrystal.  The last sharp phase 
transition occurs at 289 ºC and is associated with the melt of the imide. 
 
 
Figure 2.27. DSC trace of mixture of 3-aminobenzoic acid and phthalic anhydride 
  
 Figure 2.28. highlights the DSC trace of the mixture of 1,4-phenylenediamine and 
NTCDA.  Of the seven anhydrides employed in this study, NTCDA appears to be the 
strongest supporter of the supramolecular synthon as it is utilized in the formation of two 
out of the three cocrystals, thus considering the formation of additional cocrystals with 
NTCDA is quite likely.  The melting point of the amine is 145 ºC which can be attributed 
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to the first endothermic melt.  The initial exothermic phase transitions that occurs at ca. 
100 ºC is unique to this sample and may be an artifact of the amine.  However, after the 
melt of 1,4-phenylenediamine a recrystallization occurs wherein the cocrystal is most 
likely formed.  The cocrystal is then heated until melting at ca. 257 ºC.  The DSC does 
not show a melt for the imide as the melting point is greater than 350 ºC.   
 
Figure 2.28. DSC trace of a mixture of 1,4-phenylenediamine and NTCDA 
 
 The DSC trace of a mixture of 1,4-phenylenediamine and 1,8-naphthalic 
anhydride is shown in Figure 2.29.  The initial sharp phase transition can be attributed to 
the melt of 1,4-phenylenediamine which melts at 145 ºC.  The recrystallization that occurs 
thereafter is associated with cocrystal formation.  The melt at 178 ºC does not correspond 
to either starting material or the imide and is therefore most likely the melt of the 
cocrystal.  Once the cocrystal melts the condensation reaction occurs generating the 
imide.  The melting point of the synthesized imide was 284 ºC which is within a few 
degrees of the final phase transition from the mixture. 
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Figure 2.29. DSC trace of a mixture of 1,4-phenylenediamine and 1,8-naphthalic anhydride 
 
Figure 2.30. depicts the DSC trace of a mixture or 1,5-naphthalenediamine and 
maleic anhydride.  Maleic anhydride was the lowest melting anhydride but also proved to 
be the most reactive as solvent-drop grinding with DMF or DMSO lead to imide 
formation in many reactions.  Due to solvent-drop grinding generating the imide instead 
of the cocrystal, the potential for isolation of a cocrystal was low.  However, using a 
mixture of anhydride and amine may have generated a cocrystal in situ in the DSC.  The 
first phase transition corresponds to the melt of maleic anhydride (51 ºC).  Unlike the 
previous examples, only a subtle recrystallization is present after the melt.  But a phase 
transition that does not correlate to either starting materials occurs at 140 ºC and is 
therefore attributed to the melt of the cocrystal.  The final phase change at 209 ºC is 
consistent with the melt of the imide.    
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Figure 2.30. DSC trace of a mixture of 1,5-naphthalenediamine and maleic anhydride 
 
 The possibility of synthesizing an imide that could not be generated in the oven 
during the temperature ramp run in the DSC was also addressed.  Unfortunately, analysis 
of the 17 DSC traces of the mixtures (PA1+AA6, PA1+AA7, PA2+AA7, PA3+AA1, 
PA3+AA5, PA3+AA6, PA3+AA7, PA4+AA7, PA5+AA7, PA6+AA1, PA6+AA2, 
PA6+AA5, PA6+AA6, PA6+AA7, PA7+AA1, PA7+AA6, PA7+AA7) concluded that no 
new imides were generated as there were no unidentifiable phase transitions.   
 
2.2.5.3. Analysis of Cocrystals and Imides via PXRD  
 PXRD diffractograms were collected at two points during the reaction: once after 
solvent-drop grinding and again after heating.  For the three reactions described in detail 
in sections 2.2.1-2.2.3 the PXRD diffractogram from the bulk ground cocrystal sample 
could be compared to the calculated PXRD diffractogram from the single crystal 
structure.  An example of this is featured in Figure 2.31.  The limitation of PXRD of the 
  99
ground material is that without the calculated diffractogram, it is unclear what the new 
diffractogram corresponds to.  The calculated diffractogram for the imide can be 
compared to the resulting imide to confirm bulk sample reaction completion, such as in 
Figure 2.32.  However, to employ PXRD to confirm imide formation, a calculated pattern 
is also required.  Therefore, coupled with single crystal analysis of the imide, PXRD can 
be a powerful tool for analysis of a C3S3 type reaction. 
 
 
Figure 2.31. PXRD diffractograms of eight solvent drop grinds,  
starting materials, and calculated cocrystal 
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Figure 2.32. PXRD diffractograms of solvent drop grinds after 
heating for ca. 2 days at 150 ºC 
 
2.2.5.4. Monitoring the Condensation Reaction via FT-IR  
 Monitoring the C3S3 reaction by FT-IR was an excellent method for determining 
cocrystal formation after solvent-drop grinding due to the predictable shift in strong 
carbonyl peaks to higher wavenumbers coupled with variable shifts in the NH2 region.  
An exemplary case is shown in Figure 2.33. After heating the ground solid in the oven 
the FT-IR spectrum was again collected and examined.  Imide formation was easily 
monitored by further examination of two specified regions.  Disappearance of the NH2 
peaks and a shift to lower wavenumbers for the carbonyl peak (typically ca. 40 
wavenumbers lower), shown in Figure 2.34., was indicative of imide formation.     
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Figure 2.33. Infrared spectra (FT-IR) of NTCDA and 2-methyl-4-nitroaniline 
DMF solvent drop grind (red) compared to anhydride (purple) and amine (blue) 
 
 
 
Figure 2.34. FT-IR of imide (red) with starting materials 
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For reactions where there was no cocrystal formation from the solvent-drop 
grinding the FT-IR spectra appeared as compilations of the respective amine and 
anhydride starting material.  For reaction 4 where the solvent-drop grinding produced the 
amic-acid reaction intermediate, i.e. the anhydride ring opens affording a carboxylic acid 
and the amine covalently binds to the carbonyl producing a secondary amide, the 
carbonyl peak in the FT-IR spectrum is shifted to a lower wavenumber (Figure 2.35.) 
which could be confused with the imide formation, however, additional heating shifts the 
carbonyl region even lower by ca. 30 wavenumbers as shown in Figure 2.36. 
 
 
Figure 2.35. FT-IR of intermediate (red) formed from phthalic anhydride 
 (purple) and 1-adamantylamine (green) 
 
 
  103
 
Figure 2.36.  FT-IR of imide (red) generated from 1-adamantylamine and phthalic anhydride 
 
 
    
2.3. Conclusions 
 Cocrystal controlled solid-state synthesis is an invaluable synthetic methodology 
for the generation of new molecules with very little solvent waste and with high yield.  
Additionally, the incorporation of cocrystallization into organic synthesis is exemplary 
evidence for the vast utility of cocrystals.  Of the 49 reactions attempted in this study 32 
resulted in imide formation while 17 showed no reactivity.  3 of the 32 also proved to be 
controlled by a reactive cocrystal intermediate that, once heated, dehydrated to form the 
imide.  The formation of the cocrystals was facilitated via the well established technique 
of solvent-drop grinding.  Once the cocrystals were generated they were heated until the 
condensation reaction was completed.  The temperatures and reaction times varied 
depending upon the starting materials, however, the sample was always heated above the 
melting point of the lowest melting component.  Interestingly, a total of 4 additional 
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cocrystals may have been isolated from heating a mixture of the reactants in the DSC, 
illustrating that the cocrystal can also be generated in situ as a reactive intermediate that 
can ultimately lead to imide formation.  
The development of novel materials via C3S3 with the isolation of a cocrystal as a 
reactive intermediate provides additional insight into the method by which the reaction 
occurs.  The greater understanding of the solid-state synthesis reaction of imides gained 
in this study serves as a model to be applied to other solid-state or solution based 
reactions.  The expansion of the field of solid-state organic synthesis will lead to the 
reduction of hazardous waste production, increase reaction yields, and make the overall 
synthetic process cheaper and more environmentally friendly.   
 
2.4. Materials and Methods   
2.4.1. Materials 
 All materials were used as received without further purification from Sigma-
Aldrich or Alfa Aesar.   
 
2.4.2. Synthetic Methods 
 A typical reaction involved solvent-drop grinding with chloroform, cyclohexane, 
DMSO, DMF, ethyl acetate, methanol, toluene, and water for ca. 4 minutes by hand with 
an agate mortar and pestle.  The solid was then transferred to a glass vial and heated in an 
oven at a temperature above the melting point of the lowest melting component to 
facilitate imide formation.  Reaction conditions for each of the 32 successful imide 
formations are provided below:  
  105
2-methyl-4-nitroaniline and NTCDA (PA1+AA1): 
 100 mg (0.66 mmol) of 2-methyl-4-nitroaniline and 88mg (0.33mmol) of NTCDA 
were ground with ca. 20μL of DMF by hand in an agate mortar and pestle for 4 minutes.  
The resulting purple cocrystal was then heated for 3 hours at 180 ºC to produce the imide.  
The imide was synthesized in ca. 75% yield.   
2-methyl-4-nitroaniline and pyromellitic anhydride (PA1+AA2): 
 100 mg (0.66 mmol) of 2-methyl-4-nitroaniline and 72 mg (0.33 mmol) of 
pyromellitic anhydride were ground with ca. 20μL of DMF by hand in an agate mortar 
and pestle for 4 minutes.  The resulting orange cocrystal was then heated for 50 hours at 
150 ºC to produce the imide.  The imide was synthesized in ca. 80% yield.   
2-methyl-4-nitroaniline and maleic anhydride (PA1+AA3): 
 100 mg (0.66 mmol) of 2-methyl-4-nitroaniline and 64 mg (0.65 mmol) of maleic 
anhydride were ground with ca. 20μL of DMF by hand in an agate mortar and pestle for 4 
minutes.  The resulting solid was then heated for 40 hours at 60 ºC to produce the imide.  
The imide was synthesized in ca. 92% yield.   
2-methyl-4-nitroaniline and phthalic anhydride (PA1+AA4): 
 100 mg (0.66 mmol) of 2-methyl-4-nitroaniline and 98 mg (0.65 mmol) of 
phthalic anhydride were ground with ca. 20μL of DMF by hand in an agate mortar and 
pestle for 4 minutes.  The resulting solid was then heated for 16 hours at 150 ºC to 
produce the imide.  The imide was synthesized in ca. 73% yield.   
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2-methyl-4-nitroaniline and 3,3’,4,4’-biphenyltetracarboxylic acid dianhydride 
(PA1+AA5): 
 100 mg (0.66 mmol) of 2-methyl-4-nitroaniline and 97 mg (0.33 mmol) of 
3,3’,4,4’-biphenyltetracarboxylic acid dianhydride were ground with ca. 20μL of DMF 
by hand in an agate mortar and pestle for 4 minutes.  The resulting solid was then heated 
for 21 hours at 120 ºC to produce the imide.  The imide was synthesized in ca. 87% yield.   
3-aminobenzoic acid and NTCDA (PA2+AA1): 
 100 mg (0.73mmol) of 3-aminobenzoic acid and 98 mg (0.36 mmol) of NTCDA 
were ground with ca. 20μL of DMF by hand in an agate mortar and pestle for 4 minutes.  
The resulting purple cocrystal was then heated for 14 hours at 150 ºC to produce the 
imide.  The imide was synthesized in ca. 99% yield.   
3-aminobenzoic acid and pyromellitic anhydride (PA2+AA2): 
100 mg (0.73mmol) of 3-aminobenzoic acid and 79 mg (0.36 mmol) of 
pyromellitic anhydride were ground with ca. 20μL of DMF by hand in an agate mortar 
and pestle for 4 minutes.  The resulting solid was then heated for 16 hours at 180 ºC to 
produce the imide.  The imide was synthesized in ca. 90% yield.   
3-aminobenzoic acid and maleic anhydride (PA2+AA3): 
100 mg (0.73mmol) of 3-aminobenzoic acid and 72 mg (0.35 mmol) of maleic 
anhydride were ground with ca. 20μL of DMF by hand in an agate mortar and pestle for 4 
minutes.  The resulting solid was then heated for 19 hours at 150 ºC to produce the imide.  
The imide was synthesized in ca. 92% yield.   
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3-aminobenzoic acid and phthalic anhydride (PA2+AA4): 
100 mg (0.73mmol) of 3-aminobenzoic acid and 108 mg (0.73 mmol) of phthalic 
anhydride were ground with ca. 20μL of DMF by hand in an agate mortar and pestle for 4 
minutes.  The resulting solid was then heated for 26 hours at 150 ºC to produce the imide.  
The imide was synthesized in ca. 88% yield.  
 3-aminobenzoic acid and 3,3’,4,4’-biphenyltetracarboxylic dianhydride 
(PA2+AA5): 
100 mg (0.73mmol) of 3-aminobenzoic acid and 107 mg (0.36 mmol) of 
3,3’,4,4’-biphenyltetracarboxylic dianhydride were ground with ca. 20μL of DMF by 
hand in an agate mortar and pestle for 4 minutes.  The resulting solid was then heated for 
14 hours at 150 ºC to produce the imide.  The imide was synthesized in ca. 85% yield.  
3-aminobenzoic acid and 1,8-naphthalic anhydride (PA2+AA6): 
100 mg (0.73mmol) of 3-aminobenzoic acid and 145 mg (0.73 mmol) of 1,8-
naphthalic anhydride were ground with ca. 20μL of DMF by hand in an agate mortar and 
pestle for 4 minutes.  The resulting solid was then heated for 23 hours at 150 ºC to 
produce the imide.  The imide was synthesized in ca. 79% yield.  
melamine and pyromellitic anhydride (PA3+AA2): 
200 mg (1.6 mmol) of melamine and 519 mg (2.4 mmol) of pyromellitic 
anhydride were ground with ca. 20μL of DMF by hand in an agate mortar and pestle for 4 
minutes.  The resulting solid was then heated for 75 hours at 180 ºC and 26 hours at 150 
ºC to produce the imide.  The imide was synthesized in ca. 88% yield.  
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melamine and maleic anhydride (PA3+AA3): 
100 mg (0.79 mmol) of melamine and 26 mg (0.26 mmol) of maleic anhydride 
were ground with ca. 20μL of DMF by hand in an agate mortar and pestle for 4 minutes.  
The resulting solid was then heated for 23 hours at 115 ºC to produce the imide.  The 
imide was synthesized in ca. 79% yield.  
melamine and 1,8-naphthalic anhydride (PA3+AA4): 
100 mg (0.79 mmol) of melamine and 471 mg (2.4 mmol) of 1,8-naphthalic 
anhydride were ground with ca. 40μL of DMF by hand in an agate mortar and pestle for 4 
minutes.  The resulting solid was then heated for 23 hours at 115 ºC to produce the imide.  
The imide was synthesized in ca. 70% yield.  
1,4-phenylenediamine and NTCDA (PA4+AA1): 
100 mg (0.92 mmol) of 1,4-phenylenediamine and 247 mg (0.92 mmol) of 
NTCDA were ground with ca. 20μL of DMF by hand in an agate mortar and pestle for 4 
minutes.  The resulting solid was then heated for 5 hours at 115 ºC to produce the imide.  
The imide was synthesized in ca. 98% yield.  
1,4-phenylenediamine and pyromellitic anhydride (PA4+AA2): 
200 mg (1.8 mmol) of 1,4-phenylenediamine and 81 mg (0.36 mmol) of 
pyromellitic anhydride were ground with ca. 20μL of DMF by hand in an agate mortar 
and pestle for 4 minutes.  The resulting solid was then heated for 68 hours at 180 ºC to 
produce the imide.  The imide was synthesized in ca. 78% yield.  
1,4-phenylenediamine and maleic anhydride (PA4+AA3): 
100 mg (0.92 mmol) of 1,4-phenylenediamine and 45 mg (0.46 mmol) of maleic 
anhydride were ground with ca. 20μL of DMF by hand in an agate mortar and pestle for 4 
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minutes.  The resulting solid was then heated for 23 hours at 115 ºC to produce the imide.  
The imide was synthesized in ca. 71% yield.  
1,4-phenylenediamine and phthalic anhydride (PA4+AA4): 
100 mg (0.92 mmol) of 1,4-phenylenediamine and 98 mg (0.46 mmol) of phthalic 
anhydride were ground with ca. 20μL of DMF by hand in an agate mortar and pestle for 4 
minutes.  The resulting solid was then heated for 5 hours at 115 ºC to produce the imide.  
The imide was synthesized in ca. 85% yield.  
1,4-phenylenediamine and  3,3’,4,4’-biphenyltetracarboxylic dianhydride 
(PA4+AA5): 
100 mg (0.92 mmol) of 1,4-phenylenediamine and 54 mg (0.18 mmol) of 
3,3’,4,4’-biphenyltetracarboxylic dianhydride were ground with ca. 20μL of DMF by 
hand in an agate mortar and pestle for 4 minutes.  The resulting solid was then heated for 
68 hours at 180 ºC to produce the imide.  The imide was synthesized in ca. 82% yield.  
1,4-phenylenediamine and 1,8-naphthalic anhydride (PA4+AA6): 
100 mg (0.92 mmol) of 1,4-phenylenediamine and 183 mg (0.93 mmol) of 1,8-
naphthalic anhydride were ground with ca. 20μL of DMF by hand in an agate mortar and 
pestle for 4 minutes.  The resulting solid was then heated for 64 hours at 150 ºC to 
produce the imide.  The imide was synthesized in ca. 78% yield.  
1,5-diaminonaphthalene and NTCDA (PA5+AA1): 
100 mg (0.63 mmol) of 1,5-diaminonaphthalene and 34 mg (0.12 mmol) of 
NTCDA were ground with ca.10 μL of DMF by hand in an agate mortar and pestle for 4 
minutes.  The resulting solid was then heated for 68 hours at 180 ºC to produce the imide.  
The imide was synthesized in ca. 86% yield. 
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1,5-diaminonaphthalene and pyromellitic anhydride (PA5+AA2): 
100 mg (0.63 mmol) of 1,5-diaminonaphthalene and 137 mg (0.63 mmol) of 
pyromellitic anhydride were ground with ca.20 μL of DMF by hand in an agate mortar 
and pestle for 4 minutes.  The resulting solid was then heated for 107 hours at 120 ºC to 
produce the imide.  The imide was synthesized in ca. 84% yield. 
1,5-diaminonaphthalene and maleic anhydride (PA5+AA3): 
100 mg (0.63 mmol) of 1,5-diaminonaphthalene and 31 mg (0.31 mmol) of 
maleic anhydride were ground with ca.20 μL of DMF by hand in an agate mortar and 
pestle for 4 minutes.  The resulting solid was then heated for 23 hours at 115 ºC to 
produce the imide.  The imide was synthesized in ca. 79% yield. 
1,5-diaminonaphthalene and phthalic anhydride (PA5+AA4): 
100 mg (0.63 mmol) of 1,5-diaminonaphthalene and 47 mg (0.31 mmol) of 
phthalic anhydride were ground with ca.20 μL of DMF by hand in an agate mortar and 
pestle for 4 minutes.  The resulting solid was then heated for 19 hours at 115 ºC to 
produce the imide.  The imide was synthesized in ca. 82% yield. 
1,5-diaminonaphthalene and 3,3’,4,4’-biphenyltetracarboxylic dianhydride 
(PA5+AA5): 
100 mg (0.63 mmol) of 1,5-diaminonaphthalene and 37 mg (0.13 mmol) of 
3,3’,4,4’-biphenyltetracarboxylic dianhydride were ground with ca.20 μL of DMF by 
hand in an agate mortar and pestle for 4 minutes.  The resulting solid was then heated for 
68 hours at 180 ºC to produce the imide.  The imide was synthesized in ca. 77% yield. 
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1,5-diaminonaphthalene and 1,8-naphthalic anhydride (PA5+AA6): 
100 mg (0.63 mmol) of 1,5-diaminonaphthalene and 25 mg (0.12 mmol) of 1,8-
naphthalic anhydride were ground with ca.20 μL of DMF by hand in an agate mortar and 
pestle for 4 minutes.  The resulting solid was then heated for 68 hours at 180 ºC to 
produce the imide.  The imide was synthesized in ca. 73% yield. 
1-adamantylamine and maleic anhydride (PA6+AA3): 
100 mg (0.66 mmol) of 1-adamantylamine and 64 mg (0.66 mmol) of maleic 
anhydride were ground with ca.20 μL of DMF by hand in an agate mortar and pestle for 4 
minutes.  The resulting solid was then heated for 20 hours at 120 ºC to produce the imide.  
The imide was synthesized in ca. 92% yield. 
1-adamantylamine and phthalic anhydride (PA6+AA4): 
100 mg (0.66 mmol) of 1-adamantylamine and 97 mg (0.66 mmol) of phthalic 
anhydride were ground with ca.20 μL of DMF by hand in an agate mortar and pestle for 4 
minutes.  The resulting solid was then heated for 144 hours at 120 ºC to produce the 
imide.  The imide was synthesized in ca. 96% yield. 
triphenylmethylamine and pyromellitic anhydride (PA7+AA2): 
100 mg (0.39 mmol) of triphenylmethylamine and 84 mg (0.66 mmol) of 
pyromellitic anhydride were ground with ca.20 μL of DMF by hand in an agate mortar 
and pestle for 4 minutes.  The resulting solid was then heated for 48 hours at 140 ºC to 
produce the imide.  The imide was synthesized in ca. 77% yield. 
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triphenylmethylamine and maleic anhydride (PA7+AA3): 
100 mg (0.39 mmol) of triphenylmethylamine and 38 mg (0.39 mmol) of maleic 
anhydride were ground with ca.20 μL of DMF by hand in an agate mortar and pestle for 4 
minutes.  The resulting solid was then heated for 23 hours at 115 ºC to produce the imide.  
The imide was synthesized in ca. 86% yield. 
triphenylmethylamine and phthalic anhydride (PA7+AA4): 
100 mg (0.39 mmol) of triphenylmethylamine and 57 mg (0.39 mmol) of phthalic 
anhydride were ground with ca.20 μL of DMF by hand in an agate mortar and pestle for 4 
minutes.  The resulting solid was then heated for 26 hours at 115 ºC to produce the imide.  
The imide was synthesized in ca. 90% yield. 
triphenylmethylamine and 3,3’,4,4’-biphenyltetracarboxylic dianhydride 
(PA7+AA5): 
100 mg (0.39 mmol) of triphenylmethylamine and 113 mg (0.39 mmol) of 
3,3’,4,4’-biphenyltetracarboxylic dianhydride were ground with ca.20 μL of DMF by 
hand in an agate mortar and pestle for 4 minutes.  The resulting solid was then heated for 
48 hours at 140 ºC and 29 hours at 180 ºC to produce the imide.  The imide was 
synthesized in ca. 86% yield. 
Single crystal growth of 2-methyl-4-nitroaniline NTCDA cocrystal (1a): 
Purple single crystals were obtained from dissolving approximately 20 mg of the 
cocrystal in 2 ml of 1,4-dioxane.  The solution was partially covered with parafilm left to 
slowly evaporate under ambient conditions.  Single crystals of 1a were afforded within 
14 days in ca. 20 % yield. 
 
  113
Single crystal growth of 2-methyl-4-nitroaniline NTCDA diimide (1b): 
Orange single crystals were obtained by dissolving approximately 35 mg of 1b in 1 ml of 
DMSO.  The solution was partially covered with parafilm left to slowly evaporate under 
ambient conditions.  Single crystals of 1b?DMSO were afforded within 7 days in ca. 60 
% yield. 
Single crystal growth of 3-aminobenzoic acid NTCDA cocrystal (2a): 
Purple single crystals were obtained from dissolving approximately 20 mg of the 
cocrystal in 2 ml of 1,4-dioxane.  The solution was partially covered with parafilm left to 
slowly evaporate under ambient conditions.  Single crystals of 2a were afforded within 3 
days in ca. 43 % yield. 
Single crystal growth of 3-aminobenzoic acid NTCDA diimide (2b): 
Yellow single crystals were obtained from dissolving approximately 15 mg of 2b in 2 ml 
of pyridine.  The solution was partially covered with parafilm left to slowly evaporate 
under ambient conditions.  Single crystals of 2b?pyridine were afforded within 20 days 
in ca. 55 % yield. 
Single crystal growth of 2-methyl-4-nitroaniline pyromellitic anhydride cocrystal 
(3a): Orange single crystals were obtained from dissolving approximately 20 mg of the 
cocrystal 3a in 2 ml of a 1:1 solvent mixture of chloroform and ethyl acetate.  The 
solution was partially covered with parafilm left to slowly evaporate under ambient 
conditions.  Single crystals of 3a were afforded within 22 days in ca. 15 % yield. 
Single crystal growth of 2-methyl-4-nitroaniline pyromellitic anhydride diimide 
(3b): Yellow single crystals were obtained from dissolving approximately 30 mg of 3b in 
1 ml of DMF.  The solution was partially covered with parafilm left to slowly evaporate 
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under ambient conditions.  Single crystals of 3b were afforded within 14 days in ca. 36 % 
yield. 
Single crystal growth of 1-adamantylamine phthalic anhydride intermediate (4a): 
 Single crystals of the intermediate were obtained from dissolving approximately 50 mg 
(0.33 mmol) of 1-adamanytlamine and 49 mg (0.33 mmol) of phthalic anhydride in 4 ml 
of methanol.  The solution was partially covered with parafilm left to slowly evaporate 
under ambient conditions.  Single crystals of 4a were afforded within 6 days in ca. 68 % 
yield. 
Single crystal growth of 1-adamantylamine phthalic anhydride imide (4b):  
Single crystals of the imide product were obtained by dissolving the heated material in 
ca. 2ml of distilled methanol and slow evaporation over several days. The unit cell 
parameters match the crystal structure of Refcode QUSKUK as deposited in the 
Cambridge Structural Database. 
 
2.4.3. Characterization Methods 
Single-Crystal X-ray Diffraction: Single crystals were obtained for nine 
compounds.  Attempts to crystallize 3 did not afford crystals suitable for single crystal X-
ray crystallographic analysis.  Single crystal analysis for 1, 2, and 5-10 was performed on 
a Bruker-AXS SMART APEX CCD diffractometer with monochromatized Mo Kα 
radiation (λ = 0.71073 Å) connected to a KRYO-FLEX low-temperature device.  Data for 
1, 2, and 5-10 were collected at 100 K or 298 K. Lattice parameters were determined 
from least-squares analysis, and reflection data were integrated using SAINT.69  
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Structures were solved by direct methods and refined by full matrix least squares based 
on F2 using the SHELXTL package.70  All non-hydrogen atoms were refined with 
anisotropic displacement parameters. All hydrogen atoms bonded to carbon, nitrogen, 
and oxygen atoms were placed geometrically and refined with an isotropic displacement 
parameter fixed at 1.2 times Uq of the atoms to which they were attached.  Hydrogen 
atoms bonded to methyl groups were placed geometrically and refined with an isotropic 
displacement parameter fixed at 1.5 times Uq of the carbon atoms. 
Powder X-Ray Diffraction (PXRD): 2-8 were characterized by a D-8 Bruker X-
ray Powder Diffractometer using a Cu Kα radiation (λ = 1.54178 Å), 50kV, 40mA. Data 
was collected over an angular range of 3° to 40° 2θ value in continuous scan mode using 
a step size of 0.05° 2θ value and a scan speed of 1.0 º/min.   
Calculated PXRD: Calculated PXRD diffractograms were generated from the 
single crystal structures using Mercury 1.5 (Cambridge Crystallographic Data Centre, 
UK). 
Differential Scanning Calorimetry (DSC): Differential Scanning Calorimetry 
was performed on a TA Instruments 2920 DSC with a typical scan range of 35 ºC – 350 
ºC, scan rate of 10 ºC/min, and nitrogen purge of ca. 70 psi. 
Fourier Transform Infrared Spectroscopy (FT-IR):  FT-IR analysis was 
performed on a Nicolet Avatar 320 FT-IR spectrometer equipped with a solid-state ATR 
accessory. 
UV-Vis Spectrophotometer (UV-vis): Purple co-crystals from reactions 1 and 2 
were additionally characterized by UV-vis from 350-800nm on a PerkinElmer Lambda 
900 UV/Vis/NIR spectrometer 
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Table 2.4. Hydrogen bond distances and parameters 
 
Compound Hydrogen Bond d(H...A)/ Å d(D...A)/ Å θ/ º 
 
1a 
N-H???O 2.18 2.946(6) 145.5
N-H???O 2.55 3.194(7) 130.3
N-H???O 2.39 3.255(8) 166.9
2a 
N-H???O 2.24 3.066(4) 
155.2 
N-H???O 2.46 3.217(4) 144.4
O-H???O 1.81 2.643(3) 172.3
3a 
N-H???O 2.16 2.943(5) 148.1
N-H???O 2.31 3.089(5) 148.0
4a 
O-H???O 1.87 2.682(3) 171.6
N-H???O 2.34 3.318(3) 157.5
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Chapter 3: Lamotrigine Crystal Forms: Synthesis, Characterization, and 
Evaluation 
 
3.1 Preamble 
Crystal form development for an active pharmaceutical ingredient (API) typically 
results in a plethora of crystal forms including salts,1 cocrystals,2 solvates,3 hydrates,4 etc. 
which can be beneficial to the pharmaceutical industry.   
Pharmaceutical salts are materials formed by an ionic API and a suitable, 
pharmaceutically acceptable counterion.1, 5  They have been a part of crystal form 
selection for decades as they offer diversity of composition and can therefore exhibit a 
wide range of physicochemical properties.1 Pharmaceutical cocrystals6 are a relatively 
new technology with the first pharmaceutical cocrystal developed within the decade.  The 
current focus of pharmaceutical cocrystallization is, much like a pharmaceutical salt, their 
inherent ability to change the properties of an API.  A review of the literature reveals that 
there have been eight 7-14 pharmaceutical cocrystal case studies with pharmacokinetic 
details reported to date, all of which support that pharmaceutical cocrystals are a viable 
option to enhance the clinical performance of a poorly soluble API.  Pharmaceutical 
cocrystals are a particularly attractive crystal form option because they maintain the 
criteria for patentability.  That is, they are novel, non-obvious, and of utility to the 
pharmaceutical industry.      
 124
The importance of hydrates and solvates in pharmaceutical development has also 
been recognized.4, 15  Various examples have demonstrated that the formation of hydrates 
and solvates can significantly alter the physicochemical properties of APIs, such as 
chemical stability, solubility and dissolution rate.16-19   
With this in mind, we report a study of lamotrigine (6-(2,3-dichlorophenyl)-1,2,4-
triazine-3,5-diamine), a triazine drug amenable to crystal engineering design strategies 
that exhibits poor solubility and dissolution rate in its pure crystalline form. Lamotrigine 
is marketed as Lamictal® by GlaxoSmithKline for oral administration as a compressed or 
chewable tablet. It is primarily used as an anti-convulsant drug for the treatment of 
epilepsy as well as in the treatment of psychiatric disorders such as bipolar disorder.20, 21 
In particular, lamotrigine is used for the treatment of generalized seizures associated with 
Lennox-Gastaud syndrome22 and it can be used in conjunction with other anti-epileptic 
drugs such as carbamazepine, phenytoin, phenobarbital, primidone or valproate.23  An 
additional and perhaps less common use for lamotrigine is for the treatment of 
neuropathic pain, cluster headaches, and migraines.24  Lamotrigine, a white to pale 
cream-colored powder with a pKa of 5.7, is very slightly soluble in water (0.17 mg/mL at 
25 °C) and only slightly soluble in 0.1 M HCl (4.1 mg/mL at 25 °C).25  Various attempts 
have been made to solve the use limitations of lamotrigine due to its poor solubility.  
Briefly, these approaches have involved the exploration of a plethora of crystal forms,26-30 
including salt forms, and reduction of the particle size.31  Recently eight novel crystal 
forms of lamotrigine were reported by Galcera et al.,32 with only two salt forms 
(saccharinate and DL-hemitartrate dimethylsulfoxide solvate) reaching a greater 
maximum aqueous solubility than pure lamotrigine.  A benzoate dimethylformamide 
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solvate,33 hydrogen phthalate dimethylformamide solvate,34 methanol solvate,35 
isoethoinate,36 dimethylformamide solvate,37 methanesulfonate,38 and a monohydrate39 
have also been reported; however only limited solubility data is available concerning 
these crystal forms.  Some of the aforementioned crystal forms, particularly those 
involving certain salt forms, are undesirable for certain routes of administration, such as 
parenteral, due to their acidity.  Other formulations contain ingredients that are not safe 
for human consumption such as dimethylformamide.  Clearly, there is a strong scientific 
and clinical need to develop novel forms of lamotrigine that have significantly improved 
physicochemical properties, including aqueous solubility, which can be formulated for 
use in various delivery routes, such as oral administration.   
To generate novel crystal forms of lamotrigine an analysis based upon crystal 
engineering40-42 molecular recognition,43 and supramolecular synthons,44 was conducted 
to determine complementarities between a number of pharmaceutically acceptable and 
approved materials containing carboxylic acid, alcohol, and primary amide moieties and 
lamotrigine.  It showed that lamotrigine can form complexes with two dominant 
supramolecular synthon motifs, with or without the aminopyridine dimer. Among all 
pharmaceutically acceptable and/or approved compounds with hydrogen-bonding 
functionality, a variety of guest molecules that were likely to form either of these two 
motifs with lamotrigine were selected for this study and are shown in Figure 3.1.  All 
selected guest molecules except butylated hydroxyanisole successfully formed complexes 
with lamotrigine, resulting in ten novel lamotrigine crystal forms. Details of the 
supramolecular synthon approach and the development of ten crystal forms of 
lamotrigine from established cocrystallization techniques45-48 are presented herein.  
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Additionally, solubility and pharmacokinetic studies were conducted upon a subset of 
these crystal forms and are described herein. 
 
3.2 Results and Discussion 
3.2.1 Salt vs Cocrystal 
Lamotrigine has the ability to form both salts and cocrystals due to its relatively 
basic nature (pKa = 5.7). By selecting cocrystal formers with a range of varying acidities, 
the formation of lamotrigine pharmaceutical salts or cocrystals would be expected. The 
pKa difference between lamotrigine and the adduct, ΔpKa (i.e. ΔpKa = pKa base - pKa 
acid), is widely accepted as the key to predicting whether a salt or a cocrystal will form.5, 
49, 50 It is generally considered that if ΔpKa > 3 the resulting compound will be a salt 
(exemplified in this study by saccharin); whereas the result is typically a cocrystal if 
ΔpKa < 0.  For ΔpKa between 0 < ΔpKa  < 3  the outcome can be either a salt or 
cocrystal or a complex with partial proton transfer.51  The pKa and ΔpKa values52-55 
involved in this study are summarized in Table 3.1.  It is noted that the ΔpKa values of 
three cocrystal formers (i.e. adipic acid, L-malic acid and nicotinic acid) fall in the 
variable region. Interestingly, all of these cocrystal formers produce lamotrigine salts, as 
evidenced by the proton location and bond length analysis from the single crystal X-ray 
diffraction data.  Analysis of the carbonyl region of the solid-state FTIR spectrum also 
supports the formation of lamotrigine salts.   
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Table 3.1. pKa values and the resulting ΔpKa values for the lamotrigine salts 
 
 
 
Figure 3.1 Molecular structures of cocrystal and salt formers 
 
3.2.2 CSD Analysis 
In order to prepare novel crystal forms of lamotrigine, a crystal engineering40-42 
study incorporating supramolecular design and the molecular functionality of 
lamotrigine, i.e. the supramolecular synthon approach, was conducted. The crystal 
structure of pure lamotrigine exhibits two dominant supramolecular synthon motifs, the 
aminopyridine dimer (motif 1) and the amine-aromatic nitrogen synthon (motif 2).  Motif 
1 and motif 2 are depicted in Figure 3.2.  
Acid pKa ∆pKa
Adipic acid 4.43
3.44
4.92
1.60
1.27
2.26
0.78
4.10
L-Malic acid
Nicotinic acid
Saccharin
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Figure 3.2 Motif 1 involves breaking the aminopyridine dimer and motif 2 retains the 
aminopyridine dimer but breaks the exterior bifurcated interaction 
 
The introduction of an additional complementary component to the crystal lattice 
of lamotrigine could lead to an interruption of motifs 1 or 2 by either: breaking the 
aminopyridine dimer (breaking motif 1) or breaking the exterior bifurcated interactions 
between the aromatic nitrogen moieties of one lamotrigine to the primary amine moieties 
of two additional lamotrigine molecules (breaking motif 2). An analysis of the 
Cambridge Structural Database (CSD)56, 57 indicates that breaking either motif is feasible 
given a complementary secondary component.  Disruption of motif 1 occurs in 26 out of 
81 aminopyridine entries (32%) and disruption of motif 2 occurs in 39 out of those 81 
entries, or 48% of the time.  In order to understand the hydrogen bonding of the primary 
amine moiety of the diaminopyridine moiety, the 39 entries that break motif 2 were 
analyzed. Among those entries 95% (37/39) show the exterior amine moiety hydrogen 
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bonding to the second molecule while only 2 entries (5%) show the exterior amine 
moiety hydrogen bonding to a molecule of the same kind, i.e. another diaminopyridine 
(Refcodes: AMCQUN, GICWOF).  Based on these CSD statistics,57 breaking the 
supramolecular synthons of motif 1 and motif 2 is feasible, however, there remains a 
tendency towards persistence of the aminopyridine dimer.   
Identification of complementary cocrystal formers for lamotrigine by statistical 
examination of the percentage of occurrence of supramolecular homosynthons versus 
supramolecular heterosynthons was also addressed via a CSD analysis.57 Interactions 
between an aminopyridine moiety and carboxylic acid, primary amide, and alcohol 
moieties were examined in order to determine if the supramolecular heterosynthon or the 
supramolecular homosynthon would be more prominent (Table 3.2., aminopyridine was 
chosen instead of diaminopyridine to provide a larger dataset for the statistical analysis).  
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Table 3.2 Comparison of supramolecular homosynthon versus supramolecular  
heterosynthon with aminopyridines and complementary moieties 
 
To conduct the supramolecular homosynthon and heterosynthon analysis, a broad 
distance range was initially selected and then reduced by visual inspection to determine 
the appropriate ranges for defining hydrogen bond contact limits.  The values given in 
Table 3.2. are a refined dataset which includes only aminopyridine and one additional 
Complem
entary 
Moiety 
No. of 
entries 
w/ 
both 
group
s 
 % 
Homosynthon 
occurrence: 
Aminopyridine 
Refined dataset 
(distance 
rangeÅ) 
%Homosynth
on 
occurrence: 
Cocrystal 
former 
Refined 
dataset 
(distance 
rangeÅ) 
%Heterosyntho
n occurrence  
refined dataset 
Heterosynthon 
Distance Range (Å) 
Refined dataset 
Carboxyli
c acid 
91 40/91 (44%) 
(N N 2.92-3.17) 
0 42/91-acid  
(46%) 
28/91-
carboxylate 
(31%) 
N(py) O 2.50-2.80 
N(am) O 2.71-3.10 
(acid and 
carboxylate) 
Primary 
amide 
15 2/15 (13%) 
(N N 3.04-3.077) 
1/15 (6%) 
(N O 2.98) 
1/15 (6%) N(py) N  2.97 
N(am) O 3.06 
Alcohol 307 66/307 (21%) 
(N N 2.92-3.17) 
78/307 (25%) 
(O O 2.61-
2.92) 
100/307 (33%) N(py) O 2.67-2.90 
N(am) O 2.78-3.19 
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moiety sustained by a specified supramolecular hetero- or homosynthon interaction 
within a defined distance range.  Our analysis concluded that, in general, the 
supramolecular heterosynthons were more dominant than the homosynthons.  The 
alcohol moiety was the most statistically favored to interact with the aminopyridine 
moiety as there was 33% (100/307) versus 21% (66/307) occurrence for the 
supramolecular heterosynthon and homosynthon, respectively.  However, the addition of 
a carboxylic acid to a molecule sustained via an aminopyridine supramolecular 
homosynthon has previously been explored and successfully resulted in the formation of 
cocrystals and salts.58, 59  Thus it is not surprising that there was also a preference for the 
aminopyridine-acid supramolecular heterosynthon, with a higher percentage of 
occurrence attributed to the carboxylic acid group (43/91, 46%) than the carboxylate 
group (28/91, 31%).    Interestingly, the carboxylic acid homosynthon does not occur in 
the presence of the aminopyridine functional group.  There are 15 structures that contain 
aminopyridine and primary amide moieties, 2 of which form the aminopyridine 
supramolecular homosynthon, 1 forms the amide dimer, and 1 forms the aminopyridine-
amide supramolecular heterosynthon.  Unfortunately, this paucity of data precludes 
determination of the reliability of the aminopyridine-amide supramolecular 
heterosynthon.  However, the CSD analysis indicates that aminopyridines are likely to 
form supramolecular heterosynthons with molecules containing alcohols and carboxylic 
acids.  A general observation when searching for entries with an aminopyridine was the 
numerous examples of aminopyridines with barbituric acid derivatives.    Specifically, the 
CSD contains a set of 35 aminopyridine-barbituric acid derivative cocrystals synthesized 
by Whitesides et al.60-62  This dataset indicates that the aminopyridine-amide 
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supramolecular heterosynthon is a reliable synthon.  However, due to the nature of the 
study, cocrystal formers that are utilized must at least be on the generally regarded as safe 
(GRAS) list, precluding the selection of cocrystal formers containing amide moieties.  
Thus a range of carboxylic acids, alcohols, and amides were chosen for crystal form 
development however, only six resulted in novel crystal forms. Figure 3.1. illustrates the 
formers that resulted in novel crystal forms. 
 
3.2.3 Motif 1 versus Motif 2 
The crystal forms presented herein break either motif 1 or motif 2 present in pure 
lamotrigine by incorporating a complementary cocrystal former.  Motif 1 is broken in 4 
out of 9 structures while the remaining crystal forms contain motif 1 but break motif 2.  
Specifically, crystal forms 2, 4, 7, 9, and 10 break motif 2 while forms 1, 5, 6, and 8 
break motif 1.  The individual motifs and how they impact the physicochemical 
properties of the crystal form are discussed in the following segments.   
 
3.2.4 Crystal Structure Descriptions 
Cocrystals of lamotrigine methylparaben form I (1) crystallize in the space 
group P21/n.  1 crystallizes concomitantly in the presence of pure methylparaben and 
lamotrigine tetrahydrofuran solvate.  The asymmetric unit contains one lamotrigine and 
one methylparaben molecule.  The lamotrigine aminopyridine dimer is not observed in 1 
(Figure 3.3.).  Instead the structure is a corrugated tape comprised of individual chains of 
alternating lamotrigine methylparaben molecules sustained primarily by two hydrogen 
bonds (Figure 3.4.).  Specifically, the aromatic nitrogen N2 of the triazine ring is 
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hydrogen bonded to the hydroxyl moiety of the methylparaben [O1-H10O???N2: O???N 
2.651(4) Å, H???N 1.831 Å, O-H???N 164.8 º] and the amine in the 5-position of 
lamotrigine is hydrogen bonded to the carbonyl group of the ester moiety of 
methylparaben [N5-H3N???O2: N???O 2.823(4) Å, H???O 1.971 Å, N-H???O 162.7 º].  The 
chains of extend parallel to the 2-fold axis.  Neighboring chains are related by a center of 
inversion and are held together by various weak interactions including C-H???N and 
Cl???Cl interactions to form a corrugated tape.  The phenyl rings of the lamotrigine 
molecule are twisted to a dihedral angle of 88.03 º.   
 
 
Figure 3.3 Supramolecular synthons exhibited by 1 
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Figure 3.4 1 breaks motif 1 as shown in the hydrogen bonding pattern 
 
Lamotrigine methylparaben form II (2) can be obtained via grinding, slurry, or 
melt. Crystals of 2 exist in space group Pī with one lamotrigine and one methylparaben in 
the asymmetric unit (Figure 3). The chlorinated phenyl ring backbone of lamotrigine is 
disordered over two distinct positions with 40% and 60% occupancies, respectively. The 
attached chlorine atoms are refined over three positions with occupancies of 40%, 40% 
and 20%, respectively.  A comparison of the crystal structures of 1 and 2 reveals that they 
exhibit different molecular packing arrangements. Unlike 1, 2 exhibits lamotrigine 
centrosymmetric aminopyridine dimers [N3-H3B???N4: N???N 3.121(4) Å, H???N 2.246 
Å, N-H???N 172.3 º].  The lamotrigine dimers connect to neighboring dimers via 
methylparaben molecules, thereby forming supramolecular ribbons that extend parallel to 
the a-axis [N5-H5A???O1: N???O 3.036(4) Å, H???O 2.205 Å , N-H???O 157.3 º; O1-
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H1C???N2: O???N 2.711(4) Å, H???N 1.876 Å, O-H???N 173.3 º].  The methylparaben 
molecule also serves as a bridge to join these supramolecular ribbons via N-H???O 
interactions [N5-H5B???O2: N???O 2.931(4) Å, H???O 2.129 Å, N-H???O 151.2 º].     
 
 
Figure 3.5 Breaking motif 2 shown in the hydrogen bonding of 2 
   
 136
 
Figure 3.6 Crystal packing of 2 
 
The cocrystal of lamotrigine and nicotinamide (3) was prepared from a melt of 
a 1:1 ratio of lamotrigine and nicotinamide, as evidenced by PXRD characterization.  
Efforts to prepare quality single crystals of 3 for single crystal XRD analysis are 
unsuccessful to date.  
4 (lamotrigine nicotinamide monohydrate) crystallizes in the space group Pī, 
with the asymmetric unit consisting of one molecule of lamotrigine, one molecule of 
nicotinamide and one water molecule.  Motif 2 is broken by the double insertion of water 
molecules while the lamotrigine aminopyridine dimer persists [N3-H2N???N4: N???N 
3.039(2) Å, H???N 2.243 Å, N-H???N 154.2 º].  The water molecules facilitate the 
formation of a supramolecular ribbon motif.  The ribbon is formed along the b-axis as the 
lamotrigine dimers are linked by water molecules via N-H???O and O-H???N interactions 
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[N5-H3N???O1-H5O???N2: N???O 2.930(2) Å, H???O 2.089 Å, N-H???O 165.3 º, O???N 
2.822(2) Å, H???N 1.967 Å, O???N 171.7 º]. In addition, nicotinamide molecules form 
centrosymmetric amide dimers that pack perpendicularly in between the lamotrigine 
water ribbons forcing a separation between the supramolecular ribbons approximately the 
length of two nicotinamide molecules (Figure 3.7.) [N7-H8N???O2: N???O 2.915(3) Å, 
H???O 2.056 Å, N-H???O 176.7 º].  The water molecules within the supramolecular 
ribbons also hydrogen bond to the nicotinamide dimers via additional O-H???N 
interactions that are highlighted in Figure 3.8. [O1-H6???N6: O???N 3.039(3) Å, H???N 
2.162 Å, O-H???N 166.5 º].  The voids generated by the nicotinamide dimers separating 
the supramolecular ribbons are filled by additional supramolecular ribbon-nicotinamide 
dimer units.  These supramolecular units are stabilized by π-π interactions between the 
chlorinated lamotrigine ring and the nicotinamide aromatic ring.   
 
Figure 3.7. Supramolecular synthons present in 4 
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Figure 3.8. Crystal packing of 4 interrupting motif 2 
 
The salt of lamotrigine and saccharin (5) crystallizes in space group P21/c.  The 
asymmetric unit contains one lamotrigine cation and one saccharin anion. The structure 
of 5 does not contain the aminopyridine dimer; however, formation of the dimer is 
possible with protonation of the most basic nitrogen (N2) as it is not incorporated in the 
lamotrigine dimer.  The basic supramolecular unit in 5 is a tetramer formed between two 
lamotrigine and two saccharin ions where the N2 is protonated.  Lamotrigine and 
saccharin are associated via two 2-point recognition aminopyridine-sulfonamide 
supramolecular heterosynthons [N2+-H1N???N6: N???N  2.819(2) Å, H???N 1.940 Å, N+-
H???N 177.5 º ; N3-H2N???O1: N???O 2.830(2) Å,  H???O 1.954 Å, N-H???O 173.5 º]. The 
C3-N2-N1 angle of the triazine ring in the crystal structure of 5 is 123.4 º which 
correlates to the previously reported values for protonated lamotrigine63 and the expected 
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trend for protonated aminopyridines, i.e. higher angles than those of a neutral 
aminopyridine.63, 64  The tetramer is formed from two adjacent supramolecular 
heterosynthon dimers, shown in Figure 3.9., that are further connected by primary amine-
carbonyl interactions [N3-H3N???O1: N???O 2.818(2) Å, H???O 2.054 Å, N-H???O 144.7 
º].  Each tetramer is hydrogen bonded to four additional tetramers via either sulfonyl-
amine or sulfonyl-chlorine interactions [N5-H4N???O2: N???O 2.889(2) Å, H???O 2.194 Å, 
N-H???O 135.5 º; Cl1???O3 3.068(3) Å].  A view of the overall crystal packing can be 
seen in Figure 3.10. 
 
 
Figure 3.9. Tetrameric motif present in 5 
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Figure 3.10. Crystal packing of 5 
 
6 (lamotrigine adipate salt) crystallizes in space group of P21/c with two 
lamotrigine cations and one adipate anion in the asymmetric unit (Figure 3.11.).  The 
molecular packing of 6 is based upon 2-point supramolecular heterosynthons between the 
aminopyridinium and carboxylate moieties, involving an N-H???O hydrogen bond [N3-
H3N???O1: N???O 2.942(2) Å, H???O 2.110 Å, N-H???O 157.5 º] and a N+-H???O– charge-
assisted hydrogen bond [N2+-H1N???O2-: N???O 2.627(2) Å, H???O 1.790 Å, N-H???O 
158.1 º]. Proton transfer is evidenced by the C-O bond distances of the carboxylate group 
(1.248(2) Å and 1.272(2) Å) and the geometry of the lamotrigine triazine ring. The C3-
N2-N1 angle of the triazine ring in the crystal structure of 6 is 122.4(2) º.  Each discrete 
unit, comprised of two lamotrigine cations and one adipate anion, is hydrogen bonded to 
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eight nearby lamotrigine-adipate units through the lamotrigine NH2 moieties and 
neighboring carboxylate [N3-H2N???O1: N???O 2.861(2) Å, H???O 2.057 Å, N-H???O 
151.5 º; N5-H4N???O2: N???O 2.760(2) Å, H???O 1.931 Å, N-H???O 156.5 º].  Each 
adipate anion is hydrogen bonded to four additional discrete units via C-O???H-N 
interactions.  The overall packing can be viewed in Figure 3.12. as staggered 
supramolecular units of lamotrigine-adipate running parallel to either (010) or (001) with 
Cl???pi interactions.   
 
 
Figure 3.11. Supramolecular synthons of 6 do not form motif 1 
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Figure 3.12. Crystal packing of 6 
 
The lamotrigine and L-malic acid salt (7) crystallizes in P21/c.  The asymmetric 
unit is comprised of two lamotrigine cations and one L-malate anion (Figure 3.13.).  
Lamotrigine dimers are formed via a noncentrosymmetric dimer sustained by N-H???N 
hydrogen bonds [N5-H5N???N14: N???N 2.956(6) Å, H???N 2.078 Å, N-H???N 174.6 º; 
[N15-H15???N4: N???N 3.082(6) Å, H???N 2.215 Å, N-H???N 168.6 º].  The L-malate anion 
hydrogen bonds to the lamotrigine dimer such that a supramolecular chain is formed.  
Proton transfer occurs between both carboxylate groups (C20-O1: 1.275(5); C20-O2: 
1.235(6); C23-O4: 1.257(6); C23-O5: 1.275(6)) of L-malate and aromatic nitrogen atoms 
of lamotrigine [N12+-H12N???O1-: N???O 2.632(5) Å, H???O 1.766 Å, N-H???O 167.8 º; 
C19-N12-N11 angle 123.16 º].  The lengths of the C-O bonds are typical of a carboxylate 
moiety and the C19-N12-N11 angle of 123.2 º is consistent with that of a protonated 
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aromatic nitrogen. The supramolecular chains, generated from two lamotrigine cations 
alternating with one l-malate anion, hydrogen bond to an additional l-malate anion 
forming a sheet perpendicular to the bc-plane.  The sheets interact via NH???O hydrogen 
bonds [N3-H3NA???O1: N???O 2.790(5) Å, H???O 2.086 Å, N-H???O 136.3 º; N13-
H13A???O5: N???O 2.928(5) Å, H???O 2.135 Å, N-H???O 149.6 º] to chains that run 
through the ac-plane, thereby generating a 3D structure.  Figure 3.14. highlights the 
supramolecular sheet with only one row of perpendicular chains present for clarity. 
 
Figure 3.13. Supramolecular synthons of 7 generating motif 1, breaking motif 2 
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Figure 3.14. Crystal packing of 7 highlighting a chain running perpendicular to the sheet 
 
The dimethanol solvate of the salt formed by lamotrigine and nicotinic acid 
(8) crystallizes in space group P21/c with proton transfer observed from the carboxylic 
acid group to N2 on the triazine ring [N2+-H1N???O2-: N???O 2.729(3) Å, H???O 1.880 Å, 
N-H???O 161.7 º; C3-N2-N1 angle 122.8 º]. The basic supramolecular unit is comprised 
of one lamotrigine cation, one nicotinate anion, and two methanol molecules.  The 
structure of 8 reveals that the nicotinate anion breaks the lamotrigine dimer.  Similarly to 
5, two pairs of lamotrigine nicotinate adducts interact to form tetrameric motifs sustained 
by charge assisted N+-H???O- and N-H???O hydrogen bonds (Figure 3.15.) [N3-H2N???O3: 
N???O 2.764(3) Å, H???O 1.9223 Å, N-H???O 159.4 º, N3-H3N???O3: N???O 2.872(3) Å 
H???O 2.061 Å N-H???O 152.8 º].  In addition, four methanol molecules attach to the 
exterior of each tetramer by hydrogen bonding to lamotrigine cations and nicotinate 
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anions.  Two methanol molecules interact with carboxylate groups via O-H???O hydrogen 
bonds [O1S-H6S???O2: O???O 2.777(2) Å, H???O 1.974 Å, O-H???O 159.7 º], while the 
other two methanol molecules are inserted between N5 and the aromatic nitrogen of the 
nicotinate [N5-H4N???O4S: N???O 2.755(3) Å, H???O 1.881 Å, N-H???O 171.8 º, O4S-
H7S???N6: O???N 2.699(3) Å, H???N 1.863 Å, O???N 172.7 º].  The methanol molecules 
that interact with the carboxylate moiety act as hydrogen bond donors to the carboxylate 
while also accepting a hydrogen bond from a lamotrigine of an adjacent tetramer 
disposed perpendicularly [N5-H5N???O1S: N???O 2.816(3) Å, H???O 2.012 Å, N-H???O 
151.3 º].  The crystal packing of the tetrameric units is shown in Figure 3.16. 
 
 
Figure 3.15. Breaking motif 1 shown in the hydrogen bonded assembly of 8 
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Figure 3.16. Crystal packing of tetrameric units of 8 
 
A small set of lamotrigine solvates, including a monomethanol solvate, have 
previously been reported in the literature.  Details of the monomethanol solvate crystal 
packing that supports the overall structure were also provided.  Herein the crystal 
structures of the monomethanol solvate and a novel dimethanol solvate are explored.  The 
lamotrigine dimethanol solvate (9) was obtained from an attempted cocrystallization of 
lamotrigine and butylated hydroxyanisole from methanol.  9 crystallizes in C2/c with the 
asymmetric unit comprised of one lamotrigine and two methanol molecules. 9 retains the 
lamotrigine dimer motif and the supramolecular unit consists of one lamotrigine dimer 
and two separately hydrogen bonded methanol molecules.  The lamotrigine 
supramolecular homosynthon dimer in 9 is centrosymmetric [N3-H1N???N4: N???N 
3.084(3) Å, H???N 2.213 Å, N-H???N 170.6 º].  In addition, N3 and N5 amines form 
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hydrogen bonds with methanol molecules (Figure 3.17.) [N3-H2N???O2: N???O 2.824(2) 
Å, H???O 2.210 Å, N-H???O 126.6 º ; N5-H3N???O2: N???O 2.862(2) Å, H???O 2.109 Å,  N-
H???O 143.1 º].  Hydrogen bonds are also observed between methanol molecules and 
aromatic nitrogen atoms N1 and N2 [O1-H6O???N1: N???O 2.987(2) Å, H???N 2.159 Å, 
N-H???O 168.6 º; O2-H5O???N2: N???O 2.654(2) Å, H???N 1.824 Å, N-H???O 169.9 º].  
The lamotrigine dimers and methanol molecules hydrogen bond to form a ribbon that 
extends along the c-axis.  A ribbon is highlighted in yellow in Figure 3.18.  Two 
inversion center related ribbons interact via CH-N and Cl-π interactions thus forming a 
ribbon bilayer.  The bilayers stack along the b-axis in an abab motif, as shown in Figure 
3.18.   
 
 
Figure 3.17. Crystal form 9 breaking motif 2 
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Figure 3.18. Bilayers formed in crystal packing of 9 
 
Comparison of literature monomethanol solvate (Refcode KADPAG) 
The methanol solvate preexisting in the literature from 198935 contains one 
lamotrigine and one methanol molecule in the basic supramolecular unit and crystallizes 
in the P21/n space group.  The lamotrigine dimethanolate presented herein (Figure 3.17 
and 3.18) sustains a 1:2 ratio (lamotrigine:methanol) and crystallizes in the C2/c space 
group.  Interestingly, the monomethanol and dimethanol solvate both crystallize by 
breaking motif 2.  The centrosymmetric lamotrigine aminopyridine dimer is exhibited by 
both solvates; the distinction can clearly be seen when looking at the ribbons of 
lamotrigine aminopyridine dimers.  In the dimethanol solvate, the ribbon is flat extending 
along the b-axis (Figure 3.18., yellow ribbon), however, in the monomethanol solvate the 
ribbon is corrugated with a dihedral angle of 65.14º (Figure 3.19., yellow ribbon).  
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Variations can also be found in the hydrogen bonding scheme of the amine moieties in 
the 3 and 5-positions.  Notably the amine in the 3-position is hydrogen bonded to a 
methanol in the dimethanol solvate, whereas in the monomethanol solvate the methanol 
exhibits a short contact to a neighboring chlorine atom.    
 
Figure 3.19. Crystal packing of KADPAG in CSD highlighting a corrugated 
 chain of lamotrigine methanol units 
 
Crystals of 10 (lamotrigine ethanolate monohydrate) form in space group P21/c 
with an asymmetric unit that is comprised of one lamotrigine, one ethanol and one water 
molecule.  10 exhibits the lamotrigine dimer as shown in Figure 3.20.  In the crystal 
structure of 10, the basic supramolecular unit is the lamotrigine aminopyridine dimer 
sustained by two symmetrically related hydrogen bonds [N3-H2N???N4: N???N 3.006(2) 
Å, H???N 2.191 Å, N-H???N 153.7 º].  The lamotrigine dimers are further hydrogen 
bonded via water molecules [N3-H1N???O1: N???O 2.928(2) Å, H???O 2.295 Å, N-H???O 
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128.8 º ; N5-H3N???O1: N???O 2.848(2) Å, H???O 1.973 Å, N-H???O 173.2 º] and ethanol 
molecules [N5-H4N???O2: N???O 3.042(2) Å, H???O 2.346 Å, N-H???O 136.2 º] to form a 
supramolecular ribbon that translates along the 2-fold axis.  The ribbons, shown in Figure 
3.21., illustrate the water hydrogen bonding in the central region of the ribbon while the 
ethanol molecules hydrogen bond to the exterior.  Individual supramolecular ribbons 
interact via Cl-π interactions to form a corrugated layer.  The layers are connected 
through hydrogen bonds that occur between water and ethanol molecules [O1-H9O???O2: 
O???O 2.829(2) Å, H???O 1.942 Å, O-H???O 178.8 º], thereby generating a brickwall motif.  
The supramolecular synthons involved in the structure of 10 are reminiscent of pure 
lamotrigine; however, the insertion of the water and ethanol molecules force neighboring 
lamotrigine dimers further apart than in the pure crystalline material.   
 
 
Figure 3.20. Crystal form 10 interrupting motif 2  
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Figure 3.21. Ethanol water lamotrigine ribbons 
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Table 3.3 Crystallographic data and structure refinement parameters for compounds 1-2, 4-10 
 1 2 4 5 6 7 8 9 10 
Chemical 
formula 
C9H7Cl2N5  
C8H8O3 
 
C9H7Cl2N5
C8H8O3 
 
C9H7Cl2N5    
C6H6N2O      
H2O 
C9H8Cl2N5      
C7H5NO3S 
C9H8Cl2N5  
(C6H9O4)0 5 
(C9H8Cl2N5)2    
C4H5O5 
C9H8Cl2N5  
C6H4NO2  
(CH4O)2 
C9H7Cl2N5  
(CH3OH)2 
 
C9H7Cl2N5  
C2H5OH  
H2O 
Formula 
weight 
408.24 408.24 396.24 439.28 329.17 646.28 443.29 320.18 320.18 
Crystal 
System 
Monoclinic Triclinic Triclinic Monoclinic Monoclinic Monoclinic Monoclinic Monoclinic Monoclinic 
Space 
group 
P21/n Pī Pī P21/c P21/c P21 P21/c C2/c P21/c 
a (Å) 5.2729(9) 8.8957(18) 7.3047(6) 18.447(5) 13.068(3) 10.728(2) 7.648(3) 19.326(4) 7.1308(14) 
b (Å) 14.330(3) 11.409(2) 8.4939(7) 6.954(2) 7.498(2) 10.2003(19) 15.863(6) 17.584(3) 8.3566(16) 
c (Å) 23.822(4) 12.040(2) 14.6964(12
) 
14.762(4) 14.069(3) 12.721(2) 16.803(7) 8.2698(15) 24.018(5) 
α (o) 90 107.05(3) 105.081(5) 90 90.00 90 90 90 90 
β (o) 92.795(3) 102.10(3) 90.580(5) 107.978(4) 96.755(4) 107.634(13) 90.072 (6) 97.820(3) 94.565(3) 
γ (o) 90 112.50(3) 95.244(5) 90 90.00 90 90 90 90 
Vol (Å3) 1797.9(6) 1005.0(4) 876.21(12) 1801.2(9) 1369.0(6) 1326.6(4) 2038.5(15) 2784.2(9) 1426.7(5) 
Dcal (g cm-
3) 
1.508 1.349 1.502 1.620 1.597 1.618 1.444 1.528 1.491 
Z 4 2 2 4 4 2 4 8 4 
Reflections 
collected 
8611 4879 7400 9108 6576 9647 10331 5746 8317 
Independen
t reflections   
3159 3370 2842 3273 2407 3848 3642 2421 3273 
Observed 
reflections    
2056 2420 2406 3033 2230 3499 2698 2127 2886 
T (K) 100 100 296 100 100 100 100 100 100 
R1 0.0626 0.0642 0.0352 0.0338 0.0317 0.0461 0.0419 0.0341 0.0367 
wR2 0.1002 0.1380 0.0920 0.0893 0.0894 0.1271 0.0938 0.0889 0.0917 
GOF 1.095 1.070 1.024 1.043 1.040 1.097 1.021 1.054 1.022 
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         Figure 3.22. Dissolution profiles in water for lamotrigine and crystal forms 2-5 
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       Figure 3.23. Dissolution profiles at pH = 1 for lamotrigine and crystal forms 2-5 
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3.3. Solubility and Dissolution Study 
As shown in Figures 3.22. and 3.23., solubility and dissolution studies were 
conducted for 2, 3, 4, 5 and pure lamotrigine.  The solubility of 5 has been reported 
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elsewhere32 and is re-examined in this study.  The maximum concentration of pure 
lamotrigine in water and pH 1 HCl solution differ by approximately 10% with the higher 
solubility of lamotrigine exhibited under more acidic conditions.  The dissolution study in 
water revealed that 5 reached a maximum concentration of ca. 0.45 mg/ml.  This 
observation is in agreement with the reported literature aqueous solubility.65  However, 
given that the solubility of lamotrigine increases under more acidic conditions, the 
improved solubility of 5 in water might be rationalized by the inadvertent decrease in pH 
due to the dissolution of saccharin. The maximum concentrations of the other crystal 
forms in water were ca. 0.21 mg/ml, 0.30 mg/ml, 0.23 mg/ml, and 0.28 mg/ml for 2, 3, 4, 
and pure lamotrigine, respectively.  It was also found that 4 exhibited the lowest 
concentration in water after 4 hours, which is not surprising as hydrates are typically 
considered to be less soluble than the corresponding anhydrate.4, 66   
An examination of the dissolution profiles generated at pH 1 indicates that 2 
sustains the highest concentration throughout the four-hour study achieving a maximum 
concentration of ca. 3.8 mg/ml.  4, however, also reaches a maximum concentration of ca. 
3.8 mg/ml after only 5 minutes, but it then proceeds to decline over the remainder of the 
study.  This particular type of profile is a product of the “spring and parachute effect” and 
has been exhibited by a number of pharmaceutical cocrystals reported recently.13, 67, 68  
This profile is significant because it shows that a greater concentration of API can be 
achieved at a much faster rate depending upon the crystal form.  A similar trend is also 
exhibited by 4 under aqueous conditions; however, the maximum concentration of 4 was 
less than that of pure lamotrigine.  A slurry of 3, stirred for 5 minutes in acidic media, 
achieved a concentration ca. 36% greater than pure lamotrigine.  Interestingly, 5 which 
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exhibits the highest concentration in aqueous solution, achieves the lowest concentration 
in acidic media (1.3 mg/ml).  Overall, the dissolution profiles revealed that, in pure water, 
5 is the most soluble crystal form but under acidic conditions (pH = 1), 2 is the more 
soluble crystal form.  
A recently published article suggests that the solubility of the cocrystal is directly 
proportional to the solubility of its components,69 more specifically, the solubility ratio 
plotted against the solubility of the cocrystal former divided by the solubility of the API 
should result in a linear relationship.  A similar analysis of crystal forms 2-5 reported 
herein, however, does not generate a linear plot.  In fact, within this set of case studies, no 
clear correlation exists with respect to the solubility of the salt/cocrystal former and the 
solubility of the resulting crystal form.  The aqueous solubility of nicotinamide is ca. 1 
g/ml, the highest of all cocrystal formers studied (methylparaben = 1 g/400ml and 
saccharin = 1 g/290ml), and it is also a hydrotrope that is frequently used for solubility 
improvement,70 however, the crystal forms containing nicotinamide (3 and 4) are not the 
most soluble in aqueous solutions.  Instead 5 is the most soluble crystal form most likely 
due to the acidic saccharin molecule altering the pH of the solution to favor the 
dissolution of lamotrigine.  The low correlations may be due to the small dataset or the 
inclusion of both protonated and unprotonated species in the dataset.   
Correlations between solubility and crystal packing were also investigated.  5, 
which breaks motif 1, achieved a greater concentration in water than under acidic 
conditions (pH = 1).  2 and 4 which break motif 2, show markedly improved 
concentrations in the acidic solution (pH = 1) but exhibited much lower concentrations in 
water.  Based on this dataset it can be concluded that, for this particular case study, 
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lamotrigine cocrystals that break motif 2 are more soluble than pure lamotrigine under 
acidic conditions (pH = 1) while lamotrigine salts that break motif 1 are more soluble 
than pure lamotrigine in aqueous solutions.  However, the enhanced aqueous solubility of 
5 may be attributed to the inherent acidity of saccharin.   
 
3.4. Animal Pharmacokinetic (PK) Study 
A single dose rat pharmacokinetic study was conducted by Vasyl Sava and Shijie 
Song at the James A. Haley VA hospital in Tampa.  The serum concentration of 
lamotrigine that resulted from single-dose oral gavage of 3, 4, 5, and pure lamotrigine 
was measured in Sprague-Dawley rats over a 24-hour time period (Figure 3.24).  2 was 
not studied due to its instability after three months of aging at 40 ºC in variable humidity.  
An examination of the serum concentrations after dosing with 3, 4, and 5 shows that the 
PK profile can be substantially altered via cocrystal or salt formation.  Two hours after 
dosing the average serum concentration of 5 was 3.5 μg/ml which is ca. 1.5 times the 
level shown for pure lamotrigine (2.3 μg/ml).  3 and 4 showed a decrease in the serum 
concentration by ca. 40% and 68%, respectively, compared to the pure lamotrigine. The 
area under the curve (AUC0-24hr) for 3, 4, 5 and pure lamotrigine was calculated to be 37, 
26, 66, and 60 μg/ml, respectively.  A comparison of the average serum concentrations 
reveals that 5 is clearly the desired crystal form for further pharmaceutical development 
as 5 exhibits the highest initial serum concentration and achieves the greatest AUC0-24hr.   
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Figure 3.24. Rat serum concentrations of lamotrigine, 3, 4 and 5 
 
An analysis of the serum concentrations for 3, 4, and 5 in the rat in terms of 
crystal packing concluded that 5, which broke motif 1, experienced an initial boost in 
serum concentration of lamotrigine.  Meanwhile, serum levels for cocrystals 3 and 4, 
which retained the aminopyridine dimer and broke motif 2, were an average of ca. 54% 
less than that of pure lamotrigine, thus suggesting that crystal forms that break motif 1 
could exhibit higher serum concentrations than forms that break motif 2.  Interestingly, 
the greatest improvements in the PK study and the dissolution study occur when the 
aminopyridine dimer is broken.  This case study also illustrates that pharmaceutical 
cocrystals and salts can have a significant impact upon drug development as they can 
greatly alter the PK profile of the parent drugs.   
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3.5 Conclusions 
In summary, the work presented herein exemplifies how salt or cocrystal formers 
can generate novel crystalline forms of preexisting APIs with different physicochemical 
properties.  Lamotrigine was targeted for crystal form development with the goal of 
improving its solubility and clinical performance. Ten crystal forms of lamotrigine were 
developed via the supramolecular synthon approach. The new crystal forms differed from 
pure lamotrigine in that either supramolecular synthon motif 1 (the aminopyridine dimer) 
or motif 2 (the amine-aromatic nitrogen hydrogen bond) were broken. Motif 2 was 
broken in 5 out of 10 structures (50%) while only 4 out of 10 structures (40%) broke 
motif 1.  Interestingly, the majority of the crystal forms that did not contain motif 1, with 
the exception of 1, were all lamotrigine salts.   
Several crystal forms were tested to determine solubility, dissolution rate and rat 
PK profiles.  Out of ten crystal forms, four (2, 3, 4 and 5) were selected for dissolution 
studies and three (3, 4 and 5) were selected for PK studies.  The solubility/dissolution 
study was conducted under aqueous conditions and under acidified (pH = 1) aqueous 
conditions. The dissolution profiles for 2 and 4 achieved concentration levels similar to 
lamotrigine in aqueous media while 3 maintained a concentration equivalent to the 
maximum solubility of lamotrigine.  The average concentrations achieved from 2, 3, 4 
and 5 during dissolution measurements from the acidic media surpassed the levels of pure 
lamotrigine by ca. 48%, 19%, 18%, and 58% respectively.  In the rat PK study, the serum 
concentrations for 3 and 4 were less than pure lamotrigine by 37% and 26%, respectively.  
5, however, exhibited an initial increase in the serum concentration of ca. 66%.  After 
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approximately 3 hours the serum concentration of 5 reduced to a level similar to that of 
pure lamotrigine.   
The influence of a particular cocrystal former upon solubility and rat PK was 
examined.  The analysis compared the solubility of the cocrystal former and the solubility 
and serum concentration of the subsequent crystal form.  For this dataset, the most 
soluble cocrystal former did not lead to the most soluble crystal form.  In addition, a 
comparison of the rat PK data to the solubility of the crystal form revealed that the crystal 
forms that achieved the greatest aqueous solubility also reached the highest 
concentrations in the rat PK data.  The solubility of the crystal form in the acidic solution 
did not correspond to the PK data.   
The influence of supramolecular synthon motif upon solubility and PK was also 
examined.  Of the crystal forms where the solubility and rat PK was measured (3, 4, 5) 
the only crystal form that broke the aminopyridine dimer (5) also achieved the highest 
concentration in aqueous solution and rat serum, suggesting that breaking the lamotrigine 
aminopyridine dimer can lead to crystal forms with desirable physicochemical properties. 
Therefore when considering both aqueous dissolution and animal PK data of the crystal 
forms presented herein collectively, 5 exhibited the targeted physicochemical properties 
with substantial improvements, and would be an appropriate candidate for further 
development.   
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3.6 Materials and Methods 
3.6.1 Materials  
Lamotrigine was supplied by Jai Radhe Sales, India with a purity of 99.79% and 
was used without further purification.  All other chemicals were supplied by Sigma-
Aldrich and used without further purification. 
 
3.6.2 Synthesis of Compounds 1-10 
Lamotrigine was reacted with six compounds shown in Figure 3.1, namely 
methylparaben, nicotinamide, saccharin, adipic acid, L-malic acid, and nicotinic acid, 
resulting in the formation of ten crystalline cocrystals, salts, or solvates of lamotrigine. 
Synthesis of lamotrigine methylparaben cocrystal form I (1:1), 1. 0.0117 g 
(0.046 mmol) lamotrigine and 0.0750 g (0.490 mmol) methylparaben were dissolved in 
ca. 2 ml tetrahydrofuran (THF) and left to evaporate at room temperature.  Colorless 
crystals were afforded within seven days.  1 crystallized concomitantly with 
methylparaben and lamotrigine THF solvate.  Single crystals of 1 were isolated from this 
mixture. 
Synthesis of lamotrigine methylparaben cocrystal form II (1:1), 2. This 
cocrystal was made via multiple methods: (i) solvent-drop grinding – 0.0722 g (0.282 
mmol) lamotrigine was ground with 0.0458 g (0.301 mmol) methylparaben with 40 μl of 
THF for 30 minutes in a mechanical ball-mill with ca. 100% conversion; (ii) slurry – 
0.0486 g (0.190 mmol) lamotrigine and 0.0294 g (0.193 mmol) methylparaben were 
slurried with ca. 3 ml water at room temperature for 24 hours.  2 was isolated via 
filtration in 70% yield; (iii) melt – 0.0751 g (0.293 mmol) lamotrigine and 0.0485 g 
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(0.319 mmol) methylparaben were placed in an oven at 115 ºC for 2 hours.  2 was 
obtained via slow cooling to room temperature in 97% yield.  Single crystals of X-ray 
diffraction quality were obtained from slow cooling of the melt.   
Synthesis of lamotrigine nicotinamide cocrystal (1:1), 3.  This cocrystal was 
prepared via multiple methods: (i) solvent-drop grinding – 0.2081 g (0.813 mmol) 
lamotrigine and 0.2056 g (1.68 mmol) nicotinamide were ground with 40 μl of methanol 
for 30 minutes in a mechanical ball-mill with ca. 100% conversion; (ii) melt – 0.7105 g 
(2.77 mmol) lamotrigine and 0.3496 g (2.86 mmol) nicotinamide were heated at 125 ºC 
for 2.5 hours resulting in 98% yield; (iii) lamotrigine nicotinamide cocrystal hydrate, 4 
can be dehydrated to isolate 3 after heating at 160 ºC for 6 hours. 
Synthesis of lamotrigine nicotinamide cocrystal monohydrate (1:1:1), 4. This 
cocrystal was made from two methods: (i) slurry – 0.0641 g (0.250 mmol) lamotrigine 
and 0.0614 g (0.503 mmol) nicotinamide (1:2 molar ratio) were slurried with ca. 1 ml 
ethyl acetate for 24 hours.  The resulting solid was isolated and filtered for further use 
with 92% yield; (ii) solution – 0.1021 g (0.399 mmol) lamotrigine and 0.0515 g (0.422 
mmol) nicotinamide dissolved in 600 μl of n-butanol and left to slowly evaporate at room 
temperature. Colorless crystals of 4 were formed within two weeks in 95% yield.  The 
crystals were dehydrated in an oven at 160 ºC for 6 hours to form anhydrous cocrystal 3.  
Synthesis of lamotrigine saccharinate salt (1:1), 5. This salt was made via 
multiple methods: (i) slurry – 50.20 g (196 mmol) lamotrigine and 35.50 g (194 mmol) 
saccharin were slurried in 500 mL water overnight under ambient conditions.  The solid 
was isolated via filtration in 83% yield.  (ii) solution – 0.0102 g (0.040 mmol) 
lamotrigine and 0.0103 g (0.056 mmol) saccharin were dissolved in ca. 2 ml methanol 
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and slowly evaporated at room temperature.  Colorless crystals of 5 were afforded within 
seven days in 94% yield. 
Synthesis of lamotrigine adipate salt (2:1), 6. 0.0158 g (0.062 mmol) 
lamotrigine and 0.0108 g (0.074 mmol) of adipic acid were dissolved in ca. 2 ml 
methanol and left to slowly evaporate at room temperature.  Colorless crystals of 6 
appeared within seven days in 91% yield. 
Synthesis of lamotrigine malate salt (1:1), 7. 0.0199 g (0.078 mmol) 
lamotrigine and 0.0120 g (0.089 mmol) L-malic acid were dissolved in ca. 2 ml methanol 
and left to slowly evaporate at room temperature.  Colorless crystals of 7 appeared within 
seven days in 92% yield. 
Synthesis of lamotrigine nicotinate dimethanol solvate (1:1:2), 8. A solution of 
ca. 2 ml methanol, 0.0148 g (0.058 mmol) lamotrigine and 0.0075 g (0.061 mmol) 
nicotinic acid was left at room temperature to slowly evaporate.  Colorless crystals of 8 
formed after two days in 78% yield. 
Synthesis of lamotrigine dimethanol solvate (1:2), 9. 0.0213 g (0.083 mmol) 
lamotrigine and 0.0148 g (0.082 mmol) butylated hydroxyanisole were dissolved in ca. 2 
ml methanol and left to slowly evaporate at room temperature.  Colorless crystals of 9 
were afforded within five days in 93% yield. 
Synthesis of lamotrigine ethanol monohydrate (1:1:1), 10. 0.0819 g (0.320 
mmol) lamotrigine and 0.0415 g (0.340 mmol) nicotinamide were dissolved in ca. 3 ml of 
a 1:1 ethanol:water solution mixture while heating followed by rapid cooling.  The 
sample was left at room temperature and allowed to slowly evaporate.  Colorless crystals 
of 10 were afforded within two weeks in 74% yield.   
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3.6.3 Crystal Form Characterization   
Single-Crystal X-ray Diffraction: Single crystals were obtained for nine 
compounds.  Attempts to crystallize 3 did not afford crystals suitable for single crystal X-
ray crystallographic analysis.  Single crystal analysis for 1, 2, and 5-10 was performed on 
a Bruker-AXS SMART APEX CCD diffractometer with monochromatized Mo Kα 
radiation (λ = 0.71073 Å) connected to a KRYO-FLEX low-temperature device while 4 
was collected using Cu Kα radiation (λ = 1.54178 Å).  Data for 1, 2, and 5-10 were 
collected at 100 K.  Data for 4 was collected at 296 K. Lattice parameters were 
determined from least-squares analysis, and reflection data were integrated using 
SAINT.71  Structures were solved by direct methods and refined by full matrix least 
squares based on F2 using the SHELXTL package.72  All non-hydrogen atoms were 
refined with anisotropic displacement parameters. All hydrogen atoms bonded to carbon, 
nitrogen, and oxygen atoms were placed geometrically and refined with an isotropic 
displacement parameter fixed at 1.2 times Uq of the atoms to which they were attached.  
Hydrogen atoms bonded to methyl groups were placed geometrically and refined with an 
isotropic displacement parameter fixed at 1.5 times Uq of the carbon atoms. 
Powder X-Ray Diffraction (PXRD): 2-8 were characterized by a D-8 Bruker X-
ray Powder Diffractometer using a Cu Kα radiation (λ = 1.54178 Å), 40kV, 40mA. Data 
was collected over an angular range of 3° to 40° 2θ value in continuous scan mode using 
a step size of 0.05° 2θ value and a scan speed of 1.0 º/min.  Crystal form 1 could not be 
made in sufficient quantities to collect an experimental PXRD.  
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Calculated PXRD: Calculated PXRD diffractograms were generated from the 
single crystal structures using Mercury 1.5 (Cambridge Crystallographic Data Centre, 
UK) for the following complexes: 1-2, 4-10. 
Differential Scanning Calorimetry (DSC): Differential Scanning Calorimetry 
was performed on a Perkin Elmer Diamond DSC with a typical scan range of 25 ºC – 280 
ºC, scan rate of 10 ºC/min, and nitrogen purge of ca. 30 psi. 
Fourier Transform Infrared Spectroscopy (FT-IR):  FT-IR analysis was 
performed on a Perkin Elmer Spectrum 100 FT-IR spectrometer equipped with a solid-
state ATR accessory. 
Ultraviolet-Visible Spectroscopy (UV/Vis):  UV/Vis analysis was performed on 
a Perkin Elmer Lambda 25 UV/Vis spectrophotometer. 
High Performance Liquid Chromatography (HPLC): Analysis was performed 
on an HPLC system (Perkin Elmer Instruments LLC) comprising the following units: a 
series 200 Gradient Pump; a 785A UV/VIS Detector; a series 200 Autosampler; an NCI 
900 Network Chromatography Interface and a 600 Series Link. The system was operated 
by a Total Chrome Workstation. The sample holder temperature was kept at 4 ºC with a 
flow rate of 1 mL/min.  The column was a Microsorb-MV 300-5 C-18 (250 x 4.6 mm x 
1/4”).  The mobile phase consisted of a mixture of phosphate buffer (pH 3.0) with 
methanol (1/1, v/v). The phosphate buffer was prepared from 50 mmol/L Na2HPO3 water 
solution with pH-controlled HCl titration. 
Thermal Gravimetric Analysis (TGA): TGA analysis was performed on a 
Perkin Elmer STA 6000 with a typical scan range of 30 ºC – 300 ºC, scan rate of 10 
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ºC/min, and nitrogen purge of ca. 20 psi.  The resulting thermograms were processed 
using Pyris version 9. 
 
3.6.4 Solubility and Dissolution Study 
Dissolution studies were performed on 2, 3, 4, and 5 allowing for representative 
crystal forms from different crystal form categories (i.e. salt, cocrystal and solvate) to be 
compared against the original API. Both deionized water (25 ºC) and pH 1 aqueous 
solution (0.1 M HCl, 37 ºC) were used.  The crystal forms were sieved to achieve a 
particle size between 53 and 75 μm.  The dissolution study was conducted using an 
excess of free flowing solid in ca. 100 ml solvent that was stirred with a magnetic stir bar 
at a rate of ca. 200-300 rpm.  Aliquots were filtered with 0.45 μm filters after 5, 10, 20, 
30, 40, 50, 60, 75, 90, 105, 120, 150, 180, and 240 minutes.  The resulting solution was 
processed and the concentration of lamotrigine was measured using a UV-Vis 
spectrophotometer.  The experiment was repeated twice to allow for statistical analysis. 
 
3.6.5 Animal Pharmacokinetic (PK) Study 
Twenty-four hour animal PK studies were conducted using a single-dose oral 
administration of lamotrigine as well as 3, 4, and 5. 5 male Sprague-Dawley rats (225-
250 g) with pre-implanted indwelling jugular vein catheters were used for each crystal 
form.  The animals were allowed water ad libitum and fasted overnight before drug 
administration. The crystal forms were administered via oral gavage with a dosage of 10 
mg/kg lamotrigine or its equivalent, in the suspension vehicle of a 5% PEG and 95% 
methyl cellulose aqueous solution.  After dosing, 0.2 ml of blood was withdrawn at 0, 30, 
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60, 120, 180, 240, 480, 720, and 1440 minutes. The blood samples were processed and 
analyzed by HPLC according to the literature.73   
 
Table 3.4. Hydrogen bond distances and parameters 
Compound Hydrogen Bond d(H...A)/ Å d(D...A)/ Å θ/ º 
 
1 
NH???O 1.97 2.823(4) 162.7 
OH???N 1.83 2.651(4) 164.7 
OH???N 2.72 3.545(4) 167.1 
 
 
2 
NH???O 2.20 3.036(4) 157.4 
NH???O 2.13 2.931(4) 151.3 
NH???O 2.49 3.116(4) 129.1 
NH???N 2.25 3.121(4) 172.3 
OH???N 1.88 2.711(4) 173.3 
 
 
 
4 
NH???O 2.06 2.915(3) 176.7 
NH???N 2.43 3.192(3) 148.3 
NH???O 2.09 2.930(2) 165.3 
NH???N 2.35 3.164(3) 157.5 
NH???O 2.28 2.944(2) 133.7 
NH???N 2.24 3.039(2) 154.1 
OH???N 1.97 2.822(2) 171.7 
OH???N 2.16 3.039(3) 166.4 
 
5 
NH???O 2.05 2.818(2) 144.7 
NH???O 1.95 2.830(2) 173.5 
NH???N 1.94 2.819(2) 177.5 
NH???O 2.19 2.889(2) 135.5 
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6 
NH???O 1.93 2.760(2) 156.5 
NH???O 2.06 2.861(2) 151.5 
NH???O 2.11 2.942(2) 157.4 
NH???O 1.79 2.6270(19) 158.0 
 
 
 
 
 
7 
NH???N 2.08 2.956(6) 174.6 
NH???O 2.22 2.792(5) 122.2 
NH???O 2.09 2.790(5) 136.3 
NH???O 1.91 2.786(6) 174.5 
NH???O 1.86 2.707(5) 161.9 
NH???N 2.21 3.082(6) 168.6 
NH???O 2.11 2.968(5) 164.1 
NH???O 2.14 2.928(5) 149.5 
NH???O 1.88 2.754(5) 175.0 
NH???O 1.77 2.632(5) 167.8 
OH???O 2.09 2.744(5) 134.6 
 
 
 
8 
NH???O 1.88 2.729(3) 161.7 
NH???O 1.88 2.755(3) 171.9 
NH???O 2.01 2.816(3) 151.3 
NH???O 2.06 2.872(3) 152.8 
NH???O 1.92 2.764(3) 159.4 
OH???O 1.97 2.777(2) 159.6 
OH???N 1.86 2.699(3) 172.7 
 
 
9 
NH???O 2.21 2.824(2) 126.7 
NH???N 2.19 3.059(2) 170.0 
NH???O 2.11 2.8621(18) 143.1 
NH???O 2.24 2.930(2) 135.7 
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OH???N 1.82 2.654(2) 169.9 
OH???N 2.16 2.9874(19) 168.6 
 
 
 
10 
NH???O 2.35 3.0422(18) 136.2 
NH???O 1.97 2.8481(18) 173.2 
NH???O 2.29 2.9276(18) 128.8 
NH???N 2.19 3.0055(19) 153.7 
OH???N 2.10 2.9014(18) 158.5 
OH???O 1.94 2.8288(17) 178.8 
OH???N 1.95 2.7919(18) 168.2 
NH???O 2.52 3.1870(18) 133.2 
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Chapter 4 - Meloxicam crystal forms: Synthesis, Characterization, and Evaluation 
  
4.1. Preamble 
The ability to alter the physicochemical properties of an active pharmaceutical 
ingredient (API) by changing the crystal form has had a major impact upon the 
pharmaceutical industry 1-3 and has lead to the development of a crystal form screening 
process that is now a routine technology implemented to discover crystal forms 
including, but not limited to, salts,4 hydrates,5 solvates,6 and cocrystals7 with desired 
properties.8, 9 In this chapter a crystal engineering10-12 based crystal form screening 
process will be exploited to generate novel crystal forms of meloxicam with a particular 
focus upon generating pharmaceutical cocrystals13 with desired physicochemical 
properties.    
Meloxicam or (4-hydroxy-2-methyl-N(5-methyl-1,3-thiazol-2yl)-2H-1,2-
benzothiazin-3-carboxamide,1,1-dioxide) is a non-steroidal anti-inflammatory (NSAID) 
and antipyretic drug used for indications of rheumatoid and osteoarthritis,14 postoperative 
pain15, 16 and fever.17  Originally developed by Boehringer Ingleheim, meloxicam is 
marketed in Europe under the brand names Melox or Recoxa.  Meloxicam is available as 
a tablet (7.5 or 15 mg dose) and as an oral suspension (7.5mg/5ml dose).18  The pure 
active pharmaceutical ingredient (API) is a yellow solid that is practically insoluble in 
water, but a greater solubility can be achieved under more basic conditions.  Meloxicam 
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is also very slightly soluble in various organic solvents.19  The variability in solubility 
related to change in pH is due to the different crystal forms of meloxicam.  Under acidic 
conditions meloxicam is present in solution in its cationic form and in basic solutions 
meloxicam is present in its anionic form.  Under more neutral pH conditions meloxicam 
will either be in its zwitterionic or enolic form, depending on the polarity of the 
solvent.20, 21  The different crystal forms are shown in Figure 4.1.  
 
 
Figure 4.1 Anionic, Cationic, and Zwitterionic forms of Meloxicam 
 
Meloxicam is effective at relieving various types of pain and patients experience 
fewer side effects with meloxicam than with other NSAIDS,22, 23 however, the drug can 
take more than two hours to reach a therapeutic concentration in humans.24  This may be 
caused by the inherently low solubility of meloxicam under acidic conditions such as 
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inside the stomach.  Meloxicam dissolves and is absorbed once in the more basic 
conditions of the small intestines, achieving a bioavailability of 89% with substantial 
protein binding.25  For meloxicam, the poor solubility of the API has been determined to 
be the rate limiting step in the absorption, distribution, metabolism, and excretion 
(ADME) process.26  Enhancement of meloxicam’s low aqueous solubility has been the 
subject of many publications resulting in various solvates,27 ethanolamine salts,28  
cyclodextrin inclusion complexs,26 or metal complexes with potassium and calcium.29 
Other crystal forms include ammonium salts and sulfate salts.20  Preparation of different 
polymorphic crystal forms of meloxicam21 and improvements to the dissolution profile30, 
31 are also discussed in recent patent literature.  Due to the low solubility of meloxicam 
impairing the absorption, the goal is to improve the solubility of meloxicam via 
pharmaceutical cocrystallization to potentially reduce the time needed for absorption.  
With a faster absorption rate the patient will reach therapeutic levels in the bloodstream 
and achieve efficacy in less than two hours.   
 
4.2. Results and Discussion 
4.2.1. Reliability of Cocrystal or Salt Formation  
A literature search for crystal forms of meloxicam provided numerous examples 
including pharmaceutical salts such as those generated via complexation with mono-, di-, 
and triethanolamine.28, 32  Due to the plethora of preexisting salt forms in the scientific 
literature that do not show earlier efficacy, the purpose of this study was to generate 
pharmaceutical cocrystals of meloxicam as studies have shown that they can increase the 
plasma concentration at early time points.33-40   The pKa values for meloxicam are 1.09 
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and 4.18.32  The 1.09 is associated with the enolic OH group while the 4.18 is linked to 
the nitrogen on the sulfathiazole ring.   The enolic OH is much less accessible from a 
crystal engineering perspective as it is involved in intramolecular hydrogen bonding to 
the neighboring ketone or NH moieties.  Therefore a set of molecules containing 
carboxylic acid moieties were chosen as cocrystal formers for their ability to potentially 
interact with the sulfathiazole ring.    
It is generally accepted as a rule that the difference in the pKa of the base minus the pKa 
of the acid must be less than zero if the desired outcome is a neutral complex (i.e. 
cocrystal).41, 42  To generate a salt one would select two molecules with a difference in 
pKa of three or more units.43, 44  For the region in between (ΔpKa 0-3) the ability to 
predetermine whether the resulting complex will be neutral or charged is difficult.45  Due 
to the relatively acidic nature of the sulfathiazole moiety, there remains a fairly large 
library of molecules that possess a carboxylic acid moiety that are also generally regarded 
as safe (GRAS) that can be employed to form pharmaceutical cocrystals of meloxicam.  
The carboxylic acids that were chosen for this study include: 1-hydroxy-2-naphthoic acid 
(HNA), glutaric acid, L-malic acid, aspirin, and salicylic acid.  The acids are represented 
by line drawings in Figure 4.2.  The pKa’s of the carboxylic acids that were chosen and 
the difference in pKa between meloxicam and the former are shown in Table 4.1.46-50  
Based upon the rules described above all of the crystal forms reside in the ambiguous 
region thus a detailed analysis of the resulting crystal form will be required to determine 
salt or cocrystal formation.  
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 Table 4.1.  pKa values and ΔpKa values for meloxicam and a set of carboxylic acids 
 
 
 
 
Figure 4.2.  Line drawings of the carboxylic acids used to form  
pharmaceutical cocrystals with meloxicam 
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4.2.2. Cambridge Structural Database (CSD) Analysis 
A key step in developing pharmaceutical cocrystals is to analyze the target active 
pharmaceutical ingredient (API) from a crystal engineering10 perspective, i.e. to analyze 
the molecule from a supramolecular synthon approach.  This methodology partitions the 
target molecule into its simplest functionalities and statistically examines the percentage 
of occurrence of supramolecular homo- and heterosynthons.  The targeted 
supramolecular synthons are typically sustained via hydrogen bonds as they are strong 
and directional in nature.   
The supramolecular synthon approach can be applied for the synthesis of novel 
pharmaceutical cocrystals of meloxicam.  The strategy involves an understanding of the 
supramolecular chemistry of meloxicam including the feasibility of supramolecular 
synthon formation therefore requiring an analysis of the supramolecular synthons present 
in pure meloxicam.  Form I of meloxicam, found in the Cambridge Structural Database 
(CSD)51 (Refcode: SEDZOQ) indicates that meloxicam forms chains that are sustained 
by sulfonyl-amide dimers and sulfathiazole-alcohol supramolecular synthons, shown in 
Figure 4.3.  The chains are held together by various weak interactions, stacking along the 
a-axis in a slipped fashion.   
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Figure 4.3. Meloxicam chains sustained by sulfonyl-amide dimers  
and sulfathiazole-alcohol supramolecular synthons 
 
 
Thus for cocrystallization, one or all of these supramolecular synthon motifs must 
be interrupted.  A target moiety for meloxicam is the aromatic nitrogen of the 
sulfathiazole and the NH of the neighboring amide.  When in the proper conformation, 
these moieties have the ability to provide an ideal two-point recognition site for an 
additional molecule that contains a donor and an adjacent acceptor such as a carboxylic 
acid or amide moiety.    
A CSD analysis52 was conducted that examined the percentage of supramolecular 
synthon formation of the amino-azole functionality (5-membered ring containing a 
nitrogen and primary amine) with carboxylic acid, primary amide, and alcohol moieties.  
Specifically the analysis examined the likelihood of supramolecular homosynthon versus 
supramolecular heterosynthon formation.  A search of the CSD for entries containing the 
amino-azole moiety revealed 505 hits.  Interestingly 214/505 or 42% exhibited the 2-pt 
recognition amino-azole supramolecular homosynthon dimer.  Examining the CSD for 
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entries containing both amino-azole and carboxylic acid moieties afforded 7 entries.  The 
amino-azole supramolecular homosynthon was seen in only 1 out of the 7 entries (14%).  
The carboxylic acid dimer or catemer supramolecular homosynthon was not present in 
any of the 7 entries.  The supramolecular heterosynthon, however, was exhibited in 4/7 or 
57% of the time.  Thus the amino-azole – carboxylic acid supramolecular heterosynthon 
is more likely to occur than the supramolecular homosynthon.  Due to the potential for 
meloxicam to generate salts or neutral complexes the potential for the amino-azole to 
generate a supramolecular heterosynthon with a carboxylate was also examined.  A 
search for crystal structures that contain both moieties resulted in 24 hits.  The amino-
azole supramolecular homosynthon appeared in only 1 entry (4%) where a carboxylate 
was also present.  The carboxylate – amino-azole 2-pt recognition supramolecular 
heterosynthon dimer was much more prominent, appearing in 13/24 or 54% of the 
entries.  Thus the supramolecular heterosynthon is more likely to occur than the 
supramolecular homosynthon for an amino-azole in the presence of a carboxylate.  The 
occurrence of supramolecular homosynthon versus heterosynthon was also questioned in 
the presence of a primary amide moiety.  However, only 1 entry was revealed in the CSD 
that contained both functionalities and neither supramolecular synthon was present 
precluding a conclusion of the reliability of supramolecular synthon formation.  A search 
of the CSD for entries containing an amino-azole and alcohol was also conducted.  The 
two moieties were present in 38 entries with the amino-azole supramolecular 
homosynthon being the dominant interaction.  The alcohol supramolecular synthon 
occurs in 5 out of 38 entries or 13% of the time.  The supramolecular heterosynthon 
occurs in 6/38 entries (16%) while the amino-azole supramolecular homosynthon occurs 
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in 13/38 entries (43%).  Clearly with the supramolecular homosynthon occurrence greater 
than the supramolecular heterosynthon, the potential for cocrystal formation is low by 
employing a cocrystal former that contains an alcohol functional group.  A summary of 
the results from the amino-azole moiety supramolecular homosynthon and heterosynthon 
formation is presented in Table 4.2.   
A closer look at the data gathered from the CSD reveals that many of the searches 
for the amino-azole moiety coupled with an additional functional group consisted of a 
relatively small number of entries.  Furthermore, the conclusions from the data could be 
considered not statistically significant due to the lack of information.  Therefore further 
CSD analysis was conducted employing a simple azole (5-membered ring containing a 
nitrogen).  The reliability of supramolecular heterosynthon versus homosynthon 
formation between an azole and a carboxylic acid, primary amide, and alcohol were 
examined in the CSD.  Due to the inability of the azole to form a supramolecular synthon 
with itself; only the homosynthon formation of the carboxylic acid, primary amide, and 
alcohol moieties in the presence of an azole was examined.  A search of the CSD for 
entries that contained an azole and a carboxylic acid moiety resulted in 269 hits.  A closer 
look at the 269 entries revealed that the carboxylic acid dimer or catemer occurred in 41 
entries, or 15% of the time.  However, when the 269 entries were investigated for the 
presence of the azole-carboxylic acid supramolecular heterosynthon 120 entries were 
identified, suggesting that the heterosynthon will occur 45% of the time.  Thus when an 
azole and carboxylic acid are present in the same crystal structure the supramolecular 
heterosynthon is statistically more likely to occur.  When complexing a carboxylic acid to 
a basic moiety were the ΔpKa is large, the acid will protonate the basic moiety, resulting 
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in a carboxylate.  Due to the possibility of protonation with meloxicam, carboxylate-azole 
interactions were also searched in the CSD.  56 entries contained both moieties.  20 
(36%) contained the carboxylate-azole supramolecular heterosynthon in the crystal 
structure, suggesting that it is a viable target supramolecular heterosynthon.  A search of 
the CSD for the azole and primary amide moiety in the same crystal structure revealed 
115 entries.  66 (58%) of those entries were found to contain the amide dimer or catemer 
while only 37 (32%) were sustained via the amide-azole supramolecular heterosynthon.  
These statistics elucidate the strength of the amide supramolecular homosynthon in the 
presence of the azole functional group and further indicate that a cocrystal of meloxicam 
with a molecule containing a primary amide moiety is unlikely to occur.  The complexing 
of alcohols and azoles was also studied in the CSD.  There were 977 entries that 
contained both moieties.  21% (202) possess the alcohol homosynthon but 40% (386) 
were sustained by the supramolecular heterosynthon formation.  Statistically this suggests 
that the supramolecular heterosynthon is almost twice as likely to form as the 
homosynthon.  Collectively comparing the occurrence of the supramolecular 
homosynthon to the heterosynthon, the heterosynthon formation dominates in all cases 
except when in the presence of a primary amide.  Carboxylic acid and alcohol 
functionalities proved to be quite reliable for generating supramolecular heterosynthons 
and can be complexed with an azole moiety ca. 40% of the time.  The results of these 
searches are depicted in Table 4.3.  
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Table 4.2. Percent occurrence for supramolecular homosynthons and heterosynthons with amino-
azoles in the presence of carboxylic acids, carboxylates, primary amides, and alcohols 
 
 
Table 4.3. Percent occurrence for supramolecular homosynthons and heterosynthons with azoles 
in the presence of carboxylic acids, carboxylates, primary amides, and alcohols 
 
Based on the success rate of supramolecular heterosynthon formation with azoles 
and carboxylic acids, a meloxicam cocrystal screen with cocrystal formers containing 
carboxylic acid moieties was conducted.  Meloxicam was reacted with 1-hydroxy-2-
naphthoic acid, glutaric acid, L-malic acid, aspirin, and salicylic acid.  The 
cocrystallization attempts resulted in seven crystal forms, namely meloxicam 1-hydroxy-
2-naphthoic acid cocrystal, meloxicam glutaric acid cocrystal, meloxicam L-malic acid 
cocrystal of a salt, meloxicam aspirin cocrystal, meloxicam salicylic acid cocrystal form 
Complemen
tary 
Moiety 
No. of 
entries w/ 
both 
groups 
% 
Homosynthon 
occurrence: 
amino-azole 
% 
Homosynthon 
occurrence: 
Cocrystal 
former
% 
Heterosynthon 
occurrence 
Heterosynthon 
Distance Range 
(Å) 
Carboxylic 
acid 7 1/7 (14%) 0 4/7 (57%) 2.60-2.80 
Carboxylate 24 1/24 (4%) N/A 13/24 (54%) 2.60-2.80 
Primary 
amide 1 0 0 0 N/A 
Alcohol 38 13/38 (43%) 5/38 (13%) 6/38 (16%) 2.60-3.00 
Complementary 
Moiety 
No. of 
entries w/ 
both groups 
% Homosynthon 
occurrence: 
Cocrystal former 
% 
Heterosynthon 
occurrence 
Heterosynthon 
Distance Range 
(Å) 
Carboxylic acid 269 41/269 (15%) 120/269 (45%) 2.50-2.90 
Carboxylate 56 N/A 20/56 (36%) 2.60-2.90 
Primary amide 115 66/115 (58%) 37/115 (32%) 2.60-3.30 
Alcohol 977 202/977(21%) 386/977 (40%) 2.60-3.00 
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I, II, and III.  All crystal forms were analyzed in terms of supramolecular synthons as 
well as physical and pharmacokinetic properties and are presented herein.     
 
4.2.3. Crystal Structure Descriptions 
The meloxicam 1-hydroxy-2-naphthoic acid cocrystal, 1 crystallizes in the 
space group Pī.  The asymmetric unit contains one meloxicam and one 1-hydroxy-2-
naphthoic acid molecule.  The basic supramolecular unit is comprised of two meloxicam 
molecules and two 1-hydroxy-2-naphthoic acid molecules with the inversion center 
located in the center of the meloxicam dimer (shown in Figure 4.4.).  The meloxicam 
dimer is a common motif found in many meloxicam cocrystals and is sustained by two 
planar meloxicam molecules interacting via electrostatic interactions between the alcohol, 
ketone and sulfathiazole moieties.  In 1 meloxicam sustains intramolecular alcohol-
ketone interactions and binds to the neighboring meloxicam via an S???OH interaction at 
a distance of 3.148(6) Å to form the meloxicam dimer. The exterior of the meloxicam 
dimer hydrogen bonds to two 1-hydroxy-2-naphthoic acid molecules via two 2-point 
recognition carboxylic acid-thiazole/NH interactions [O2-H2???N1: O???N 2.596(6) Å, 
H???N 1.763 Å, O-H???N 170.90 º, N2-H2???O2: N???O 2.935(6) Å, H???O 2.086 Å, N-
H???O 161.66 º].  This two point recognition supramolecular synthon motif is quite robust 
as it is found in all cocrystal forms reported herein.  The hydroxyl group of the 1-
hydroxy-2-naphthoic acid ortho to the carboxylic acid moiety is involved in 
intramolecular hydrogen bonding which is expected based upon Etter’s rules.53  The 
overall packing, illustrated in Figure 4.5 is sustained by supramolecular units of 
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meloxicam and 1-hydroxy-2-naphthoic acid molecules that stack upon each other along 
the a-axis in a slipped fashion with an interplanar spacing of 3.735 Å. 
 
 
Figure 4.4. Supramolecular unit of 1 
 
 
 
 
 
Figure 4.5. Crystal packing of four supramolecular units of 1 
 
 
Crystal form 2 is the meloxicam glutaric acid cocrystal.  The asymmetric unit of 
2 is comprised of one meloxicam and one glutaric acid molecule and crystallizes in the 
space group Pī.  The meloxicam centrosymmetric dimer is also present in 2 and is 
sustained by an S???OH interaction between two planar meloxicam molecules with a 
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distance of 3.224(2) Å.  Meloxicam also participates in OH???O (ca. 2.62 Å) 
intramolecular hydrogen bonding.  Interestingly, glutaric acid utilizes one of its 
carboxylic acid moieties to form a centrosymmetric carboxylic acid dimer [O4-H4???O3: 
O???O 2.646(2) Å, H???O 1.808 Å, O-H???O 175.96º] with a neighboring glutaric acid.   
The second free carboxylic acid moiety hydrogen bonds to the meloxicam molecule 
resulting in the unexpected 1:1 stoichiometery.  The carboxylic acid-azole 
supramolecular heterosynthon dimer is sustained by hydrogen bond interactions that 
afford the common 2-point recognition motif.  The OH???N and NH???O interaction are 
shown in Figure 4.6. [O2-H2???N1: O???N 2.675(2) Å, H???N 1.837 Å, O-H???N 174.24º; 
N2-H2???O1: N???O 2.849(2) Å, H???O 1.990 Å, 165.07º].   The culmination of 
supramolecular homosynthon and heterosynthon dimers ultimately results in the 
formation of a zig-zag chain that cuts through the ac-plane.  The chains stack along the a-
axis and are separated by a meloxicam plane to plane distance of 3.502 Å.  Figure 4.7. 
highlights the crystal packing of multiple chains with the meloxicam dimers and glutaric 
acid dimers disposed in a columnar arrangement.  The angle sustained between the C1-
C2-C3 of the glutaric acid molecule in 2 is atypical.  The C1-C2-C3-C4 torsion angle in 
both polymorphs of pure glutaric acid is ca.170º, however, in 2; the same angle is 52.89º.  
A search of the CSD for additional glutaric acid cocrystals afforded multiple hits 
however; examining the glutaric acid molecules for the similar smaller torsion angle 
resulted in only two hits: caffeine glutaric acid cocrystal (REFCODE: EXUQUJ) and  
theophylline glutaric acid cocrystal (REFCODE: XEJXIU).  The conformations of the 
glutaric acid molecules present torsion angles of 79.34º and 65.18º, respectively.         
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Figure 4.6. Meloxicam glutaric acid cocrystal (2) supramolecular synthons 
 highlighting the meloxicam and glutaric acid dimers 
 
 
 
Figure 4.7. Crystal packing of multiple chains of 2 
 
 
 190
The asymmetric unit of the meloxicam L-malic acid cocrystal of a salt (3) 
contains one meloxicam cation, one neutral meloxicam, and one L-malate anion.  3 is 
therefore considered a cocrystal of a salt and crystallizes in the space group P1.  Based 
upon the ΔpKa it was not predicted that the L-malic acid would protonate meloxicam, 
however, crystal forms do not always follow the ΔpKa general guidelines.  In 3 the 
meloxicam dimer persists but is unique as it is comprised of one cation and one neutral 
meloxicam and is sustained by two S???OH interactions (3.20(2) Å, 3.28(2) Å).  Figure 
4.8. illustrates the interactions between the anion, cation, and neutral molecule.  3 is 
primarily sustained by the L-malate anion acting as a bridge to connect the meloxicam 
dimers ultimately forming a chain.  The L-malate bridge protonates the sulfathiazole ring 
via the O-???+HN interactions [O1-???+H1-N1: O-???+N 2.70(3) Å, H???O 1.849 Å, O-???+H-
N 168.90º ; O2-???+H2-N2: O-???+N 2.89(3) Å, H???O 2.045 Å, O-???+H-N 168.31º] and 
hydrogen bonds to the sulfathiazole of the neutral meloxicam via OH???N and NH???O 
interactions [O4-H4???N4: O???N 2.73(3) Å, H???N 1.919 Å, O-H???N 172.42 º ; O5???H5-
N5: O???N 2.90(3) Å, H???O 2.078 Å, O-H???N 160.08 º].  Thus the L-malate and 
meloxicams generate a 2D structure comprised of chains that stack parallel along the a-
axis with an interplanar spacing of 3.176 Å, shown in Figure 4.9.  The supramolecular 
chains exhibited by 3 are reminiscent of those seen in 2 which is unsurprising due to the 
employment of a diacid as a cocrystal former in both cocrystallization experiments.  The 
supramolecular synthon analysis of 3 proves that the sulfathiazole ring and the NH of the 
amide is an excellent synthon recognition point for both carboxylic acids and 
carboxylates. 
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Figure 4.8. Supramolecular synthons in 3 showing a neutral  
and cationic meloxicam and an anionic L-malate 
 
 
Figure 4.9. Stacked layers of the meloxicam L-malic acid cocrystal of a salt (3),  
L-malate anions are shown in green. 
 
 
The meloxicam aspirin cocrystal (4) crystallizes in the space group P21/c.  The 
asymmetric unit contains one meloxicam molecule and one aspirin molecule, shown in 
Figure 4.10.  The meloxicam dimer is again present in 4; however, the planar meloxicam 
molecules are held into the dimer conformation at a distance of 3.632(2) Å apart by weak 
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interactions.  This distance is the furthest distance of all the cocrystals in this study that 
contain the dimer.  The primary interactions sustaining the cocrystal are the hydrogen 
bonds present between the carboxylic acid moiety of the aspirin molecule and the 
sulfathiazole/NH moiety of the meloxicam.  The resulting supramolecular heterosynthon 
is the 2-point recognition hydrogen bonded dimer which affords the basic 
meloxicam:aspirin supramolecular unit shown in Figure 4.10.  The OH???N hydrogen 
bond distance is 2.665(3) Å[O2-H2???N1: O???N 2.665(3) Å, H???N 1.850 Å, O-H???N 
173.36º] and the NH???O distance is 2.856(3) Å [N2-H2???O1: N???O 2.856(3) Å, H???O 
2.015 Å, N-H???O 165.60 º].  Additional meloxicam:aspirin supramolecular units are 
generated by translation along the 21 screw axis running parallel to the a-axis (Figure 
4.11.).  As the meloxicam:aspirin units extend along the a-axis they simulate a corrugated 
sheet that propagates with a dihedral angle of 73.69 º.  The corrugated sheets then stack 
upon each other separated by a distance of ca. 3.87 Å producing a herringbone motif.     
 
 
Figure 4.10. Meloxicam aspirin cocrystal (4) basic supramolecular unit 
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Figure 4.11. Units of the meloxicam aspirin cocrystal (4) translating along a 21 screw axis 
 
The supramolecular unit of the meloxicam salicylic acid cocrystal form III (5) 
is comprised of one molecular meloxicam and one molecular salicylic acid, shown in 
Figure 4.12. and crystallizes in the space group P21/c.  The cocrystal is primarily 
sustained by the salicylic acid hydrogen bonding to the meloxicam via the carboxylic 
acid to sulfathiazole/NH supramolecular heterosynthon.  The carboxylic acid-
sulfathiazole OH???N hydrogen bond distance is 2.627(5) Å[O2-H2???N1: O???N 2.627(5) 
Å, H???N 1.836 Å, O-H???N 161.74 º] and the NH-carboxylic acid NH???O distance is 
2.975(5) Å [N2-H2???O1: N???O 2.975(5) Å, H???O 2.139 Å, N-H???O 164.02º].  This 
hydrogen bonding motif generates a discrete unit containing one meloxicam and one 
salicylic acid molecule.  The salicylic acid OH moiety is involved in intramolecular 
hydrogen bonding with its carboxylic acid.  The meloxicam dimer does not exist in 5 as 
the meloxicam molecules in the neighboring supramolecular units are perpendicular 
rather than parallel.  The supramolecular units in 5 translate along the 21 screw axis at a 
dihedral angle of 88.80º and are sustained by various weak interactions (Figure 4.13.).  5 
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is the only cocrystal reported herein that does not exhibit the meloxicam dimer.  The 
absence of the dimer may contribute to its unique solubility and pharmacokinetic 
properties.  Single crystals of suitable quality for single crystal X-ray diffraction of the 
meloxicam salicylic acid form I (7) or form II (6) could not be obtained. 
 
 
Figure 4.12. Meloxicam salicylic acid cocrystal form III (5)  
2-point recognition supramolecular synthon 
 
 
 
 
Figure 4.13. Meloxicam salicylic acid units translating along a 21 screw axis 
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Table 4.4. Crystal structure parameters for cocrystals 1-5 
 
 
4.2.4. Melting Point Analysis 
It has been shown that the melting point of the cocrystal can typically be found in 
between the melt of the cocrystal former and the target active pharmaceutical 
ingredient.54, 55  Recent literature has also attempted to predict melting points56 and 
correlate melting points of materials to chemical structure of small simple molecules with 
some success.57  However, predicting melting points of larger molecules such as 
pharmaceuticals proves to be a nontrivial task.   
 1 2 3 4 5 
Chemical 
formula 
C14H13N3O4S2  
C11H8O3 
 
C14H13N3O4S2
C5H8O4 
 
C14H14N3O4S2  
C14H13N3O4S2    
C4H5O5     
C14H13N3O4S2       
C9H8O4 
C14H13N3O4S2  
C7H6O3 
 
Form weight 539.60 483.51 836.88 531.55 489.50 
Crystal 
System 
Triclinic Triclinic Triclinic Monoclinic Monoclinic 
Space group Pī Pī P1 P21/c P21/c 
a (Å) 6.978(2) 7.202(3) 7.278(9) 6.8015(7) 11.1028(9) 
b (Å) 12.135(2) 8.462(3) 8.550(2) 19.1397(2) 11.8549(9) 
c (Å) 15.189(2) 18.428(7) 15.150(2) 18.752(2) 16.4728(2) 
α (o) 113.07(3) 80.761(7) 84.11(2) 90 90 
β (o) 92.68(3) 85.486(7) 81.62(4) 94.907(8) 97.255(6) 
γ (o) 95.85(2) 70.877(6) 70.489(15) 90 90 
Vol (Å3) 1172(3) 1046.9(7) 877.6(19) 2432.1(4) 2150.8(3) 
Dcal (g cm-3) 1.529 1.534 1.583 1.452 1.509 
Z 2 2 1 4 4 
Reflections 
collected 
2414 6350 3902 17777 15380 
Independent 
reflections    
2414 4554 3151 4302 3662 
Observed 
reflections    
1875 3752 1719 3163 2281 
T (K) 100 100 298 293 293 
R1 0.0471 0.0375 0.1124 0.0411 0.0556 
wR2 0.1075 0.0973 0.2846 0.1015 0.1526 
GOF 0.991 1.009 1.253 0.987 1.072 
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The melting points of the meloxicam crystal forms 1-7 were measured via 
differential scanning calorimetry (DSC) and compared to the melting points of both 
meloxicam and the respective cocrystal former.  The melting points of the cocrystal 
formers were obtained from materials safety datasheets.58-62  A summary of the results are 
presented in Table 4.5.  The melting points for all the cocrystals were found to follow the 
trends found in the literature.  The cocrystals melted above the melt of the cocrystal 
former and below the melting point of meloxicam.  The polymorphic salicylic acid 
cocrystals resulted in similar melting points with little variation between crystal forms.  A 
graphical representation of the data is shown in Figure 4.12. where the melting point of 
the cocrystal is plotted vs. the melting point of the cocrystal former.  The R2 value was 
calculated to be 0.7335 thus showing an overall good correlation between the melting 
points of the two materials.   
 
Table 4.5. Melting points for meloxicam, cocrystal formers, and there corresponding cocrystals 
 
 
Crystal form 
 
Melting point 
of former 
ºC 
Melting point 
of cocrystal 
ºC 
Meloxicam 254 254 
1-Hydroxy-2-naphthoic 
acid 
183 225 
Glutaric acid 95 149 
L-Malic acid 101 200 
Aspirin 136 164 
Salicylic acid form III 159 210 
Salicylic acid form I 159 205 
Salicylic acid form II 159 206 
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Figure 4.14. Plot for analysis of melting point of cocrystal versus  
melting point of cocrystal former 
 
4.2.5. Solubility and Dissolution Study  
Solubility and dissolution measurements of five cocrystal forms (1-5) and pure 
meloxicam were conducted at 37 ºC in pH 8 phosphate buffer.  A pH 8 buffer was chosen 
because it is believed that meloxicam is absorbed in the more basic conditions of the 
intestine where the most basic regions can reach a pH of 8.26, 63  A phosphate buffer was 
employed so that the pH of the solution could not vary with the addition of acidic 
cocrystal formers.  6 was not tested because the cocrystal could not be made in gram 
level quantities.  7 was also not tested because it did not pass 1 month of the accelerated 
stability test (40 ºC, uncontrolled humidity).  The dissolution profiles are shown in Figure 
4.15. 
The maximum solubility achieved for pure meloxicam after four hours was ca. 0.8 
mg/mL which is similar to the reported literature solubility of (ca. 1 mg/mL in a pH 8 
solution).27  The cocrystal that achieved the highest and lowest solubility after four hours 
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was 1 and 2, respectively.  Since the project goal was to reduce the time it takes for the 
meloxicam to reach therapeutic levels, the cocrystals that obtained the highest 
concentrations at the earliest time points were the most desirable.  3 reached a 
concentration of 1.06 mg/ml at the 5 minute time point, the highest of all the cocrystals 
tested.  5 was second with a concentration of 0.967 mg/ml after 5 minutes.  Cocrystals 1, 
2, and 4 obtained similar low concentrations (ca. 0.4 mg/ml) and pure meloxicam reached 
a 0.100 mg/ml concentration after 5 minutes.   
The dissolution profile for 3 was an exemplary “spring and parachute” model that 
unfortunately experienced a receding concentration that decreased by half after 1 hour.  
The inflated early concentration was most likely due to the high solubility of the cocrystal 
former, L-malic acid, which was the most soluble cocrystal former in the pH 8 buffer 
solution (961 mg/ml).   
The spring and parachute type dissolution profile is becoming more of a common 
occurrence amongst cocrystals.55, 64-66  First shown by Childs in the dissolution of 
fluoxetine HCl succinic acid cocrystal,64 the spring and parachute model portrays the 
ability of the cocrystal former to improve the solubility of the API at early time points.  
This can be advantageous for decreasing the time required for the API to reach maximum 
concentration.  Over time, at a rate that is cocrystal dependant, the cocrystal falls apart 
and the concentration in solution reduces back down to a level similar to that of the pure 
API.  It has been postulated by Rodríguez-Hornedo that the change in solubility of the 
API is related to the solubility of the cocrystal former.  Specifically, the solubility of the 
cocrystal former is directly proportional to the solubility of the related cocrystal.67  Her 
theory is predicated upon the analysis of a selected set of carbamazepine, theophylline, 
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and caffeine cocrystals.   To determine if her findings were more of a general occurrence 
or an anomaly, the solubility of the cocrystal formers employed herein were compared to 
the solubility of the resulting cocrystals. 
The solubility of glutaric acid, aspirin, 1-hydroxy-2-naphthoic acid, and salicylic 
acid were measured at 741, 14, 11, and 10 mg/ml, respectively.  Based upon the 
observations with L-malic acid one would expect that 2 (meloxicam glutaric acid 
cocrystal) would achieve the second highest initial solubility, but it did not.  5, with a 
cocrystal former solubility of 10 mg/ml was second, with a dissolution profile that was 
also a spring and parachute.  Therefore the solubility of the cocrystal former did not 
correlate to the solubility of the cocrystals presented here.  These findings are 
contradictory to recently published results.67   
The maximum concentration achieved by 5 was 1.29 mg/ml after 20 minutes of 
slurring, which was greater than a 3-fold improvement over meloxicam.  This 
improvement in solubility could provide the improved absorption required for patients to 
reach an earlier efficacy.  Interestingly, the dissolution profile for 5 and 4 merge after 
approximately 1 hour and both cocrystals maintain a similar concentration for the 
remainder of the study.  This may be due to the hydrolysis of aspirin to salicylic acid in 
aqueous solutions.   
The dissolution profile for 1 was unique as the thermodynamic solubility was not 
obtained after 4 hours of slurring.  The maximum concentration measured for 1 in this 
study was 1.35 mg/ml.  1 was also intriguing because the solid material remaining after 
the dissolution study was intact cocrystal based on powder X-ray diffraction.  The 
remaining solids post dissolution study for 2-5 and pure meloxicam were found to be 
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meloxicam form I also based upon powder X-ray diffraction.  The stability of 1 in 
solution is most likely a reflection of its high melting point which is indicative of high 
lattice energy68 (225 ºC, the highest of all reported cocrystals).          
 
 
Figure 4.15. Dissolution profiles for meloxicam and five crystal forms in pH 8 buffer, 37 ºC 
 
4.2.6. Animal Pharmacokinetic (PK) Study  
The single dose rat pharmacokinetic study was conducted by Vasyl Sava and Shijie Song 
at the James A. Haley VA hospital in Tampa.  Samples 1-6 and pure meloxicam were 
tested.  The plasma concentrations as a function of time are shown in Figure 4.16.  7 was 
not studied because the cocrystal lattice collapsed after 1 month of exposure to 40 ºC in 
uncontrolled humidity.  The maximum plasma concentration achieved at the end of the 4 
hour study was 60.9 μg/ml by form 4.  The concentrations for 3 and 6 were similar to the 
maximum obtained for meloxicam; however, all three crystal forms showed similarly low 
plasma levels averaging ca. 38 μg/ml.  The plasma concentration for 2, however, led to a 
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very intriguing profile.  During the first hour of the study 2 had a profile similar to the 
meloxicam profile.  But, during the last 3 hours the concentration increased at a faster 
rate than pure meloxicam resulting in a 4 hour plasma concentration that was 15 μg/ml 
greater than pure meloxicam.  An examination of the areas under the curve (AUC) for the 
cocrystals presented in this study shows that 4 has the highest AUC, followed by 1.  The 
AUC’s for 3 and 6 are similar and greater than pure meloxicam, however, they exhibit 
the lowest for all cocrystals in this study.  5 exhibits a similar profile to 1, but 5 
experiences a much higher plasma concentration after 15 minutes.  Since the goal of the 
study was to generate cocrystals with an earlier onset of efficacy, the desired crystal form 
must show a plasma concentration at the earliest time point that is equivalent to the 
maximum obtained by pure meloxicam.  This criterion eliminates 1 and 4 even though 
they show the greatest AUCs because they take over an hour to reach their maximum 
concentrations.  5 is therefore the cocrystal to take further into additional studies.   
Interestingly, 5 obtains the highest plasma concentration after 15 minutes and is 
also the most soluble cocrystal after a 10 minute slurry in pH 8 solution at 37°C.  The 
solubility of cocrystals 1-4 after 10 minutes and their plasma concentrations after 15 
minutes were examined further to determine if a general correlation existed between the 
solubility and plasma concentration.  Figure 4.17. highlights the linear trend ( R2 = 
0.8651) that can be drawn illustrating that the more soluble the cocrystal at 10 minutes 
the greater the improvement in plasma concentration at early time points.  These results 
show that to quicken the onset of a drug that is well absorbed but has low solubility; a 
more soluble cocrystal will increase the early plasma concentrations such that the drug 
could reach therapeutic concentrations at a faster rate.    
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Figure 4.16. Rat plasma concentrations after single dose administration of  
meloxicam and six cocrystals 
 
 
Figure 4.17. Cocrystal and meloxicam solubility versus rat plasma concentration 
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4.3. Conclusions 
The ability to modify the physical properties of an API but still maintain its 
therapeutic attributes by altering the crystal form is an important area of research and 
discovery.  In this contribution seven novel crystal forms of meloxicam are presented and 
analyzed based upon their supramolecular synthons, melting points, solubility, and PK 
profiles.  A prominent aspect of cocrystals 1-4 is the presence of the meloxicam dimer.  
The meloxicam molecules in 5, however, are juxtaposed such that the dimer cannot form.  
A salient feature in 1-5 is the 2-point recognition carboxylic acid-azole/NH 
supramolecular heterosynthon.  An analysis of the melting points of 1-7 and the 
respective cocrystal formers illustrated that the melting points of the cocrystals were 
typically in between the melting points of meloxicam and the cocrystal former.  The 
highest melting cocrystal, 1, was also the only cocrystal to remain intact throughout the 
solubility/dissolution study.   
The solubility and dissolution profiles for 1-5 showed that after 4 hours 1 was the 
most soluble and 2 was the least soluble cocrystal.  The solubility of the cocrystal was not 
related to the solubility of the cocrystal former.  Due to the purpose of the study, i.e. 
decrease the time taken for meloxicam to reach therapeutic concentrations, the greater 
solubility of the cocrystal at the early time points was of greater importance than the 
solubility at 4 hours thus narrowing the desirable cocrystal list down to 3 and 5.  To select 
one both solubility/dissolution and PK data was considered.  
The AUCs from the rat PK data were the lowest for 2, 3, and 6.  1 and 4 showed a 
plasma concentration that gradually increased over the 4 hour period resulting in 
therapeutic concentrations after approximately 30 minutes to 1 hour.  5, however, reached 
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the therapeutic concentration after 15 minutes thus 5 would be the desired crystal form 
for future product development as it experienced the solubility and pharmacokinetic 
profile that is most likely to reduce the time needed to obtain the therapeutic 
concentration and patient efficacy.  Unfortunately, there are known complications when 
aspirin, which hydrolyzes to salicylic acid, is administered concomitantly with 
meloxicam.  The acid causes an increase in the AUC by 10% and the maximum 
concentration increases by 24%.  There is no explanation in the literature for this 
conundrum but results presented in this study indicate that the effect is most likely due to 
cocrystal formation.    
The cocrystals of meloxicam presented herein provide further evidence that 
cocrystals can change the physical and pharmacokinetic properties of an API.  The 
greatest improvements in solubility and PK profile were shown with meloxicam salicylic 
acid form III (5), however, due to the clinical warnings the meloxicam 1-hydroxy-2-
naphthoic acid cocrystal (1) would be taken further into clinical trials as the 
pharmacokinetic profile suggests that 1 will achieve similar efficacy after 30 minutes.                 
 
4.4. Materials and Methods 
4.4.1. Materials 
Meloxicam was purchased from Jai Radhe Sales, India with a purity of 99.64% 
and was used without further purification.  All other chemicals were supplied by Sigma-
Aldrich and used without further purification. 
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4.4.2. Synthesis of Compounds 1-7 
Meloxicam was reacted with five cocrystal formers shown in Scheme 4.2.  They 
were 1-hydroxy-2-naphthoic acid, glutaric acid, L-malic acid, aspirin, and salicylic acid.  
The cocrystallization attempts resulted in seven crystal forms.  All of the crystal forms 
can be made from solvent-drop grinding and slurrying, however, only five crystal forms 
can be made from solution crystallization.   
Synthesis of meloxicam 1-hydroxy-2-naphthoic acid cocrystal (1) – (a) 
solvent-drop grinding – 0.176 g (0.501 mmol) meloxicam was ground together with 
0.0957 g (0.508 mmol) of 1-hydroxy-2-naphthoic acid and 40 μl of tetrahydrofuran 
(THF) for 30 minutes in a ball-mill.  1 was generated in ca. 100% yield.  (b) slurry – 
0.700 g (1.99 mmol) meloxicam and 0.391 g (2.07 mmol)of 1-hydroxy-2-naphthoic acid 
were slurried in 3ml of THF overnight sealed under ambient conditions at ca. 250 rpm. 
The resulting solid was filtered and washed with THF.  1 was obtained in ca. 90% yield.  
(c) solution crystallization – 0.0176 g (0.0501mmol) meloxicam and 0.0095 g (0.505 
mmol) of 1-hydroxy-2-naphthoic acid dissolved in 10 ml of ethyl acetate and left to 
slowly evaporate.  1 was obtained in ca. 93% yield.   
Synthesis of meloxicam glutaric acid cocrystal (2) – (a) solvent-drop grinding – 
0.179 g (0.511 mmol) meloxicam was ballmilled together with 0.0699 g (0.529 mmol) of 
glutaric acid and 40 μl of chloroform for 30 minutes, producing 2 in ca. 100% yield. (b) 
slurry – 0.892 g (2.54 mmol) meloxicam and 0.351 g (2.66 mmol) of glutaric acid were 
slurried in 3 ml of ethyl acetate overnight sealed under ambient conditions at ca. 250 rpm.  
The resulting solid was filtered and washed with ethyl acetate.  2 was made in ca. 96% 
yield.  (c) solution crystallization – 0.0194 g (0.0552 mmol) meloxicam and 0.159 g (1.20 
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mmol) of glutaric acid dissolved in 2 ml of ethyl acetate and left to slowly evaporate.  2 
was isolated in ca. 89% yield. 
Synthesis of meloxicam L-malic acid cocrystal of a salt (3) – (a) solvent-drop 
grinding – 0.176 g (0.501mmol) meloxicam was ground together with 0.0361 g (0.269 
mmol) of L-malic acid and 40 μl of THF for 30 minutes in a mechanical ball-mill. 3 was 
generated in ca. 100% yield.  (b) slurry – 0.897 g (2.55 mmol) meloxicam and 0.182 g 
(1.36 mmol) of L-malic acid were slurried in 3ml of THF overnight sealed under ambient 
conditions at ca. 250 rpm.  The solid was filtered and washed with THF resulting in ca. 
92% yield of 3.  (c) solution crystallization – 0.0214 g (0.0609 mmol) meloxicam and 
0.0416 g (0.301 mmol) of L-malic acid dissolved in 2 ml of a 1:1 mix of dioxane and 
ethyl acetate and left to slowly evaporate.  The resulting single crystals of 3 were isolated 
in ca. 82% yield. 
Synthesis of meloxicam aspirin cocrystal (4) – (a) solvent-drop grinding – 0.182 
g (0.517 mmol) meloxicam was ball-milled together with 0.0966 g (0.536 mmol) of 
aspirin and 40 μl of chloroform for 30 minutes to obtain 4 in ca. 100% yield. (b) slurry – 
0.905 g (2.56 mmol) meloxicam and 0.452 g (2.51 mmol) of aspirin were slurried in 3ml 
of THF overnight sealed under ambient conditions at ca. 250 rpm. The resulting solid was 
filtered and washed with THF.  4 was isolated in 96% yield.  (c) solution crystallization  - 
0.0232 g (0.0660 mmol) meloxicam and 0.110 g (0.611 mmol) of aspirin dissolved in 8 
ml of ethyl acetate and left to slowly evaporate, generating single crystals of 4 (ca. 35% 
yield) concomitantly with meloxicam form I and aspirin.   
Synthesis of meloxicam salicylic acid form III (5) – (a) solvent-drop grinding – 
0.174 g (0.495 mmol) meloxicam was ball-milled together with 0.0724 g (0.524 mmol) 
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of salicylic acid and 40 μl of ethyl acetate for 30 minutes.  5 was synthesized in ca. 100% 
yield.  (b) slurry – 0.876 g (2.49 mmol) meloxicam and 0.350 g (2.53 mmol) of salicylic 
acid were slurried in 2 ml of THF overnight sealed under ambient conditions at ca. 250 
rpm. The resulting solid was filtered and washed with THF.  5 was isolated in ca. 84% 
yield.  (c) solution crystallization – 0.0226 g (0.0643 mmol) meloxicam and 0.0787 g 
(0.570 mmol) of salicylic acid was dissolved in 8 ml of a 6:2 mixture of ethyl acetate and 
dioxane, respectively, and left to slowly evaporate.  Single crystals of 5 (ca. 33% yield) 
grew concomitantly with meloxicam form I and salicylic acid. 
Synthesis of meloxicam salicylic acid form I (6) – (a) solvent-drop grinding – 
0.177 g (0.504 mmol) meloxicam was ball-milled together with 0.0675 g (0.489 mmol) 
of salicylic acid and 40 μl of THF for 30 minutes.  6 was made in ca. 100% yield.  (b) 
slurry – 0.871 g (2.47 mmol) meloxicam and 0.352 g (2.55 mmol) of salicylic acid were 
slurried in 2 ml of methanol overnight sealed under ambient conditions at ca. 250 rpm. 
The resulting solid was filtered and washed with methanol.  6 was obtained in ca. 91% 
yield.   
Synthesis of meloxicam salicylic acid form II (7) – (a) solvent-drop grinding – 
0.175 g (0.498 mmol) meloxicam was ball-milled together with 0.0705 g (0.510 mmol) 
of salicylic acid and 40 μl of chloroform for 30 minutes, generating 7 in ca. 100% yield. 
(b) slurry – 0.869 g (2.47 mmol) meloxicam and 0.356 g (2.58 mmol) of salicylic acid 
were slurried in 2 ml of chloroform overnight sealed under ambient conditions at ca. 250 
rpm. The resulting solid was filtered and washed with chloroform.  7 was isolated in ca. 
89% yield.  
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4.4.3. Crystal Form Characterization   
Single-Crystal X-ray Diffraction: Single crystals were obtained for five 
compounds.  Attempts to crystallize 6 and 7 did not afford crystals suitable for single 
crystal X-ray crystallographic analysis.  Single crystal analysis for 1-3 was performed on 
a Bruker-AXS SMART APEX CCD diffractometer with monochromatized Mo Kα 
radiation (λ = 0.71073 Å) connected to a KRYO-FLEX low-temperature device while 
4and 5 was collected using a Cu Kα radiation (λ = 1.54178 Å).  Data for 1, 2 was 
collected at 100 K.  Data for 3- 5 was collected at 293 K. Lattice parameters were 
determined from least-squares analysis, and reflection data were integrated using 
SAINT.69  Structures were solved by direct methods and refined by full matrix least 
squares based on F2 using the SHELXTL package.70  All non-hydrogen atoms were 
refined with anisotropic displacement parameters. All hydrogen atoms bonded to carbon, 
nitrogen, and oxygen atoms were placed geometrically and refined with an isotropic 
displacement parameter fixed at 1.2 times Uq of the atoms to which they were attached.  
Hydrogen atoms bonded to methyl groups were placed geometrically and refined with an 
isotropic displacement parameter fixed at 1.5 times Uq of the carbon atoms. 
Powder X-Ray Diffraction (PXRD): 1-7 were characterized by a D-8 Bruker X-
ray Powder Diffractometer using a Cu Kα radiation (λ = 1.54178 Å), 40kV, 40mA. Data 
was collected over an angular range of 3° to 40° 2θ value in continuous scan mode using 
a step size of 0.05° 2θ value and a scan speed of 1.0 º/min.   
Calculated PXRD: Calculated PXRD diffractograms were generated from the 
single crystal structures using Mercury 1.5 (Cambridge Crystallographic Data Centre, 
UK) for the following complexes: 1-5 for comparison to the bulk sample. 
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Differential Scanning Calorimetry (DSC): Differential Scanning Calorimetry 
was performed on a Perkin Elmer Diamond DSC with a typical scan range of 25 ºC – 280 
ºC, scan rate of 10 ºC/min, and nitrogen purge of ca. 30 psi. 
Fourier Transform Infrared Spectroscopy (FT-IR):  FT-IR analysis was 
performed on a Perkin Elmer Spectrum 100 FT-IR spectrometer equipped with a solid-
state ATR accessory. 
Ultraviolet-Visible Spectroscopy (UV/Vis):  UV/Vis analysis was performed on 
a Perkin Elmer Lambda 25 UV/Vis spectrophotometer. 
High Performance Liquid Chromatography (HPLC): Analysis was performed 
on an HPLC system (Perkin Elmer Instruments LLC) comprising the following units: a 
series 200 Gradient Pump; a 785A UV/VIS Detector; a series 200 Autosampler; an NCI 
900 Network Chromatography Interface and a 600 Series Link. The system was operated 
by a Total Chrome Workstation. The sample holder temperature was kept at 4 ºC with a 
flow rate of 1 mL/min.  The column was a Microsorb-MV 300-5 C-18 (250 x 4.6 mm x 
1/4”).  The mobile phase consisted of a mixture of phosphate buffer (pH 3.0) with 
methanol (1/1, v/v). The phosphate buffer was prepared from 50 mmol/L Na2HPO3 water 
solution with pH-controlled HCl titration. 
 
4.4.4. Solubility and Dissolution Study 
Dissolution profiles and thermodynamic solubility were obtained for five crystal 
forms (1-5) in pH 8 phosphate buffer at 37 ºC.  The study was conducted using excess 
free flowing solid, stirring with a magnetic stir bar at a rate of ca. 250-300 rpm.  The 
solids were sieved to achieve a particle size between 53-75μm.  Aliquots were taken out 
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after 5, 10, 20, 30, 40, 50, 60, 75, 90, 105, 120, 150, 180, and 240 minutes and filtered 
with 0.45 μm filters.  The resulting solution was processed and the concentration of 
meloxicam was measured using a UV/Vis spectrophotometer.  The experiment was 
repeated twice to allow for statistical analysis. 
 
4.4.5. Animal Pharmacokinetic (PK) Study 
  Six crystal forms (1-6) were submitted for pharmacokinetic analysis via a single 
dose oral gavage administration to Sprague-Dawley rats (225-250 g).  The rats were pre-
implanted with jugular vein catheters for withdrawing of blood samples.  The animals 
were allowed water ad libitum and fasted overnight before drug administration. The 
crystal forms were administered a dosage of 10 mg/kg of meloxicam or meloxicam 
cocrystal, in the suspension vehicle of a 5% PEG and 95% methyl cellulose aqueous 
solution.  After dosing, 2 ml of blood was withdrawn at 0, 15, 30, 45, 60, 120, and 240 
minutes. The blood samples were processed and analyzed by HPLC according to the 
literature procedure.71 
 
Table 4.6. Hydrogen bond distances and parameters  
Compound Hydrogen Bond d(H...A)/ Å d(D...A)/ Å θ/ º 
 
1 
N-H???O 2.09 2.935(6) 161.7 
O-H???N 1.76 2.596(6) 170.9 
O-H???O 2.59 3.075(5) 118.3 
O-H???O 1.85 2.585(5) 145.8 
O-H???O 1.87 2.603(5) 145.1 
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2 
O-H???O 2.45 2.917(2) 115.9 
O-H???N 1.84 2.675(2) 174.2 
N-H???O 1.99 2.849(2) 165.1 
O-H???O 1.81 2.646(2) 176.0 
O-H???O 1.89 2.6226(18) 144.4 
 
 
 
 
3 
N-H???O 2.08 2.90(3) 159.9 
N-H???O 2.05 2.89(3) 168.5 
N-H???O 1.85 2.70(3) 169.0 
O-H???N 1.92 2.73(3) 172.3 
O-H???O 2.42 2.90(3) 117.8 
N-H???N 2.23 2.67(3) 112.1 
O-H???O 1.86 2.59(3) 148.4 
O-H???O 2.49 2.92(2) 114.1 
O-H???O 1.98 2.67(3) 141.4 
O-H???O 2.32 2.81(2) 119.5 
O-H???O 2.51 3.04(3) 123.8 
 
4 
O-H???O 1.85 2.568(2) 145.7 
N-H???O 2.01 2.856(3) 165.6 
O-H???N 1.85 2.665(3) 173.4 
 
5 
N-H???O 2.14 2.975(5) 164.0 
O-H???N 1.84 2.627(5) 161.7 
O-H???O 1.84 2.556(4) 145.7 
O-H???O 1.97 2.678(5) 143.9 
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Chapter 5 – Summary and Future Directions 
 
5.1. Summary 
The field of supramolecular chemistry has grown dramatically since the early 
works of Jean-Marie Lehn, Donald Cram and others both in complexity and in scope.  
The subtopic crystal engineering has also grown alongside it from a [2+2] 
photodimerization topochemical reaction to pharmaceutical cocrystals with improved 
physicochemical properties. The research presented in this dissertation is a contribution 
to the current knowledge base of the crystal engineering of cocrystals with a particular 
focus upon two separate applications: cocrystal controlled solid-state synthesis and 
pharmaceutical cocrystallization.  Cocrystal controlled solid-state synthesis targets the 
cocrystal as the key intermediate stage that brings the two reactive components in close 
proximity such that the reaction can take place.  Once the cocrystal is formed then the 
reaction can occur faster and with greater yield than traditional solution methods.  The 
cocrystal controlled solid-state synthesis of imides was targeted due to the potential for 
supramolecular heterosynthon formation with the primary amine and carboxylic acid 
anhydride starting materials.  Three cocrystals: 1, 2-methyl-4-nitroaniline 1,4,5,8-
naphthalenetetracarboxylic dianhydride, (2:1), 2, 3-aminobenzoic acid 1,4,5,8-
naphthalenetetracarboxylic dianhydride, (2:1)), 3 (2-methyl-4-nitroaniline pyromellitic 
anhydride, (2:1))) were isolated and characterized by single crystal analysis, DSC, FTIR, 
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1HNMR, and PXRD.  Their transformations in the solid-state to their corresponding 
imides were closely monitored and the imides were also characterized.  Interestingly, the 
envisioned supramolecular synthon (amine-anhydride hydrogen bonding) did not occur, 
the cocrystals were instead sustained by π system interactions of the aromatic rings that, 
in some cases, was determined to be charge-transfer interaction.  The project concluded 
in an approximate 50% success rate of imide formation.    
Cocrystals were also studied in relevance to pharmaceuticals.  Lamotrigine and 
meloxicam were the targeted pharmaceuticals due to their inherently low solubility but 
high bioavailability.  The goal for both drugs was to improve the solubility by 
cocrystallizing with a pharmaceutically acceptable cocrystal former.  Additionally since 
meloxicam is a drug used for indications of acute pain, the goal was to reduce the time 
taken to reach the maximum concentration by at least half.   
Ten crystal forms were isolated for lamotrigine: lamotrigine methylparaben 
cocrystal form I (1:1) (1), lamotrigine methylparaben cocrystal form II (1:1) (2), 
lamotrigine nicotinamide cocrystal (1:1) (3), lamotrigine nicotinamide cocrystal 
monohydrate (1:1:1) (4), lamotrigine saccharin salt (1:1) (5), lamotrigine adipate salt 
(2:1) (6), lamotrigine malate salt (2:1) (7), lamotrigine nicotinate dimethanol solvate 
(1:1:2) (8), lamotrigine dimethanol solvate (1:2) (9), and lamotrigine ethanol 
monohydrate (1:1:1) (10).  An underlying theme for the lamotrigine cocrystals, salts, and 
solvates was the supramolecular synthon motifs.  All of the crystal forms either hydrogen 
bonded to the exterior of the lamotrigine dimer or they broke the lamotrigine dimer.  
Crystal forms 1, 5, 6, and 8 break the lamotrigine dimer while 2, 4, 7, 9, and 10 hydrogen 
bond to the exterior of the dimer.   
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Solubility and dissolution measurements were conducted on crystal forms 1-5 and 
pure lamotrigine in water and pH 1 HCl solution.  5 was the most soluble crystal form in 
water, however, it was the least soluble in the pH 1 HCl solution.  Instead, 2 exhibited the 
highest concentration in the acidified solution.  The average concentration for 2 and 4 in 
aqueous solution were similar to that of lamotrigine while 3 was similar to the maximum 
of lamotrigine.  In the acidic media the concentrations for 2, 3, 4, and 5 all surpassed that 
of pure lamotrigine.  The solubility of the cocrystal former did not correlate to the 
solubility of the corresponding cocrystal.        
The animal pharmacokinetic data was gathered via a single dose rat study.  The 
area under the curve for the serum concentrations after administration of 5 was increased 
by 66% compared to lamotrigine.  The other crystal forms, 3 and 4, however, resulted in 
a decrease in serum concentration by 37% and 26%, respectively. 
Analyzing the solubility and pharmacokinetic data in light of the original goal 
shows that the crystal forms of lamotrigine show great potential for an improved drug in 
clinical studies.  5 exhibits the greatest improvements in solubility and serum 
concentration thus 5 is the best candidate for further clinical studies. 
Pharmaceutical cocrystallizations of meloxicam afforded seven novel cocrystals: 
meloxicam 1-hydroxy-2-naphthoic acid cocrystal (1:1) (1), meloxicam glutaric acid 
cocrystal (1:1) (2), meloxicam L-malic acid cocrystal of a salt (1:1:1) (3), meloxicam 
aspirin cocrystal (1:1) (4), meloxicam salicylic acid cocrystal form III (1:1) (5), 
meloxicam salicylic acid cocrystal form II (1:1) (6), and meloxicam salicylic acid 
cocrystal form I (1:1) (7).  Five of the seven resulting crystal forms were analyzed in 
terms of their crystal packing, solubility, dissolution rate, and pharmacokinetic properties.   
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Crystal structures of cocrystals 1-5 were obtained from single crystal X-ray 
diffraction analysis of high quality single crystals grown from slow evaporation of a 
solution.  Examination of the crystal packing revealed the common motif of the 
meloxicam dimer and the two-point recognition carboxylic acid-azole/NH 
supramolecular synthon.  The meloxicam dimer was only prevalent in crystal forms 1-4 
while the carboxylic acid-azole/NH supramolecular synthon sustained forms 1-5.  The 
lack of the meloxicam dimer in 5 is unique and possibly contributes to the unique 
solubility and pharmacokinetic properties of 5.    
The dissolution profiles, conducted in pH 8 buffer, predicated the improved 
solubility of many of the cocrystals.  1 was the most soluble cocrystal while 2 was the 
least soluble cocrystal at the end of the 4 hour trial.  However, due to the desire to 
improve the concentration in solution at the fastest rate to decrease the onset of efficacy, 
the concentration after the first 15 minutes was the most crucial point.  Examining of the 
concentrations at the early time points illustrated that 3 and 5 were the most soluble after 
5 minutes but 3 quickly decreased in concentration while 5 maintained an elevated level.  
The solubility of the cocrystal former did not correlate to the of the corresponding 
cocrystal. 
The single dose rat pharmacokinetic study administered forms 1-5, 7, and 
meloxicam.  The area under the curves for the plasma concentrations of 2, 3, and 6 were 
lower than pure meloxicam.  Two hours into the 4-hour study 1 and 4 had achieved 
concentrations similar to meloxicam, 5 however, reaches therapeutic concentrations 15 
minutes after administration.   
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A consideration of the solubility and pharmacokinetic data for the meloxicam 
cocrystals led to the selection of 5 as the product that should be taken further into clinical 
trials.  Unfortunately, there remains a problem with marketing 5 as it is well known that 
meloxicam should not be taken with other NSAID pain killers.  With this in mind the 
next best crystal form, 1, would be selected for clinical trial testing.   
 
5.2. Future Directions   
 The future for the field of crystal engineering is glowing bright.  The interest in 
developing solids as functional materials is progressing rapidly as scientists are learning 
how to utilize the principles of crystal engineering and expand upon the existing synthetic 
methods for the design of novel materials.  The advent of novel synthetic techniques such 
as cocrystal controlled solid-state synthesis, have been instrumental in the development 
of new molecules.  Furthermore, with the facile generation of new molecules one can 
synthesize functional materials such as metal-organic frameworks that are currently being 
explored for applications such as hydrogen storage. 
 Crystal engineering has within the last decade also had a major impact upon the 
pharmaceutical industry with a particular emphasis upon crystal form and pharmaceutical 
cocrystals.  Currently the physical properties of pharmaceutical cocrystals that result from 
the screening process are unpredictable.  Perhaps with the knowledge gained from the 
studies presented herein coupled with future studies will allow for the generation of a 
library that will facilitate the estimation or possibly predict the solubility or maybe even 
the bioavailability of pharmaceutical cocrystals.  
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The scientific literature surrounding pharmaceutical cocrystals has also grown 
exponentially over the past decade containing many articles from major pharmaceutical 
companies as well as academic scientists.  Furthermore, there are now more 
collaborations than ever between industry and academia resulting in fascinating science 
and influential papers.  The conglomeration of industry and academia appears to be the 
wave of the future and cocrystals will continue to play a major role in crystal form 
development.  The ability to control the properties of a crystal form still remains for 
futuristic development but as the future draws near Feynman’s dreams of possessing the 
ability to arrange the molecules exactly as we want them are growing one step closer to 
becoming the reality.                 
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Appendix 1. Experimental data for PA1+AA1 (2-methyl-4-nitroaniline+NTCDA) 
IR and Powder X-ray diffractogram of heated and ground material and 1HNMR of imide 
 
 
 
 
 226
 
 
 227
Appendix 2. Experimental data for PA1+AA2 (2-methyl-4-nitroaniline+pyromellitic 
anhydride) IR and Powder X-ray diffractogram of heated and ground material and 
1HNMR of imide 
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Appendix 3. Experimental data for PA1+AA3 (2-methyl-4-nitroaniline+maleic 
anhydride) IR, Powder X-ray diffractogram, and DSC of heated and ground material and 
1HNMR of imide 
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Appendix 4. Experimental data for PA1+AA4 (2-methyl-4-nitroaniline+phthalic 
anhydride) IR, Powder X-ray diffractogram, and DSC of heated and ground material and 
1HNMR of imide 
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Appendix 5. Experimental data for PA1+AA5 (2-methyl-4-nitroaniline+3, 3’, 4, 4’-
biphenyltetracarboxylic dianhydride) IR, Powder X-ray diffractogram, and DSC of 
heated and ground material and 1HNMR of imide 
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Appendix 6. Experimental data for PA2+AA1 (3-aminobenzoic acid+NTCDA) IR 
and Powder X-ray diffractogram of heated and ground material and 1HNMR of imide 
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Appendix 7. Experimental data for PA2+AA2 (3-aminobenzoic acid+pyromellitic 
anhydride) IR, Powder X-ray diffractogram, and DSC of heated and ground material and 
1HNMR of imide 
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1HNMR could not be obtained due to low solubility 
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Appendix 8. Experimental data for PA2+AA3 (3-aminobenzoic acid+maleic 
anhydride) IR, Powder X-ray diffractogram, and DSC of heated and ground material and 
1HNMR of imide 
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Appendix 9. Experimental data for PA2+AA4 (3-aminobenzoic acid+phthalic 
anhydride) IR, Powder X-ray diffractogram, and DSC of heated and ground material and 
1HNMR of imide 
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Appendix 10. Experimental data for PA2+AA5 (3-aminobenzoic acid+3, 3’, 4, 4’-
biphenyltetracarboxylic dianhydride) IR, Powder X-ray diffractogram, and DSC of 
heated and ground material and 1HNMR of imide 
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1HNMR could not be obtained due to low solubility 
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Appendix 11. Experimental data for PA2+AA6 (3-aminobenzoic acid+1,8-
naphthalic anhydride) IR, Powder X-ray diffractogram, and DSC of heated and ground 
material and 1HNMR of imide 
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1HNMR could not be obtained due to low solubility 
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Appendix 12. Experimental data for PA3+AA2 (melamine+pyromellitic anhydride) 
IR, Powder X-ray diffractogram, and DSC of heated and ground material and 1HNMR of 
imide 
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XPDS of heated material are not provided because the material was amorphous. 
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Appendix 13. Experimental data for PA3+AA3 (melamine+maleic anhydride) 
IR, Powder X-ray diffractogram, and DSC of heated and ground material and 1HNMR of 
imide 
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Appendix 14. Experimental data for PA3+AA4 (melamine+phthalic anhydride) IR, 
Powder X-ray diffractogram, and DSC of heated and ground material and 1HNMR of 
imide 
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Appendix 15. Experimental data for PA4+AA1 (1,4-phenylenediamine+NTCDA) IR, 
Powder X-ray diffractogram, and DSC of heated and ground material and 1HNMR of 
imide 
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1HNMR could not be obtained due to low solubility 
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Appendix 16. Experimental data for PA4+AA2 (1,4-phenylenediamine+pyromellitic 
anhydride) IR, Powder X-ray diffractogram, and DSC of heated and ground material and 
1HNMR of imide 
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Appendix 17. Experimental data for PA4+AA3 (1,4-phenylenediamine+maleic 
anhydride) IR, Powder X-ray diffractogram, and DSC of heated and ground material and 
1HNMR of imide 
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Appendix 18. Experimental data for PA4+AA4 (1,4-phenylenediamine+phthalic 
anhydride) IR, Powder X-ray diffractogram, and DSC of heated and ground material and 
1HNMR of imide 
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1HNMR could not be obtained due to low solubility 
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Appendix 19. Experimental data for PA4+AA5 (1,4-phenylenediamine+3, 3’, 4, 4’-
biphenyltetracarboxylic dianhydride) IR, Powder X-ray diffractogram, and DSC of 
heated and ground material and 1HNMR of imide 
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Appendix 20. Experimental data for PA4+AA6 (1,4-phenylenediamine+1,8-
naphthalic anhydride) IR, Powder X-ray diffractogram, and DSC of heated and ground 
material and 1HNMR of imide 
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Appendix 21. Experimental data for PA5+AA1 (1,5-naphthalenediamine+NTCDA) 
IR, Powder X-ray diffractogram, and DSC of heated and ground material and 1HNMR of 
imide 
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XPD of heated material not included because the compound is amorphous. 
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Appendix 22. Experimental data for PA5+AA2 (1,5-naphthalenediamine+ 
pyromellitic anhydride) IR, Powder X-ray diffractogram, and DSC of heated and 
ground material and 1HNMR of imide 
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XPD of heated material not included because the compound is amorphous. 
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Appendix 23. Experimental data for PA5+AA3 (1,5-naphthalenediamine+maleic 
anhydride) IR, Powder X-ray diffractogram, and DSC of heated and ground material and 
1HNMR of imide 
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Appendix 24. Experimental data for PA5+AA4 (1,5-naphthalenediamine+phthalic 
anhydride) IR, Powder X-ray diffractogram, and DSC of heated and ground material and 
1HNMR of imide 
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Appendix 25. Experimental data for PA5+AA5 (1,5-naphthalenediamine+3, 3’, 4, 4’-
biphenyltetracarboxylic dianhydride) IR, Powder X-ray diffractogram, and DSC of 
heated and ground material and 1HNMR of imide 
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XPD of heated material not included because the compound is amorphous. 
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Appendix 26. Experimental data for PA5+AA6 (1,5-naphthalenediamine+1,8-
naphthalic anhydride) IR, Powder X-ray diffractogram, and DSC of heated and ground 
material and 1HNMR of imide 
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XPD of heated material not included because the compound is amorphous. 
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Appendix 27. Experimental data for PA6+AA3 (1-adamantylamine+maleic 
anhydride) IR, Powder X-ray diffractogram, and DSC of heated and ground material and 
1HNMR of imide 
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Appendix 28. Experimental data for PA6+AA4 (1-adamantylamine+phthalic 
anhydride) IR, Powder X-ray diffractogram, and DSC of heated and ground material and 
1HNMR of imide 
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Appendix 29. Experimental data for PA7+AA2 (triphenylmethylamine+pyromellitic 
anhydride) IR, Powder X-ray diffractogram, and DSC of heated and ground material and 
1HNMR of imide 
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Appendix 30. Experimental data for PA7+AA3 (triphenylmethylamine+maleic 
anhydride) IR, Powder X-ray diffractogram, and DSC of heated and ground material and 
1HNMR of imide 
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Appendix 31. Experimental data for PA7+AA4 (triphenylmethylamine+phthalic 
anhydride) IR, Powder X-ray diffractogram, and DSC of heated and ground material and 
1HNMR of imide 
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Appendix 32. Experimental data for PA7+AA5 (triphenylmethylamine+3, 3’, 4, 4’-
biphenyltetracarboxylic dianhydride) IR, Powder X-ray diffractogram, and DSC of 
heated and ground material and 1HNMR of imide 
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Appendix 33. Histograms for specified contacts between aminopyridine to 
carboxylic acid and aminopyridine to alcohol moieties (comprised of entries in the 
CSD) 
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Appendix 34. Experimental data for lamotrigine methylparaben form I 
Powder X-ray diffractogram comparison of cocrystal to starting material 
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An experimental PXRD is not shown because the crystallization results in multiple 
products in the same vial. 
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Appendix 35. Experimental data for lamotrigine methylparaben form II 
Powder X-ray diffractogram, DSC, and IR for lamotrigine methylparaben form II 
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Appendix 36. Experimental data for lamotrigine nicotinamide cocrystal 
Powder X-ray diffractogram, DSC, and IR for lamotrigine nicotinamide cocrystal 
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Appendix 37. Experimental data for lamotrigine nicotinamide monohydrate 
Powder X-ray diffractogram, DSC, IR, and TGA for lamotrigine nicotinamide 
monohydrate
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Appendix 38. Experimental data for lamotrigine saccharinate salt 
Powder X-ray diffractogram, DSC, and IR for lamotrigine saccharinate salt 
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Appendix 39. Experimental data for lamotrigine adipate salt 
Powder X-ray diffractogram, DSC, and IR for lamotrigine adipate salt 
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Appendix 40. Experimental data for lamotrigine malate salt 
Powder X-ray diffractogram, DSC, and IR for lamotrigine malate salt 
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Appendix 41. Experimental data for lamotrigine nicotinate dimethanol solvate 
Powder X-ray diffractogram, DSC, IR, and TGA for lamotrigine nicotinate dimethanol 
solvate 
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Appendix 42. Experimental data for lamotrigine dimethanol solvate 
Powder X-ray diffractogram, DSC, IR, and TGA for lamotrigine dimethanol solvate 
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Appendix 43. Experimental data for lamotrigine ethanol hydrate 
Powder X-ray diffractogram, DSC, IR, and TGA for lamotrigine ethanol hydrate 
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Appendix 44. Histograms for specified contacts between carboxylic acid-azole, 
alcohol-azole, and primary amide-azole compiled from entries in the CSD 
 
(a)      (b)  
Acid homosynthon in the presence of azole           Acid-azole supramolecular heterosynthon 
 
(c)      (d)  
Alcohol homosynthon in the presence of azole     Alcohol-azole supramolecular heterosynthon 
 
(e)      (f)  
Amide homosynthon in the presence of azole      Amide-azole supramolecular heterosynthon 
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Appendix 45. Experimental data for meloxicam 1-hydroxy-2-naphthoic acid 
cocrystal Powder X-ray diffractogram, DSC, IR, and for meloxicam 1-hydroxy-2-
naphthoic acid cocrystal 
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Appendix 46. Experimental data for meloxicam glutaric acid cocrystal 
Powder X-ray diffractogram, DSC, IR, and for meloxicam glutaric acid cocrystal 
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Appendix 47. Experimental data for meloxicam L-malic acid cocrystal of a salt 
Powder X-ray diffractogram, DSC, IR, and for meloxicam L-malic acid cocrystal of a salt 
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Appendix 48. Experimental data for meloxicam aspirin cocrystal 
Powder X-ray diffractogram, DSC, IR, and for meloxicam aspirin cocrystal 
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Appendix 49. Experimental data for meloxicam salicylic acid cocrystal form III 
Powder X-ray diffractogram, DSC, IR, and for meloxicam salicylic acid cocrystal form 
III 
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Appendix 50. Experimental data for meloxicam salicylic acid cocrystal form I 
Powder X-ray diffractogram, DSC, IR, and for meloxicam salicylic acid cocrystal form I 
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Appendix 51. Experimental data for meloxicam salicylic acid cocrystal form II 
Powder X-ray diffractogram, DSC, IR, and for meloxicam salicylic acid cocrystal form II 
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